Optimization and quantification of stimulation parameters in subthalamic nucleus deep brain stimulation for Parkinson's disease by Martínez Torres, Irene
  
 
FACULTAD DE MEDICINA Y ODONTOLOGIA  
DEPARTAMENTO DE MEDICINA  
 
 
OPTIMIZACIÓN Y CUANTIFICACIÓN DE LOS PARÁMETROS 
DE ESTIMULACIÓN EN LA ESTIMULACIÓN CEREBRAL 
PROFUNDA DEL NÚCLEO SUBTALÁMICO EN LA 
ENFERMEDAD DE PARKINSON 
 
OPTIMIZATION AND QUANTIFICATION OF STIMULATION 
PARAMETERS IN SUBTHALAMIC NUCLEUS DEEP BRAIN 
STIMULATION FOR PARKINSON’S DISEASE  
 
TESIS DOCTORAL INTERNACIONAL 
 
Presentada por  
Irene Martínez Torres  
 
Dirigida por 
Dra. Patricia Limousin  
Dr. Juan J Vílchez Padilla 
 
Valencia, Marzo 2014 
 
 



D. Juan J. Vílchez Padilla, Profesor Titular del Departamento de Medicina de  la 
Universidad de Valencia, 
 
 
CERTIFICA : 
Que Dña. Irene  Martínez Torres, Licenciada en Medicina y Cirugía por la 
Universidad de Valencia, ha realizado bajo mi dirección el trabajo titulado 
“Optimización y cuantificación de los parámetros de estimulación en 
la  Estimulación Cerebral Profunda del Núcleo Subtalámico en la  
Enfermedad de Parkinson”, para obtener el grado de Doctora en 
Medicina.  
 
Revisado el trabajo, autorizo su presentación para optar al grado de 
Doctora en Medicina. 
 
Y para que así conste y surta los efectos oportunos, firmo el presente 
certificado en Valencia, a 10 de Marzo de  2014. 
 
 
 
 
 
Dr. Juan J Vílchez Padilla 
Profesor Titular Facultad de Medicina  
Jefe de Servicio de Neurología 
Hospital Universitario y Politécnico La Fe 
  

  
 
 
 
 
 
 
La presente Tesis Doctoral forma parte del 
proyecto de investigación del  Programa de 
Ayudas Predoctorales de Formación En 
Investigación En Salud, financiado por el 
Instituto de Salud Carlos III (FI08/00108). 
 
  

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A Luis y Silvia 
 
 
 
 
 
 

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“No, no em puc aturar  
I mirar la vida  
des del finestral” 
 
 De Irene, canción de Lluis Llach 
  

AGRADECIMIENTOS 
Durante mi último año de residencia, me planteaba la difícil decisión de cómo 
continuar mi formación académica y como neuróloga. La inmersión durante 
este último año en la consulta de Enfermedad de Parkinson y Trastornos del 
Movimiento del Hospital La Fe fue clave para tomar esta decisión. Finalmente 
decidí, y creo que muy acertadamente, realizar una estancia en la Unidad de 
Neurocirugía Funcional de Queen Square,  un centro con una amplia 
experiencia en Enfermedad de Parkinson y  Estimulación Cerebral Profunda. 
La idea inicial era realizar un año de formación, sin embargo, cuando fui a 
entrevistarme con la Dra. Patricia Limousin, ésta me sugirió y apoyó para que 
la misma fuera de dos años. Esto supuso un nuevo planteamiento, 
fundamentalmente, en mi vida personal. Por eso, a la persona a la que estoy 
más agradecida durante todo este periodo de investigación en Londres y 
posteriormente en Valencia es a mi pareja, Luis, que supo entender mis 
aspiraciones y me brindó todo su apoyo para desarrollarlas.  
Mi estancia en Londres la recuerdo con gran felicidad, la calurosa – a pesar de 
las inclemencias meteorológicas - acogida por todos los miembros de la Unidad 
fue excepcional. Agradezco especialmente a la Profesora Patricia Limousin 
toda su dedicación en mi formación y al desarrollo de esta tesis. Al Profesor 
Marwan Hariz, agradecerle todo su apoyo y  las estimulantes conversaciones 
que teníamos cuando solo quedábamos él y yo en la Unidad. También a Elina 
y Steve, por haber sido unos espléndidos compañeros.  
Agradecer también a todos los compañeros que me han apoyado en mi 
regreso a Valencia, al Dr. Vílchez y muy especialmente a Juan Andrés y a 
Antonio porque gracias a ellos mi sueño - dedicarme a la enfermedad de 
Parkinson  y la estimulación cerebral profunda - ha sido posible.  
También me encuentro en deuda con el Dr. Antonio Salazar, por  su dedicación 
en la siempre ardua tarea del estudio estadístico. A la Profesora Amparo Ruiz, 
agradecerle sus ánimos durante el último año de escritura de este trabajo; y a 
Vicente, su paciencia y sus consejos.  
A mis padres, porque siempre me han apoyado en todas mis inquietudes y a mi 
hija Silvia, para que me perdone por todos los momentos que este trabajo me 
ha alejado de su lado.  
Finalmente a todos mis pacientes, pasados, presentes y futuros, con la ilusión 
que todos nuestros esfuerzos sirvan para aliviar su sufrimiento.  

TABLE OF CONTENTS 

Table of Contents  
1 
TABLE OF CONTENTS  
Abbreviations …………………………………………………………….. 3  
I. INTRODUCTION ……………………………...………….        7 
1. The Basal Ganglia....................................................        9 
2. Pathophysiology of the Basal Ganglia in 
Parkinson’s disease  ………………………………… 35 
3. Subthalamic nucleus deep brain stimulation for 
Parkinson’s Disease …………………………… …… 45 
4. Stimulation parameters in Subthalamic nucleus 
deep brain stimulation: strategies for selection of 
appropriate stimulation parameters ………………... 49 
5. Subthalamic area and optimal stimulation site in 
STN DBS for Parkinson’s disease  …………………  56 
6. Subthalamic nucleus local field potentials 
recordings in STN DBS in Parkinson’s disease …..    63 
II. OBJECTIVES ……………………………………………. 65 
III. METHODS ……………………………………………….. 69 
1. General methodology ………………………………..       71 
2. Study design ………………………………………….  78
IV. RESULTS ………………………………………………… 99 
1. Longitudinal assessment of the impact of 
consecutive adjustment sessions of stimulation 
parameters in STN DBS in PD: evaluation of the 
acute and chronic effects of stimulation 
parameters……………………………………………..    101
Table of Contents  
2 
2. Clinical outcome of STN DBS with 
reprogramming……………………………………….. 128 
3. Optimal stimulation site in STN DBS for PD………. 138 
4. Study of type of adjustment “change in contact” ….  160 
5. The value of the LFP recordings in STN DBS 
intraoperative targeting and optimization of 
stimulation parameters………………………………. 167
V. DISCUSSION …………………………………………....      175 
1. Longitudinal assessment of the impact of 
consecutive adjustment sessions of stimulation 
parameters in STN DBS in PD: evaluation of the 
acute and chronic effects of stimulation 
parameters……………………………………….  177
2. Clinical outcome of STN DBS with 
reprogramming……………………………………….. 183 
3. Optimal stimulation site in STN DBS for PD………. 186 
4. Study of type of adjustment “change in contact” ….  196 
5. The value of the LFP recordings in STN DBS 
intraoperative targeting and optimization of 
stimulation parameters………………………………. 199 
VI. CONCLUSIONS ………………………………………....      203 
VII. REFERENCES ……………………………………………    209 
VIII. APPENDIX I: STIMULATION PARAMETERS  ….……     229 
IX. APPENDIX II: SPANISH SUMMARY …………………..    233 
ABBREVIATIONS

Abbreviations  
5 
LIST OF ABBREVIATIONS 
A  Adjustment session 
AL  Ansa Lenticularis 
DBS  Deep brain stimulation 
DRS  Dyskinesia rating scale 
GPe  Globus pallidus externus 
GPi  Globus pallidus internus 
IC  Internal capsule 
LEDD Levodopa equivalent daily dose 
LFP  Local Field Potentials 
MRI  Magnetic resonance imaging 
PD   Parkinson’s disease 
PMd  Dorsal premotor cortex 
PPN  Pedunculopontine nucleus 
Pre-DBS before DBS 
Off M Off medication condition 
Off S Off stimulation condition 
On M On medication condition  
On S On stimulation condition 
RN  Red nucleus 
SE  Standard error 
SD  Standard deviation 
SMA  Supplementary motor area 
SN  Substantia nigra 
SNc          Substantia nigra pars compacta 
Abbreviations  
6 
SNr          Substantia nigra pars reticulata 
SP  Stimulation parameters 
STN  Subthalamic nucleus 
TEED Total electrical energy delivered  
UPDRS Unified Parkinson’s disease Rating Scale 
V  Visit 
I. INTRODUCTION

Introduction  
9 
1. THE BASAL GANGLIA 
 
The basal ganglia are a group of nuclei located in the diencephalon and 
mesencephalon. The classical concept of the basal ganglia as involved in motor 
control has been largely modified during the last decades on the basis of the 
extensive research carried out. These nuclei are involved not only in motor 
behaviours but also in cognition and emotion. They are intimately related with 
cortical areas and thalamus as well as with other brainstem nuclei. Cortical 
information is processed by the basal ganglia in well differentiated parallel loops 
and each of these loops project back to the cortical area of origin. Although 
there is some segregation, cortical information from different areas is also 
integrated throughout the basal ganglia circuits for the selection of appropriate 
behaviours in relation with the environment, learning and rewards.  
Basal ganglia dysfunction is involved in a wide range of diseases. Traditionally 
basal ganglia disorders have been classified in hypokinetic and hyperkinetic 
disorders. Hypokinetic disorders, such as Parkinson’s disease (PD), are 
characterized by slowness of movements, loss of movements, rigidity and 
tremor. In contrast, hyperkinetic disorders (chorea, ballism, dystonia) are 
distinguished by an excess of movements. Although disorders of the basal 
ganglia were classified on the basis of the “amount” of movement, impairment 
of cognition and behaviour are also common features of some of these 
diseases. The basal ganglia have also been related with neuropsychiatric 
disorders such as Tourette syndrome and, obsessive-compulsive disorder 
supporting their role in emotional functions.  
The resurgence of functional neurosurgery and in particular the development of 
deep brain stimulation for certain of these conditions has allowed to confirm in 
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humans some of the data found in animal studies and it has contributed to our 
understanding of neuronal activity in pathological and physiological conditions.  
 
ANATOMY OF THE BASAL GANGLIA 
The basal ganglia comprise four major nuclei: the striatum (caudate 
nucleus and putamen), the globus pallidus (GP, internal and external segment), 
the subthalamic nucleus (STN), and the substantia nigra (SN, pars compacta 
and pars reticulata) (figure 1). The striatum is the main input structure. It 
receives massive afferents from the entire cerebral cortex as well as from the 
thalamus and to a lesser degree from the dorsal raphe nucleus and the 
amygdala. The output nuclei are the internal segment of the globus pallidus 
(GPi) and the pars reticulata of the substantia nigra (SNr). Gamma-amino- 
butyric acid (GABA), which is considered the main neurotransmitter of the basal 
ganglia, is used by the striatum to project directly or indirectly - via the external 
segment of the GP (GPe) and the STN - to the output nuclei, which in turn 
project to the thalamus.  
The globus pallidus is divided into the internal and external segment (GPi and 
GPe) by the internal medullary lamina. Although GPi and GPe share similar 
morphology and a common neurotransmitter, GABA, they are functionally 
distinct. The GPi is one of the output nuclei of the basal ganglia whereas the 
GPe could be considered as a modulator nucleus of the activity of the basal 
ganglia.  Similarly the SN consists of two major sub-nuclei, the pars compacta 
(SNc) and the SNr. These two parts share similar inputs from other basal 
ganglia nuclei and have mostly different outputs and are neurochemically 
distinct. The SNr uses GABA as neurotransmitter whereas the SNc uses 
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dopamine. The STN uses glutamate as neurotransmitter and can be considered 
as both modulator and input structure. 
Cortical information is processed in a segregated topographical manner that is 
maintained along the whole axis of the basal ganglia. Three main territories can 
be identified within the nuclei: sensorimotor, associative and limbic (Alexander 
et al., 1986; Alexander and Crutcher, 1990). Within the sensorimotor territory it 
is also possible to identify a body map (somatotopy), analogous to the cortical 
homunculus, and the information for the different body parts is also processed 
in parallel. Although there is a high degree of segregation of cortical information, 
convergence also exists within the basal ganglia.  
Figure 1. Brain slices in the coronal plane showing the basal ganglia 
nuclei. Abbreviations: Cau: caudate nucleus; CC: cerebral cortex; GPe: Globus 
pallidus externus; GPi: Globus palllidus internus; IC: Internal capsule; Put: 
putamen; SN: Substantia nigra; STN: subthalamic nucleus; Tha: Thalamus 
(From Martinez-Torres I et al., 2008) 
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The input nucleus of the Basal Ganglia: The striatum 
The striatum is the major input structure of the basal ganglia and comprises the 
caudate, putamen and accumbens (ventral striatum) nuclei. The striatum 
receives glutamatergic afferent from all cortical areas. These corticostriatal 
projections are topographically organized and project to three distinct regions of 
the striatum: the sensorimotor, the associative and limbic striatum  (Alexander 
et al., 1986; Parent and Hazrati, 1995a; Middleton and Strick, 2000). The 
sensorimotor territory in the dorsolateral putamen and caudate receives 
projections from primary motor cortex, somatosensory cortex, premotor cortex, 
supplementary motor area, and cingulate motor area. A study revealed that the 
sensorimotor striatum also received axon collaterals from corticofugal axons 
that descend toward the brainstem (Parent and Parent, 2006). 
Electrophysiological studies have shown that neurons located in the 
sensorimotor striatum respond to passive and active movements of the limbs 
and a well-defined somatotopic organization has been described, with the leg 
being dorsal and the trunk, arm and head more ventral (Crutcher and DeLong, 
1984; Flaherty and Graybel, 1991; Miyachi et al., 2006). The associative 
territory comprises large part of the putamen rostral to the anterior commissure 
and most of the head, body and tail of the caudate nucleus. It receives 
projections from associative cortices in frontal, parietal and temporal lobes 
(Alexander et al., 1986). The limbic striatal territory is located in the ventral part 
of the caudate and putamen, the nucleus accumbens and portions of the 
olfactory tubercle. It receives projections form the limbic and paralimbic cortex, 
the amygdala and hippocampus.  
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The striatum receives dopaminergic afferents from the SNc. Other sources of 
dopaminergic inputs come from the retrorubral region (A8) and the 
ventrotegmental area (VTA). Dopaminergic nigral neurons make synaptic 
contacts with necks of the dendrites spines, but only in those spines that also 
receive cortical input. Such synaptic organization allows dopamine to modulate 
the excitatory effect of corticostriatal projections.  
The striatum receives major thalamic glutamatergic afferents from the 
centromedian/parafascicular (CM-Pf) complex of the thalamus (Sadikot et al., 
1992). The CM nucleus projects mainly to the putamen (sensorimotor striatum) 
and receives afferents from the motor cortex and GPi. The Pf nucleus projects 
to the caudate nucleus (associative striatum) and the pallidum and its afferents 
come from the premotor cortex. The ventromedial part of the Pf nucleus also 
projects to the limbic striatum. 
The inputs from the STN are glutamatergic and are also segregated in the three 
main domains. Suthalamostriatal projections are scarce and exert an en 
passant excitatory effect over striatal neurons (Parent and Hazrati, 1995a).  
Other inputs to the striatum are: serotoninergic projections from the midline 
raphe nuclei and noradrenergic from the locus ceruleus. More recently 
serotoninergic projection has gained increasing attention because 
serotoninergic axons have been suggested to underlie graft-induced 
dyskinesias and by extension levodopa-induced dyskinesias in Parkinson’s 
disease (Carta et al., 2010).  
The striatum contains two different types of neurons: projection neurons and 
interneurons. Projection neurons, also called medium spiny neurons, are 
GABAergic neurons (Smith et al., 1987)  which project mainly to GPe, GPi or 
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SNr where they inhibit the neurons within these target structures (Chevalier and 
Deniau, 1990). Spiny neurons can be divided into two subgroups according to 
their neurochemical features: spiny neurons containing enkephalin and 
expressing predominantly D2 subtype of dopamine receptors that project to the 
GPe (indirect pathway) and, spiny neurons containing   substance P (SP) and 
dynorphin, and expressing mainly D1 subtype receptors that project to the SNr 
and the GPi (direct pathway) (Bertran-Gonzalez et al., 2010). Efferent 
projections to the pallidum are mainly from the putamen and convey 
sensorimotor information. Those to the SNr originate mainly in the caudate 
nucleus and convey information from the associative cortex.  
In addition to spiny medium neurons, the striatum also contains local-circuit 
neurons (interneurons) with different neurochemical profiles.  
Control nuclei of the Basal Ganglia: Globus pallidus external segment and 
subthalamic nucleus 
Globus pallidus external segment 
The GPe receives massive GABAergic afferents from the striatum and 
glutamatergic afferents from the STN. Both, striatum and STN send convergent 
fibers to pallidal neurons suggesting that cortical information received by these 
two structures could be integrated at the level of single pallidal neurons (Hazrati 
and Parent, 1993). Other inputs to the GPe come from the cerebral cortex, 
intralaminar thalamic nuclei (CM/Pf), GPi, SNc, raphe and pedunculopontine 
nucleus (PPN). 
The majority of the projections of the GPe end at the STN (indirect pathway), 
GPi/SNr, and striatum. Reciprocal loops exist between the GPe-striatum and 
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the GPe-STN. The GPe has been classically seen as an indirect link between 
the striatum and the output nuclei of the basal ganglia. However, the existence 
of a massive inhibitory projection from the GPe to the GPi/SNr, places the GPe 
in an essential position to directly control the output stations of the basal ganglia 
(Parent and Hazrati, 1995b). 
Subthalamic nucleus 
The STN can be considered as an input and control nucleus of the basal 
ganglia. It receives massive projections from the primary motor cortex, 
supplementary motor area, and premotor cortex that terminate in the 
sensorimotor STN. These cortico-subthalamic projections constitute the fastest 
pathway by which cortical information reach the basal ganglia and is known as 
the hyperdirect pathway (Hazrati and Parent, 1993; Nambu et al., 2002). Other 
important input to the STN comes from the GPe with which it forms a reciprocal 
loop and constitutes the indirect pathway from the striatum to the output nuclei. 
The STN also receives projections from the intralaminar thalamic nuclei 
(Lanciego et al., 2004; Lanciego et al., 2008) keeping a topographical 
organization where the CM nucleus projects to the sensorimotor STN and the Pf 
nucleus innervates its associative and limbic territories. It is also worth noting 
that the STN receives sparse dopaminergic projection from the SNc 
(Rommelfanger and Wichmann, 2010). 
The dorsolateral part of the STN is the largest portion of the nucleus and 
corresponds to the sensorimotor territory. Neurons in this area change their 
discharge rate during movements. A representation of the body map has also 
been delineated: the leg is dorsal, the face ventral and the arm is in-between. 
Associative cortical areas and frontal eye fields project to the ventromedial part 
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of the STN (associative territory). The medial tip of the STN is connected with 
limbic structures and is considered the limbic territory. 
The major efferent projections from the STN project to both segments of the 
globus pallidus in a topographic arrangement. These projections form parallel 
bands in the GPe and GPi. Part of the subthalamo-nigral projections that reach 
the SNr are involved, together with the caudatonigral projections, in the control 
of saccadic eye movements. Some of the axons of subthalamonigral neurons 
located in the ventromedial part of the STN ascend and synapse the neurons in 
the SNc, comprising one of the mechanism for the control of dopamine release. 
STN also sends scant projections to the striatum with a topographic 
organization and to the PPN and ventral tegmental area (Parent and Hazrati, 
1995b; Hamani et al., 2004).  
The output nuclei of the basal ganglia: globus pallidus internal segment 
and the substantia nigra pars reticulata  
The output nuclei of the basal ganglia are the GPi and the SNr. Both structures 
have similar connections and differ in their functions and topographical 
organization.  They receive cortical information processed by the striatum, both, 
directly and indirectly, through the GPe and STN. GPi receives more prominent 
projections from the striatal sensorimotor territory, while SNr receives 
projections mainly from the associative striatum.  Both nuclei consist of 
inhibitory GABAergic neurons with a high rate of discharge that fire tonically to 
inhibit their targets.  
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Globus pallidus internal  segment  
The GPi receives inputs from the striatum (direct pathway), STN (indirect 
pathway) and GPe. Other inputs come from the intralaminar thalamic nuclei, the 
dorsal raphe nucleus, the PPN, and from the SNc.  
The sensorimotor area of the GPi is localized in the ventral two-third of the GPi, 
displaying a somatotopic arrangement: with the leg being dorsal, the head 
ventral and the arm in-between. The associative territory is localized in the 
dorsal one-third of the GPi and the limbic in the medial tip. Afferents from the 
GPe and STN project onto the same neurons in the GPi. Reciprocal 
connections exist between GPi and GPe.  
Neurons in the GPi are GABAergic and fire spontaneously at high frequencies 
without pauses which entails a tonic inhibition of thalamic target. The pattern of 
arborization of pallidal neurons is different within each target. They project to 
the ventral anterior (VA, pars principalis) and ventral lateral (VL, pars oralis) 
thalamic nuclei onto the thalamocortical neurons and thalamic interneurons, 
suggesting that they exert a double inhibition onto the thalamic projection 
neurons, one directly and other by inhibiting the excitation that the interneurons 
exert on them. Pallidothalamic projections to the VA/VL give off collaterals to 
the CM nucleus in primates, which in turn projects back to the striatum forming 
an ancillary subcortical loop (Striatum-GPi-CM-striatum) that conveys 
sensorimotor information. The existence of a similar parallel loop involving the 
Pf nucleus has been proposed to convey associative type information.  
Other output structures receiving projections from the GPi are the habenula, 
which is involved in limbic functions, and the PPN (Parent and Hazrati, 1995a).  
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Substantia nigra pars reticulata 
The SNr receives afferents from the striatum, GPe and STN. Striatonigral, 
pallidonigral, and subthalamonigral inputs are topographically organized and 
converge onto the same SNr output neurons. SNr neurons and nigral afferents 
are topographically organized following a laminar arrangement in an onion-like 
manner.  The lateral half of the SNr processes information coming from sensory 
and motor cortical areas. The medial part of the SNr is innervated by striatal 
subterritories related to prefrontal and limbic cortical areas (Deniau et al., 2007). 
SNr efferents, keep topographical subdivisions, are GABAergic, inhibitory and 
project to the VA and VL thalamic nuclei, mesopontine tegmentum, SNc, 
superior colliculus and pedunculopontine nucleus (Parent and Hazrati, 1995a).  
 
2. INTRINSIC CIRCUITS OF THE BASAL GANGLIA 
The striatum receives massive cortical input, which is then processed and 
projected through the other basal ganglia structures. The arrangement of the 
striatal output is classically divided into the direct and indirect pathway (Albin et 
al., 1989; DeLong, 1990). In the direct pathway, the striatal spiny neurons (D1 
receptor/SP/Dynorphin) project monosynaptically onto the GPi/SNr which 
project to the thalamus, facilitating thalamocortical projections and cortical 
initiated movements. In the indirect pathway, spiny neurons (D2 receptor/ENK) 
project onto the GPi and SNr via  the GPe, and  STN. The direct and indirect 
pathways are considered to produce opposing effects on the thalamic targets of 
the basal ganglia outflow, to respectively facilitate or suppress cortically initiated 
activity. Activation of the direct pathway inhibits GPi/SNr tonic activity, inducing 
a pause of neuronal firing – and therefore disinhibition of thalamic nuclei – 
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which is associated with the occurrence of an action. In contrast, the net effect 
of the indirect pathway is increased inhibition of the thalamic targets and 
consequently reduced thalamic input to cortical areas (figure 2). Recent studies 
in the rat using optogenetics have provided strong support for the classical 
model (Kravitz et al., 2010).  
The basal ganglia nuclei also participate in several subsidiary circuits: 1) the 
CM/Pf thalamic nuclei-striatum-GPi-CM/Pf which is probably a positive 
feedback loop leading to increase striatal neuronal activity; 2) CM/Pf-STN-GPi-
CM/Pf circuit, which is probably a negative loop leading to reduced neuronal 
activity; 3) STN-GPe-STN circuit, which is an excitatory-inhibitory loop with 
autostabilizing characteristics and; 4) the STN-GPe/GPi dual projections.  
Another important connection is the direct cortical projection to the STN, which 
may be important in synchronizing oscillatory activity in the cortex, STN and 
pallidum (Nambu et al., 2000) (figure 3).  
 
The direct and indirect pathway model has become widely accepted and 
provides a framework for understanding basal ganglia diseases such as 
Parkinson’s disease, chorea and dystonia. According to this model in 
Parkinson’s disease, loss of striatal dopamine leads to underactivity of the direct 
and overactivity of the indirect pathways, resulting therefore in overactivity of 
STN and GPi, which results in excessive inhibition of thalamocortical 
projections. Per contrast, in hyperkinetic disorders, such as dystonia and 
chorea,  the basal ganglia output is reduced leading to a disinhibition of the 
thalamocortical projections and development of involuntary movements 
(DeLong and Wichmann, 2007). However, the direct and indirect pathway 
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model, while providing a conceptual framework has major limitations. It is best 
illustrated in the paradox that GPi lesions are beneficial for both Parkinson’s 
disease and dystonia (Marsden and Obeso, 1994a). This led Marsden and 
Obeso (1994a) to propose a major refinement of the model, namely that the 
pattern rather than the rate of activity within basal ganglia structures carries the 
information signal for both normal and disease states.  
 
Figure 2. Schematic representation of the direct and indirect pathway 
between the striatum and the GPi/SNr. Abbreviations: D1: D1 subtype of 
dopaminergic receptor; D2: D2 subtype of dopaminergic receptor; Dyn: 
dynorphin; ENK: encephalin; GABA: gamma amino butyric acid; Glu: glutamate; 
GPe: globus pallidus externus; GPi: globus pallidus internus; MD: mediodorsal 
thalamic nucleus; SNr: substantia nigra pars reticulate; STN: subthalamic 
nucleus; VA: ventral anterior thalamic nucleus; VL: ventral lateral thalamic 
nucleus (From Martinez-Torres et al., 2008) 
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Figure 3. Schematic representation of the organization of the basal 
ganglia-thalamocortical circuits. Abbreviations: Ach: acetylcholine; CM/Pf: 
centromedian and parafascicular thalamic nuclei; D1: D1 subtype of 
dopaminergic receptor; D2: D2 subtype of dopaminergic receptor; DA: 
dopamine; Dyn: dynorphine; ENK: encephalin; GABA: gamma amino butyric 
acid; Glu: glutamate; GPe: globus pallidus externus; GPi: globus pallidus 
internus; MD: mediodorsal thalamic nucleus; MEA: midbrain extrapyramidal 
area; PPN: pedunculopontine nucleus. (From Martinez-Torres et al., 2008). 
3. BASAL GANGLIA-THALAMOCORTICAL CIRCUITS 
Traditionally the basal ganglia were seen as structures that funnelled the 
information originating in distinct cortical areas and then projected back to the 
primary motor cortex.  In 1986 Alexander et al. on the basis of the anatomical 
and physiological findings accumulated described the existence of five circuits 
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between cortical areas and the basal ganglia: the motor circuit, the oculomotor 
circuit, two prefrontal circuits (the dorsolateral prefrontal circuit and the lateral 
orbitofrontal circuit) and the limbic circuit (figure 4). The designation of the 
circuits was made according to its cortical area of origin and termination. The 
segregated organization of these loops has been given further support by 
studies using retrogradely transported virus particles. Two additional circuitries 
were later described (Middleton and Strick, 1996; Clower et al., 2001), as well 
as an open loop between the primary motor cortex and the ventral putamen, 
which may allow interaction between the limbic and motor systems (Kelly and 
Strick, 2004). All circuits share similar characteristics, they originated in specific 
cortical areas, pass through separated portions of the basal ganglia and 
thalamus and end in the cortical area of origin. Within each circuit the 
information is processed following the direct and indirect pathways that link the 
striatum with the output nuclei. However this last organization is less clear in the 
limbic circuit.  
The circuits maintain a clear topographical organization of inputs and outputs. 
The segregation is such that further channels within circuits can be found. For 
example, in the motor circuit, which is the best studied, the information from 
different cortical areas (somatosensory, motor and premotor cortices) is 
processed in parallel. These channels within the motor circuit are subdivided in 
somatotopic subchannels representing each body part (Romanelli et al., 2005). 
Furthermore, neurons in the putamen that represent a single body part respond 
to different characteristics of the movement: some respond to preparation of the 
movement, others are movement related and, others are specific to the 
direction of the movement.  
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Despite the high level of segregation convergence also exits. This idea is 
support by the comparison of the large number of corticostriatal versus the 
much smaller number of striatal and pallidal output neurons. Anatomical and 
electrophysiological studies have demonstrated that convergence of information 
occurs within distinct territories of the same nuclei and at the level of single 
cells.  
This classical view of functional organization of basal ganglia as a loop has 
been recently modified. It is now known that the basal ganglia have several 
loops, where cortical and subcortical projections interact with internal re-entry 
loops. This complex network is designed for selecting and inhibiting 
simultaneously occurring events and signals. Although feedback loops between 
basal ganglia and several subcortical regions were not well considered in the 
initial model, they have been extensively studied during the last years 
(Redgrave et al., 2011; Smith et al., 2011). There is as well increasing evidence 
for direct anatomical interactions between cerebellar and basal ganglia 
circuitries (Bostan et al., 2010). These connections may become of relevance  
in the future to explain aspects of tremor and dystonia.  
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Figure 4. Schematic diagram illustrating the main cortico-basal ganglia-
thalamocortical circuits within human brain. This figure shows a pseudo-
anatomical arrangement of the motor, associative and limbic pathways. (a) 
Motor circuit. Neurons from the sensorimotor cortex project to the posterolateral 
putamen (Put). From the putamen there are two main projections 
topographically organised onto the posterolateral region of the target nuclei: (i) 
the direct circuit to the GPi and (ii) the indirect circuit connecting the posterior 
putamen to the globus pallidus pars externa (GPe), the STN and the GPi. The 
GPi is the primary output nucleus of the basal ganglia to the cortex via the 
ventrolateral thalamus. (b) Associative circuit. This circuit originates in the 
dorsolateral prefrontal and lateral orbitofrontal cortices, which project to the 
caudate nucleus (Cn) and anteromedial portion of the putamen. From the 
striatum (Cn + Put) it projects to the dorsomedial region of the GPi and 
anteromedial parts of the GPe and STN to converge onto the GPi and back to 
the cortex via the ventral anterior nuclei of the thalamus. (c) Limbic circuit. This 
loop starts in the hippocampus, amygdala and paralimbic and limbic cortices 
and projects to the ventral striatum (ventral portion of the caudate and putamen, 
including NAcc). The ventral striatum projects to the limbic portion of the GPe 
and medioventral STN and ventral GPi and to the cortex via the mediodorsal 
nucleus of the thalamus. (From Krack et al., 2010 – modified from Obeso et al., 
2008-).
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4. FUNCTION AND PHYSIOLOGY OF THE BASAL GANGLIA
Research in recent years has challenged the traditional view of basal ganglia as 
only involved in control of movement. Anatomical studies have demonstrated 
the connection between basal ganglia and cortical areas concerned with 
cognition. The activity of the neurons within the basal ganglia nuclei is more 
related to cognitive or sensory tasks than to motor function. Finally, some 
lesions in the basal ganglia produce cognitive and sensory disturbance, sparing 
the motor function.   
 
Motor function 
Despite the recent interest in non-motor function of the basal ganglia, most of 
the research has focused in motor aspects of basal ganglia physiology.  
Microelectrode studies in primates have allowed us to describe the neuronal 
activity within the basal ganglia nuclei. Neuronal activity is defined by: firing 
rate, pattern of discharge and the degree of synchronization and frequency of 
oscillation of neuronal populations. Variation in these parameters can influence 
the function of the basal ganglia in normal and pathological conditions. The 
firing rates of neurons vary by nuclei. At rest striatal neurons show a low 
frequency rate, GPi and SNr neurons show a high rate and tonic discharging 
pattern. In the GPe two types of activity have been recognized: neurons with a 
pausing and slightly lower discharge rate than GPi neurons, and other neurons 
with very low spontaneous rate with occasional high frequency bursts. STN 
neurons fire tonically at medium frequencies (20-30 Hz). Thus, at rest basal 
ganglia nuclei neurons discharge tonically, independent and mainly in a non-
oscillatory way.  
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These studies have demonstrated the existence of neurons within the basal 
ganglia nuclei that change their firing rate (increase or decrease) in relation to 
movement. A clear somatotopic organization within the sensorimotor territory of 
the nuclei has been delineated. Pallidal neurons respond selectively to single 
joint and direction of movement (Brotchie et al., 1991a). Some studies have 
also found specificity related with some parameters of the movement such as 
amplitude and velocity (Crutcher and DeLong, 1984). The majority of pallidal 
neurons increase their firing rates in response to movement thus leading to an 
inhibition of thalamocortical projections and only a small number of cells 
decrease in firing rate. On the basis of these finding Mink (1996) proposed the 
center-surround model, where the primary role of the basal ganglia is to focus 
selection of desired movement and to inhibit competing movements. In this 
model the direct pathway constitute the excitatory center and the indirect 
pathway is proposed to provide the inhibitory surround suppressing competing 
motor programs. Electrophysiological studies have also revealed that neuronal 
activity of the basal ganglia structures occurs relatively late to be involved in 
execution or planning of movements. Initiation of movement is most likely to 
occur at cortical levels.  
Neurons in oculomotor circuit do not change their discharge in respond to all 
saccades, but appear to be activated in respond to attractive targets in the 
environment or to remembered points in visual space. This suggests that basal 
ganglia will respond most likely to facilitate movement in particular 
circumstances or contexts than to operate in a particular type of movement. In 
this line, Brotchie et al. (1991b) demonstrate that GP appears to be more 
involved in movements that are predictable and well practiced. They found that 
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pallidal neurons discharge in a phasic way during a sequential movement task. 
They suggested that phasic discharge may be the “internal cue” to switch from 
one movement to another, particularly when the second movement is 
predictable and automatic (after learning). Further studies have also pointed the 
participation of the GPi in sequential movements (Mushiake and Strick, 1995). 
Other regions of the striatum different to the motor territory respond to 
environmental cues in preparation of the movement.  
Further studies have demonstrated that distinct parts of the striatum respond to 
visual stimuli (tail of caudate and ventral putamen), to visual stimuli of emotional 
significance (ventral striatum) or, environmental events that are cues for 
behavioral responses (head of caudate). The dopaminergic nigrostriatal 
neurons also show responses that are context dependent, particularly they 
respond in relation to reward or predicted reward after learning (for review see 
Marsden and Obeso, 1994a).  
More recently, studies have emphasized the role of neuronal oscillations and 
synchrony in pathological conditions such as Parkinson’s disease. However 
oscillatory activity, although weak, also exists in the physiological state. 
According to the frequency, oscillatory activity can be divided in different bands. 
Oscillations in the 8-30 Hz are the best documented in human striatum, GPi and 
STN. This band is subdivided into 8-13 Hz and 14-30 Hz bands. Oscillations in 
the latter range are known as beta band. Suppression in the beta band is seen 
prior to voluntary movements in normal conditions. An augmentation of the 
power in this band occurs when a pre-prepared movement requires 
cancellation. Beta activity in the cortex behaves in a similar manner that in the 
basal ganglia. These findings suggest that beta band oscillatory activity may 
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play a role in the normal function of the basal ganglia and that their attenuation 
may be necessary for generation of motor behaviours (Brown and Williams, 
2005). 
Alterations in the degree of oscillations and pattern of discharge are seen in 
pathological conditions. Parkinson’s disease is associated with an abnormal 
increase in discharge rate, a greater tendency of neurons to discharge in burst 
and an increase in oscillatory and synchronized activity. The direct connection 
between the cortex and the STN as well as the basal ganglia and thalamus may 
serve to predispose the circuit to synchronize oscillatory activity.  
Cognitive and behaviour functions 
On the basis of anatomical observation is apparent that cortical areas such as 
dorsolateral prefrontal cortex, the lateral orbitofrontal cortex and the anterior 
cingulate/medial orbitofrontal cortices are connected with the basal ganglia. 
These frontal regions are involved in planning, working memory, rule-based 
learning attention, and other aspects of higher executive function. More recently 
a new output from the basal ganglia to the area TE (visual area) of 
inferotemporal cortex has been identified. This cortical area participates in 
higher-order visual functions and in visual working memory.  
The role of basal ganglia in cognition and behaviour is supported by 
electrophysiological, functional imaging and clinical studies (for review see 
Middleton and Strick, 2000). 
Electrophysiological studies in monkeys have stressed that the majority of the 
neurons of the output nuclei do not respond to movement. These neurons are 
located within regions of the GPi and SNr that project to prefrontal cortices. 
Recordings of single neurons in trained primates showed neurons in the SNr 
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that change their activity during the cue and delay periods of the tasks but not 
during the movement period. Other studies have revealed that the responses of 
striatal neurons depend strongly on the reward contingencies of the task. 
Inactivation of the caudate and anterior striatum of primates leads to deficits in 
learning sequences. Moreover some studies have shown that certain outputs 
from the GPi participate in tasks involving the use of working memory. A study 
in primates demonstrated that the inactivation of the GPe using a GABA 
antagonist induced stereotyped behaviours when performed in the limbic part of 
the GPe and, attention deficit and/or hyperactivity when performed in the 
associative territory of the GPe (Grabli et al., 2004). 
Functional imaging studies have demonstrated the activation of caudate 
nucleus during learning of new sequences (Jueptner et al., 1997) and the 
participation of GPi in planning and spatial working memory (Owen et al., 1998). 
Clinical studies support the role of the basal ganglia in cognition.  Lesions or 
diseases involving the striatum in humans (Parkinson’s disease, Huntington 
disease) as well as of the output nuclei are correlated with cognitive impairment. 
In Parkinson’s disease, which is characterized by a reduction in the 
dopaminergic nigrostriatal inputs, deficits in attentional set shifting, working 
memory, planning and problem solving can be identified.  Bilateral lesions of the 
SNr produce deficits in working memory, visual hallucinations and other 
neurological symptoms. Lesions in the pallidum can also produce cognitive 
deficits, particularly in implicit learning, compulsive behaviours and “psychic” 
akinesia.  
Overall there is growing evidence that alterations of the basal ganglia occur with 
neuropsychiatric disorders, such as depression, obsessive-compulsive disorder, 
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Tourette’s syndrome, autism, and attention deficit disorder. DBS of different 
nuclei of the basal ganglia are currently being used or explored to treat some of 
these disorders with encouraging results.  
 
5. PHARMACOLOGY OF THE BASAL GANGLIA 
Four main neurotransmitters act in the basal ganglia: glutamate, GABA, 
dopamine and acetylcholine (Ach). Cortical and thalamic inputs to the striatum 
are glutamatergic as well as thalamocortical projections. With the exception of 
the STN that also uses glutamate, the rest of the basal ganglia nuclei use 
GABA as neurotransmitter. Dopamine has an important modulatory effect on 
the striatum and the levels of dopamine are crucial to determine the output 
activity of the basal ganglia. The role played by acetylcholine is far from being 
ancillary and it might influence striatal output by neuromodulating corticostriatal 
glutamatergic projections. All the basal ganglia nuclei also receive 
serotoninergic input from the rostral raphe nuclei in the midbrain and upper 
pons. The major target for the serotoninergic projections is the medium spiny 
neurons. Animal studies suggest that serotonin may exert a tonic inhibitory 
effect on striatal glutamatergic input and on stimulated dopamine release.  
Glutamate 
Glutamate is an excitatory neurotransmitter employed by corticostriatal, 
thalamostriatal and, thalamocortical projections. It is also the neurotransmitter 
employed by the STN; therefore glutamate is not only the major driving input to 
the basal ganglia but also participates in the intrinsic basal ganglia circuits. 
Glutamate transmission is modulated by dopamine, acetylcholine, GABA and 
nitric oxide. Glutamate has been recently related with the pathogenesis of PD. 
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Studies in rats have demonstrated an increase of concentration and release of 
glutamate from corticostriatal terminals in the striatum following nigrostriatal 
denervation. Accordingly, studies using glutamate receptor antagonists have 
shown that they can promote motor behaviours and intensify the effect of 
Levodopa (Lindefors and Ungerstedt, 1990; Blanchet et al., 1997). 
GABA (Gamma amino butyric acid)
GABA is an inhibitory neurotransmitter used by all the basal ganglia nuclei with 
the exception of the STN. It is used by the medium spiny neurons to project to 
the other basal ganglia nuclei. At the same time the activity of medium spiny 
neurons is also regulated by GABAergic inputs from striatal interneurons. 
Moreover GABA is the neurotransmitter used by the output nuclei to project 
outside the basal ganglia. GPi/SNr neurons fire tonically at rest suppressing 
thalamocortical projections. Among all the cortical inputs that basal ganglia 
receive, they select the desired and appropriate input by suppressing the 
competing and unwanted programs (Hikosaka, 2007). 
Dopamine  
Dopaminergic system innervates all basal ganglia nuclei and probably exerts 
powerful modulatory control of the basal ganglia intrinsic circuits. It arises from 
three main groups of neurons designated as areas, A8 (retrorubral area, RRA), 
A9 (SNc) and, A10 (VTA). According to connectivity and morphological features 
midbrain neurons are divided in a ventral and dorsal tier. The dorsal tier 
includes the dorsal SNc and VTA, and the RRA. Neurons in the dorsal tier are 
calbindin-positive and innervate the ventral striatum and limbic and cortical 
areas, as well as the dorsal striatum. The ventral tier is located in the ventral 
part of the SN and VTA and project to the striatum. Cells in the ventral tier are 
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calbindin-negative and can be divided in a densocellular part and columns of 
dopaminergic neurons that penetrate deeply into the SNr. This last group 
seems to be the first to degenerate in PD.  
The dopaminergic system is separated into three different projection systems: 
the nigrostriatal, mesolimbic and mesocortical system. Although the projections 
of these systems are clearly separated, their neurons of origin in the SN and 
VTA intermingle.  
The nigrostriatal system arises from the SNc, VTA and RRA and project to the 
sensorimotor striatum. The mesolimbic and mesocortical systems originate in 
the VTA and in the dorsal tier of the SN and RRA. Mesolimbic system projects 
onto the limbic striatum, the amygdala and hippocampus, and mesocortical 
system projects onto prefrontal and associative cortices (Smith and Kieval, 
2000). 
There are five types of dopamine receptors that can be classified in two main 
groups, D1-like and D2-like. D1-like receptors include D1 and D5 receptors and 
stimulate adenylyl cyclase. D2-like receptors include D2, D3, and D4 receptors 
and inhibit adenylyl cyclase. They are heterogeneously distributed along the 
striatum and other basal ganglia nuclei.  
The nigrostriatal dopaminergic projections are characterized by their 
convergence with cortical terminals on individual dendritic spine of the spiny 
neurons, which suggests that one of the main functions of dopamine is to 
regulate corticostriatal projections. Dopamine also modulates striatal efferents 
by facilitating the direct pathway via D1 receptors and inhibiting the indirect 
pathway via D2 receptors. Therefore the net effect of dopamine in basal ganglia 
is the facilitation of thalamocortical projections. Activation of dopamine 
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receptors influences neuroplasticity at corticostriatal synapses. Dopamine 
seems to be necessary not only for maintaining and modulating neuroplasticity 
but also for inducing it (long-term potentiation and long-term depression). 
Dopamine also induces plasticity exerted by other neurotransmitters 
(acetylcholine, nitric oxide, endogenous cannabinoids) (Calabresi et al., 2007).  
The action of dopamine is more widespread; Dopaminergic neurons innervate 
the GP and the STN and probably regulate intrinsic circuits of the basal ganglia. 
Interestingly, dopaminergic neurons regulate not only the dopaminergic neurons 
themselves but also the release of GABA within the SNr and therefore the 
output projections of the basal ganglia.  
The mesolimbic system is involved in reward. Dopamine neurons are activated 
by rewards and reward-predicting stimuli. Aversive stimuli however produce 
slower dopamine responses that consist predominantly on depression (Schultz, 
2007). The striatum, frontal cortex, and amygdala also process specific reward 
information but do not participate in the prediction of reward.  
Acetylcholine
The cholinergic system is of crucial importance in determining the final output 
from the striatum to other basal ganglia nuclei. Despite only around 1-2% of the 
striatal neurons are cholinergic interneurons, the striatum contains the highest 
concentration of all the cholinergic markers in the brain. Other source of 
acetylcholine to the striatum comes from the PPN. Cholinergic neurons receive 
glutamatergic and dopaminergic inputs from the cortex and the SNc, 
respectively. Although they are sparse, their dendritic trees arborize profusely 
projecting to the spiny neurons. The fact that cortical glutamatergic and striatal 
cholinergic inputs converge at the level of striatal projection neurons supports 
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the idea that Ach influences striatal function by modulating the corticostriatal 
glutamatergic transmission (Pakhotin and Bracci, 2007; Calabresi et al., 2000). 
Striatal cholinergic neurons act over two main subtypes of muscarinic receptors 
that have opposing effects: M1 receptors, which activate spiny neurons and M2 
receptors with an inhibitory effect. The overall effect of the Ach in the striatum 
might be the long-term potentiation of the glutamate activation of striatal 
projection neurons. 
The classical view that balance between dopamine and Ach is necessary for the 
normal motor control and that the imbalance of both systems is responsible for 
parkinsonian motor symptoms has been recently modified and the current 
evidence is that the main adaptive response to loss of striatal dopaminergic 
afferents is, in fact, the hyperactivity of corticostriatal glutamatergic 
neurotransmission. The benefits observed in PD with anticholinergic drugs 
might be explained by interaction with glutamate-mediated transmission. There 
is also evidence that striatal cholinergic neurons participate in reward-related 
learning although this process seems to be dopamine dependent. 
 
 
 
This chapter has been adapted from Martinez-Torres I, Tisch S, Limousin P. 
The Basal Ganglia. In: Conn M. Eds. Neuroscience in Medicine 3rd edition. 
2008; 401-414
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2. PATHOPHYSIOLOGY OF THE BASAL GANGLIA IN PARKINSON’S 
DISEASE 
2.1 THE BASAL GANGLIA IN  PARKINSON’S DISEASE
The classical model of organization of the basal ganglia into a direct and 
indirect pathway has been used to explain the phenomenology observed in PD. 
Dopamine depletion produced an imbalance between the direct and indirect 
striatal output pathways. The loss of dopaminergic input to the striatum removes 
inhibition from the D2 receptor-mediated GABA/enkephalin indirect pathway to 
GPe, increasing the GABAergic inhibitory tone on the GPe-STN pathway. This 
pathway, which is also inhibitory, becomes underactive, and this results in 
increased burst firing of glutamatergic STN-GPi/SNr pathway, activating the 
GABAergic output of GPi and SNr towards the thalamus and brainstem. 
Dopamine depletion on the direct D1-mediated GABA/substance P/dynorphine 
pathway leads as well to decrease inhibitory tone on GPi/SNr. The final 
consequence of both processed is the increased activity of GPi/SNr neurons 
and therefore an increased inhibition of thalamocortical projections (Figure 1) 
(Obeso et al., 2000). Therefore, depletion of dopamine predicts an 
overinhibition of the GPe, disinhibition of the STN and increased excitation 
(indirect pathway) and reduction of inhibition (direct pathway) of GPi/SNr 
neurons. The result is an excessive activation of basal ganglia output neurons 
and excessive inhibition of motor circuitry, which leads to parkinsonian state.  
The classical model for levodopa-induced dyskinesias (LID) proposed the 
opposite of events that occur in the parkinsonian state. Excessive dopaminergic 
stimulation of the striatum would in turn lead to a decreased basal ganglia 
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output to the motor thalamus by an increase of inhibition of the indirect pathway 
and reduced excitatory input to the direct pathway (figure 1). Several studies in 
animals and patients confirm the imbalance between direct and indirect 
pathways in parkinsonian and dyskinetic state (table 1).  
However, this model has turned out to be far too simplistic to explain the 
amount of biochemical and electrophysiological data known nowadays and 
there are some observations that cannot be explained by this model. The most 
prevailing apparent paradox of experimental and clinical findings has been that 
although reduction of GPi neuronal firing rates is associated with choreic 
dyskinesias, lesions or blockade of the GPi is not (Marsden and Obeso, 1994b). 
According to the model, one would expect that the more GPi activity is 
decreased, the more severe dyskinesias should be. In contradiction to this 
expectation, dyskinesias are only not worsening by GPi lesions but they are 
largely improved after pallidotomy of DBS of the GPi. More recently, Dybdal and 
colleagues (Dybdal et al., 2013) reported that chemical blockade of the SNr in 
monkeys does in fact induce choreiform dyskinesias, which is exactly the 
expected consequence of reducing basal ganglia output. Nevertheless, this 
finding needs to be further confirmed. 
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Figure 1 Classic model of BG in normal, parkinsonian and dyskinetic 
conditions. Black arrows indicate inhibitory projections and white arrows 
represent excitatory projections. The thickness of the arrows indicates the 
degree of activation of each projection. Note that the striatum communicates 
with output neurons in the globus pallidus pars intema (GPi) and substantia 
nigra pars reticularis (SNr) through a direct pathway, and with synaptic 
connections in the globus pallidus pars externa (GPe) and the subthalamic 
nucleus (STN) through an indirect pathway. Dopamine is thought to inhibit 
neuronal activity in the indirect pathway and to excite neurons in the direct 
pathway. In the parkinsonian state, dopamine depletion leads to disinhibition of 
dopamine D2-receptor-bearing striatal neurons in the indirect pathway leading 
to increased inhibition of the GPe, and disinhibition of the STN. The resulting 
overactivity in STN neurons leads to excess excitation of neurons in the 
GPi/SNr and overinhibition of thalamo-cortical and brainstem motor centres 
resulting in parkinsonism. Dyskinesia induced by L-dopa is characterized by 
reduced activity in the STN. The classical model proposes that this is due to 
dopamine-induced overinhibition of striato-GPe neurons, resulting in excess 
inhibition of the STN and reduced activation of GPi/SNr. The net result is 
reduced inhibition of thalamo-cortical neurons with excess drive of cortical 
motor areas resulting in dyskinesia. Abbreviations: DA, dopamine; PPN: 
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pedunculopontine nuclei; SNc, substantia nigra pars compacta; VL, ventralis 
lateralis (Adapted from Guridi et al., 2012).  
 
Table 1. Observations supporting the classical model  
 In MPTP-treated monkeys, an increase in STN and GPi/SNr activity has been 
demonstrated using 2-deoxyglucose uptake as a marker of synaptic afferent activity 
(Mitchell et al., 1989),  in situ hybridization of cytochrome oxidase subunit I mRNA 
as a measure of mitochondrial activity (Vila et al., 1997), glutamic acid 
decarboxylase (GAD) mRNA as a measure of GABA activity (Herrero et al., 1996) 
and neurophysiological studies measuring the mean neuronal firing rate in single-
cell recordings (Filion and Tremblay, 1991). 
 
 Lesions or high frequency stimulation of the STN in MPTP-treated monkeys and 
patients with PD improves parkinsonian features and reduces hyperactivity in the 
GPi/SNr (Wichmann et al., 1994; Guridi et al., 1996; Limousin et al., 1998).  
 
Abbreviations: GPi: Globus pallidus pars interna internus; MPTP: 1-methyl-4-
phenyl-1,2,3,6 tetrahydropyridine;  SNr: substantia nigra pars reticulate;  STN: 
subthalamic nucleus (Adapted from Obeso et al., 2000). 
 
Considering the limitations of the classical model, Obeso and colleagues (2004) 
proposed a new scheme for the model. The new model incorporates 
dopaminergic projections to other basal ganglia nuclei rather than striatum and 
the importance of internal loops such as the STN-GPe-GPi loop. This model 
proposes that in the presymptomatic phase dopamine depletion would affect 
mainly projections to STN rather than striatal innervation, rendering the STN 
hyperactive. Therefore the GPe would be overstimulated by the STN and 
functionally operative. In turn this would lead to an increased inhibition of GPi, 
which may partially compensate for the augmented excitation from the STN and 
reduced inhibition on the direct pathway. With progression of nigrostriatal 
degeneration both striatopallidal projections are altered and parkinsonian 
symptoms become evident. There is an increased inhibition of the GPe from the 
striatum, which becomes hypoactive and is no longer compensated by STN 
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hyperactivity, resulting in overactivity of GPi output and abnormal inhibition of 
motor areas (figure 3).  
Additionally, glutamate corticostriatal system has become more and more 
involved in PD pathophysiology. In PD and animal models, striatal dopaminergic 
denervation alters glutamatergic synapses in medium spiny neurons, affecting 
their capacity to function normally and to modulate basal ganglia output. This 
hypothesis is supported by the fact that cortical stimulation in animal PD models 
reverses akinesia and reduced firing rate of GPi and STN (Drouot et al., 2004). 
Despite the complexity derived from cellular and electrophysiological studies in 
BG functioning, the hypothesis of the classical model has been fully supported 
using transgenic animals and optogenetics (Kravitz et al., 2010). In this study, 
direct stimulation of the indirect pathway promoted movement arrest while 
activation of the direct pathway was prokinetic and ameliorated parkinsonian 
signs in a mouse model of PD. 
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Figure 3 Modification of basal ganglia circuitry in different stages of 
Parkinson’s disease. (a) Main basal ganglia connections in the normal state. 
Green arrows correspond to the dopaminergic nigrostriatal and extrastriatal 
projection. Blue and red arrows indicate inhibitory GABAergic efferents and 
excitatory glutamatergic efferents, respectively. Thickness of the arrows 
indicates relative functional activity. Abbreviations: GPe, globus pallidus pars 
externa; GPi, globus pallidus pars interna; SNc, substantia nigra pars 
compacta; STN, subthalamic nucleus. (b) Proposed basal ganglia modifications 
induced by dopamine depletion in the presymptomatic stage of Parkinson’s 
disease. Loss of dopaminergic projections leads to hyperactivity of the STN 
before the onset of functional changes in the putamen. GPi output is maintained 
at this stage through increased inhibition from the GPe, which is excited by the 
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STN. (c) Further dopamine loss in the putamen reaches a level that cannot be 
compensated for by intra- striatal mechanisms. This decreases inhibition of the 
‘direct’ putamen–GPi projection and excessive inhibition of the GPe, which 
becomes hypoactive. The latter leads to further hyperactivity of the STN and 
GPi, accounting for the onset of parkinsonian motor features. (From Obeso et 
al., 2004). 
 
2.2 OSCILLATORY ACTIVITY OF THE BASAL GANGLIA  
Due to the limitations of the classical model, over the past decade attention has 
switched from considerations of discharge rate to characterisation of 
synchronised activity within the BG network. There is increased evidence of a 
variety of oscillatory phenomena in the BG and in associated regions of the 
thalamus and cortex. Most of these studies have been performed in rodents and 
primates and significant advances have been done from implanted DBS 
electrodes in PD patients. It now appears that exaggerated synchronisation of 
neural activity plays an important role in pathological conditions. Although less 
well established, oscillatory activity is also present in normal conditions and 
might be important for normal motor processing (Gatev et al., 2006). 
There are two principal modes of synchronised activity within the human 
subthalamo-pallidal-thalamo cortical circuit:  < 30 Hz and > 60 Hz.  Local field 
potential activity in the 8-30 Hz range is the best characterized. Because its 
association with pathological conditions it has been further subdivided into two 
bands: 8-13 and 14-30 Hz. The later range is named as “beta band” and it is 
particularly prominent in parkinsonian states on withdrawal of dopaminergic 
treatment in both the STN and GPi.  
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Oscillatory activity is modulated by movement as well as by the level of 
dopaminergic activity; beta band is associated with maintenance of posture and 
inhibition of new movements; a strong beta band in the STN and GPi is found in 
the akinetic state and it is suppressed prior to and during movement as well as 
following dopaminergic treatment. On the contrary, activity at frequencies above 
60 Hz is found in parkinsonian patients during levodopa treatment and, these 
oscillations are enhanced by voluntary movement (Brown, 2003). These 
findings suggest that beta band activity would be antikinetic while activity above 
60 Hz would be mostly prokinetic. On the other hand oscillatory activity at low 
frequencies (below 10 Hz) have been linked to dystonia and levodopa induced 
dyskinesias in PD patients (Silberstein et al., 2003; Alonso-Frech et al., 2006). 
 
PATHOLOGICAL OSCILLATORY ACTIVITY IN BASAL GANGLIA-
THALAMOCORTICAL CIRCUITRY IN PARKINSON’S DISEASE
Loss of dopaminergic innervation is known to induce abnormalities in neuronal 
firing rate in the BG and connected regions of the thalamus and cortex. 
(Rommelfanger and Wichmann, 2010).  Considering the mass of evidence in 
conflict with the classical animal model, it now seems more clear that neuronal 
discharge pattern, more than firing rate alone, plays a central role in the genesis 
of parkinsonian signs. Increased burst neuronal discharge and abnormal 
synchronization in the neurons of the GPi, GPe, STN, thalamus and motor 
cortices - in animal models and/or PD patients – have been reported (Rubin et 
al., 2012; Brown, 2003). Burst discharges are often described as “oscillatory” 
and, indeed both may represent two aspects of one underlying phenomenon 
(Rivlin-Etzion et al., 2008). Oscillatory activity has been documented in the 
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STN, GPi, GPe and tonically active striatal interneurons in animal models and 
PD patients (Rubin et al., 2012). There is also evidence for increased synchrony 
in the neurons of the BG nuclei in PD (Hammond et al., 2007). Excessive 
synchronization is lower with systemic dopamine receptor agonist treatment, 
suggesting that segregation of neuronal activity is, at least in part, maintained 
by dopamine presence. Synchronous firing – closely linked to oscillatory 
discharges – is found across the BG nuclei  (Hammond et al., 2007). Oscillatory 
and synchrony recorded at the level of single neurons has been shown to be 
coherent with concomitant recorded beta-band LFP oscillations (Kuhn et al., 
2005). Synchronized oscillatory activity in the BG is closely linked to oscillations 
in cortex in Parkinsonism, suggesting the existence of large-scale oscillatory 
synchronization of the entire basal ganglia-thalamocortical circuitry. Global 
engagement of basal ganglia-thalamocortical circuitry in synchronized 
oscillations may severely disrupt information processing at all levels of the 
circuitry and contribute to akinesia. However, the mechanism by which 
dopamine loss promotes synchrony and the anatomical location at which this 
occurs is still uncertain. As commented above, dopamine input is not only lost in 
the striatum but also in other BG nuclei and BG-related structures (thalamus 
and cortex), which may therefore suffered changes in their neuronal activity 
(Rommelfanger and Wichmann, 2010). There is experimental evidence that 
oscillatory patterns can arise and perpetuate in the GPe-STN loop (Holgado et 
al., 2010). Other mechanism proposed is oscillations driven to the STN by 
cortico-subthalamic inputs and propagated to related nuclei (Magill et al., 2004).  
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LFP recording from DBS implanted electrodes in GPi and STN of PD patients 
after an overnight withdrawal of antiparkinsonian medication have shown power 
spectra to predominate in the 8 to 30 Hz range  - beta band – (Brown et al., 
2001; Levy et al., 2002). Levodopa reduces beta synchrony and this reduction 
is correlated with improvement in rigidity and bradykinesia (Kühn et al., 2006). 
In contrast to these studies, several animal studies have found that oscillatory 
activity appears only after the emergence of parkinsonism and, therefore, 
cannot be fully responsible for it (Leblois et al., 2007). Motor impact of BG 
oscillations at various frequencies can be tested through the implanted DBS 
electrodes. Motor impairments can be induced with stimulation at beta band 
frequencies (Moro et al., 2002; Timmermann et al., 2004; Chen et al., 2007; 
Eusebio et al., 2009) while high frequency stimulation (above 100 Hz) is widely 
used because its antikinetic effects (Moro et al., 2002).  Indeed, several studies 
corroborate a reduction of beta LFP power in the STN after STN high frequency 
stimulation Bronte-Stewart et al., 2009; Kühn et al., 2008; Meissner et al., 2005) 
although this was not replicated in another study (Foffani et al., 2006).   
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3. SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION FOR 
PARKINSON’S DISEASE
Overview of Parkinson’s disease treatment  
Because most of the major motor symptoms of PD are related to striatal 
dopaminergic deficit, the first line of treatment  is dopaminergic medication. 
Levodopa continues to be the most powerful dopaminergic agent. Unfortunately 
up to 75% of patients develop motor complications (motor fluctuations and 
dyskinesias) after 5 years of treatment (Quinn et al., 1987). The next most 
powerful dopaminergic drugs after levodopa are the dopamine agonists: 
bromocriptine, pergolide, lisuride, piribedil, ropinirole, pramipexole, rotigotine, 
cabergoline, apomorphine. They may differ in their affinity for dopamine 
receptor subtypes and in their effectiveness. The majority of them are effective 
orally, while others have to be administered subcutaneously (apomorphine) or 
trandermically (rotigotine). They can be used as monotherapy or in combination 
with levodopa. They are less powerful than levodopa but they are less likely to 
induce dyskinesias (Schrag et al., 1998).  However, adverse effects are more 
common with dopamine agonist than with levodopa. Other drugs aim to reduce 
levodopa metabolism. Catechol-O-methyltransferase (COMT) inhibitors - 
tolcapone and entacapone – extend the plasma half-life of levodopa and 
prolong the duration of action of each dose of levodopa. Therefore they have 
been proved to be useful treating the wearing off phenomenon. Monoamine 
oxidase (MAO) inhibitors type B – selegiline and rasagiline - offer mildly 
symptomatic benefit. A possible neuroprotective effect has been shown with 
rasagiline (Olanow et al., 2009). Other non-dopaminergic agents are also useful 
to treat some motor symptoms. Anticholinergic drugs, although less effective 
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than dopaminergic drugs, may be especially useful for alleviating tremor. 
Amantadine, which has both dopaminergic and antiglutamatergic properties, 
reduces choreic dyskinesias induced by levodopa (Del Dotto et al., 2001). Other 
agents, such as adenosine A2A antagonist have shown conflicting effects. 
In the lack of any neuroprotective treatment, onset of PD treatment should be 
delayed until symptoms become troublesome to the patient. Older patients are 
usually started on levodopa due to the risk of side effects related to dopamine 
agonists. In younger patients (less than 60 years of age) treatment is started 
with dopamine agonist in order to postpone levodopa induced motor 
complications. However, as the disease progresses levodopa has to be added 
to the treatment. Motor fluctuations in an early stage can be improved by adding 
COMT inhibitors, MAO inhibitors and decreasing the interval of levodopa doses. 
Peak of dose dyskinesias may benefit by adding amantadine and also 
fractioning the dose of levodopa. However, when motor fluctuations and 
dyskinesias aggravate, oral treatment may be insufficient controlling the 
symptoms. At this stage, surgical therapies, such deep brain stimulation, or 
continuous infusion of dopaminergic agents – subcutaneous apomorphine or 
intrayeyunal levodopa/carbidopa – provide additional benefit.  
Deep brain stimulation for Parkinson’s Disease
Deep brain stimulation (DBS) can provide additional help for selected patients 
whose symptoms are not controlled sufficiently by medication. DBS has 
progressively replaced brain lesioning, such as thalamotomies and 
pallidotomies, over the last 20 years. After a few earlier reports on the use of 
DBS (Sem-Jacobsen, 1965; Bechtereva et al., 1972), the first target in the 
modern era of DBS was the ventro-intermediate nucleus (Vim) of the thalamus 
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in 1985 (Benabid, 1987). Thalamic DBS was initially performed contralateral to 
thalamotomies to try to reduce the morbidity of bilateral ablative procedures, 
particularly on speech and balance. In view of its efficacy on tremor, 
adaptability, and low morbidity, thalamic DBS was progressively performed 
bilaterally and the positive effect on tremor was confirmed (Benabid et al., 
1991). Thalamic DBS provided limited effect on other symptoms, however, such 
as limb bradykinesia or rigidity and no favourable effects on gait and balance.  
The limits to the effectiveness of thalamic DBS prompted the application of this 
procedure to new targets, the internal part of the globus pallidus (GPi) and the 
subthalamic nucleus (STN), in parallel in 1993 (Limousin et al., 1995; Siegfried 
and Lippitz, 1994).  The application of DBS to GPi was based on the noted 
similarities of the effects of a lesion and high-frequency stimulation to the 
thalamus and the knowledge on the effect of pallidotomies (Laitinen et al., 
1992). The application to the STN was based on basic research work on the 
STN in 1-methyl1-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys; 
the animals displayed and excess of activity in the STN and improvement of 
parkinsonian symptoms with lesion or high-frequency stimulation of the STN 
(Bergman et al., 1990; Aziz et al., 1992; Benazzouz et al., 1991). STN has 
progressively become the preferred target for DBS in PD, because it has been 
found to have a positive effect on a wide range of symptoms (Limousin et al., 
1998).  Furthermore, STN DBS has been shown to be superior to best medical 
treatment (Williams et al., 2010; Weaver et al., 2009; Deuschl et al., 2006) and 
it is a cost-effective procedure (Valldeoriola et al., 2007; Fraix et al., 2006; 
Meissner et al., 2005; Weaver et al., 2012a; Dams et al., 2013). Literature 
suggests a greater impact of STN DBS on parkinsonian symptoms; however 
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three randomized controlled trials comparing the effect of both STN and GPi 
DBS found similar effectiveness for both targets but lower risk for cognitive and 
neuropsychiatric problems favouring the GPi (Anderson et al., 2005; Follet et 
al., 2010; Weaver et al., 2012b). More recently, another randomized trial found 
similar effectiveness for STN and GPi and similar frequency of cognitive and 
psychiatric side effects. Nevertheless, STN DBS was associated with larger 
improvements in the off-medication phase and levodopa equivalent daily dose 
reduction, suggesting that STN should be the preferred target (Odekerken et al., 
2013).  
STN DBS has the advantages of reduction of dopaminergic medication and 
needs lower stimulation parameters than GPi DBS leading to a longer battery 
life. Nevertheless it has been found to be associated with greater risk of 
cognitive and neuropsychiatric problems compared to GPi DBS   
 Long term STN DBS outcome has shown a progressive decline over time. Axial 
symptoms such as freezing, postural stability, and speech deteriorate both off 
and on-medication. However at 5 and 8 years STN DBS still provides a 55% 
and 39% improvement on off-medication scores, respectively (Krack et al., 
2003; Fasano et al., 2010).  Nevertheless, benefit on dyskinesia and 
antiparkinsonian medication remains steady over time.  
Preoperative response to levodopa predicts good STN DBS outcome in the 
short term (Welter et al., 2002).  In the long term STN DBS outcome is mainly 
limited by deterioration on axial symptoms. Main predictors for long-term 
deterioration of postural stability are worse scores on postural stability pre-DBS 
both off and on-medication and higher doses of dopaminergic medication pre-
DBS (Fasano et al., 2010). 
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4. STIMULATION PARAMETERS IN SUBTHALAMIC NUCLEUS DEEP 
BRAIN STIMULATION: STRATEGIES FOR SELECTION OF APPROPIATE 
STIMULATION PARAMETERS 
STN DBS is a clinically effective treatment for selected patients with PD. 
Although high-frequency (HF) DBS mimics the effects of ablation, its 
mechanism of action is unclear. Presently there are few guidelines to inform 
selection of stimulation parameters (SP), and programming of stimulation is 
essentially an empirical process, with associated difficulties of time and 
expenses. Along with accurately placed electrodes, successful DBS depends 
on properly set stimulation parameters. Rationally selected stimulation 
parameters may increase the range between clinical effects and side effects, 
use less power, and required less time-intensive programming. The parameters 
that can be controlled are: electrode polarity (electrode’s geometry), voltage, 
pulse width duration and frequency (figure 1). 
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Figure 1. Stimulation parameters for deep brain stimulation  
4.1 ELECTRODE GEOMETRY 
The DBS electrode used in STN DBS (model 3389, Medtronic Neurological 
Division, Minneapolis, Minnesota, USA) has four platinum-iridium cylindrical 
surfaces (1.27 mm diameter and 1.5 mm length) and a centre to centre 
separation of 2 mm. Contact 0 is the lowermost and contact 3 is the uppermost. 
Electrode geometries include monopolar and bipolar stimulation. In each 
configuration there is a cathode or negative electric potential (sink of current), 
and an anode, or positive electric potential (source of current). The 
neuroestimulator can only be set as an anode, and if so, no electrode’s contact 
can be set as an anode. Current flows from the anode to the cathode, 
depolarizing the neuronal elements nearest the cathode and hyperpolarizing 
neuronal elements nearest the anode. In monopolar stimulation one (single 
monopolar) o more contacts (double, triple monopolar) of the electrode are 
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selected to be the cathode and the neurostimulator is set as the anode. In these 
cases the anode and cathode are relatively distant from each other leading to a 
broad extracellular electric potential distribution. In bipolar stimulation one or 
more electrode’s contact are set as the cathode and one as the anode, and the 
current is more focus than in monopolar configuration. Monopolar stimulation is 
generally the first option for current delivery. Double monopolar is reserved 
when a single electrode’s contact is insufficient to produce an optimal effect. 
Bipolar stimulation may be preferred if a narrower current to reduce side effects 
is desired (figure 2) (Volkmann et al., 2002; Deuschl et al., 2006).  
 
 
Figure 2. Electrode’s geometry configuration and current field generation. 
A) Unipolar or monopolar stimulation and B) Bipolar stimulation. In monopolar 
configuration radial current diffusion covers an approximate spherical field 
around the electrode and lower stimulation intensity is required than with bipolar 
to achieve equivalent clinical benefit. With bipolar stimulation current field is 
narrower and more focussed with maximal effect near the cathode; higher 
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stimulation intensity is required than with monopolar stimulation (Modified from 
IMPACT-MD: DBS Programming and Troubleshooting, Medtronic).  
 
4.2 STIMULATION PARAMETERS 
Stimulation parameters that can be adjusted are voltage, pulse width and 
frequency. While voltage and pulse width can be set independently for each 
channel (right or left electrode), frequency has to be set at the same range for 
both.  Mean STN DBS stimulation parameters are 3 volts (V), 82 microseconds 
(s), and 152 Herts (Hz) (Obeso et al., 2001). The optimal combinations of the 
stimulation parameters would best reduce symptoms, minimize side effects and 
power consumption.  
AMPLITUDE 
The stimulus amplitude required to activate neural elements depends on the 
spatial relationship between the electrode and the nerve fibres. As the distance 
between the active contact and the neural element is increased, the stimulus 
amplitude required to stimulate neural elements increases non-linearly. Voltage 
is a crucial factor for ameliorating parkinsonian symptoms (tremor, rigidity and 
bradykinesia). Nevertheless, DBS studies have shown that the clinical benefits 
saturate above a certain voltage. Tremor, bradykinesia and rigidity improved 
between 2 and 3 volts (V) and do not continue to improve beyond 3 V (Moro et 
al., 2002).  Besides higher voltage is associated with adverse effects.  
FREQUENCY 
DBS has been found to be effective for reduction of rigidity, tremor and 
bradykinesia at frequencies above 50 Hz (Limousin et al., 1995) with a 
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maximum benefit at 185 Hz but larger stimulation amplitudes are required at low 
frequencies. A significant improvement on symptoms occurs increasing 
frequency from 50 to 130 or 185 Hz, whereas no significant improvement is 
found for increments from 130 to 185 Hz (Moro et al., 2002).  A positive effect 
on freezing episodes has been found with stimulation at 60 Hz (Moreau et al., 
2008; Xie et al., 2012). Frequency of 5 Hz significantly worsens bradykinesia 
and frequencies around 30 Hz can induce postural tremor (Moro et al., 2002). 
Rigidity improves above 33 Hz and continues improving up to 185 Hz. 
Bradykinesia and tremor do not improve with frequencies below 50 Hz 
regardless the voltage used (Moro et al., 2002). This shows that frequency is 
along with voltage a critical parameter for DBS.  
 
PULSE WIDTH 
Pulse widths used in STN DBS are usually of 60 or 90 μs. Short pulse widths 
increase the therapeutic window (range from clinical benefit and appearance of 
adverse effects). However, as pulse width is decreased the stimulus intensity to 
elicit a clinical improvement on parkinsonian symptoms increases (Rizzone et 
al., 2001). Improvement on parkinsonian symptoms are seen with higher pulse 
widths but the effect is not as clear as for voltage or frequency.  Bradykinesia 
improves at pulse widths of 60 μs while rigidity experience a progressive 
improvement as pulse width is increased. Variation of pulse width does not 
affect tremor (Moro et al., 2002). This favours the use of narrowest pulse widths 
(60 μs), a setting that has a beneficial impact on energy consumption. 
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4.3 CURRENT CHALLENGES FOR STIMULATION PARAMETERS 
SELECTION 
Current challenges for selection of optimal stimulation parameters include a 
large number of degrees of freedom, electrode geometries combinations, the 
unknown effects of stimulation, the complexity of the responses and the 
variability and uncertainty in electrode positioning.  
Electrode geometry results in 65 possible electrode configurations and there are 
nearly 13 000 combinations of pulse width, frequency and voltage within the 
recommended charge density (Kuncel and Grill, 2004). 
The complexity of symptoms responses also contributes to the difficulty of 
selecting the appropriate stimulation parameters. The impact of stimulation on 
rigidity, tremor and bradykinesia is usually seen within minutes, although 
reaching a maximal effect may take longer (from hours to days) (Krack et al., 
2002; Volkmann et al., 2002; Temperli et al., 2003). Programming is further 
complicated by the residual effect of stimulation as symptoms may take hours to 
return completely once the stimulation is switched off (Temperli et al., 2003).  
This has probably a major impact when programming involves a change in the 
stimulated contact and therefore of the stimulation area.  
Since the mechanism of action of DBS is not well known, there is no way to 
select stimulation parameters bases on its physiological action. General 
guidelines are available to help clinicians selecting the appropriate parameters 
(Krack et al., 2002; Volkmann et al., 2002); however, these algorithms are 
vague and based on the acute effect of the stimulation and do not warrant a 
long-term sustained benefit. Furthermore, placebo effect is well known to occur 
in Parkinson’s disease and it is present on STN DBS programming as well, 
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especially for bradykinesia (Mercado et al., 2006).  One of the aims of this study 
is to investigate whether the acute and chronic effect of stimulation parameters 
differ and if the acute effect can consistently predict a sustained benefit.  
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5. SUBTHALAMIC AREA AND OPTIMAL STIMULATION SITE IN STN DBS 
FOR PARKINSON’S DISEASE
5.1 THE SUBTHALAMIC AREA: SUBTHALAMIC NUCLEUS AND 
SURROUNDING STRUCTURES 
The subthalamic nucleus is a complex, biconvex lens-shape structure 
surrounded by dense bundles of myelinated fibres. Its dimensions are 
approximately  9x7x4 mm (length x height x breadth). STN is bordered on its 
anterior and lateral sides by fibres of the internal capsule, while posteromedially 
limits with the prelemniscal radiation and red nucleus. The dorsal border of the 
STN is with the Forel’s Field H2 (lenticular fasciculus) anteriorly, and field H1 
(thalamic fasciculus) posteriorly (Gross et al., 2006). Dorsomedially to the STN 
lays the rostral zona incerta and posterior to the STN the caudal zona incerta 
(Plaha et al., 2006).  Ventral limits of the STN are the cerebral peduncle and the 
substantia nigra ventromedially (Gross et al., 2006). Pallidolfugal fibres crossing 
the internal capsule pass over the dorsal and medial surfaces of the STN (figure 
1). 
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Figure 1. Superior view of a three-dimensional atlas model of the 
subthalamic area. Subthalamic nucleus (STN), Red Nucleus (RN), fasciculus 
cerebellothalamicus (fct), ansa lenticularis (al), fasciculus lenticularis (fl), 
fasciculus thalamicus (ft), substantia nigra pars reticulata (SNr), substantia nigra 
pars compacta (SNc), internal segment of the globus pallidus (GPi), and 
external segment of the globus pallidus (GPe). A DBS electrode is placed in the 
posterodorsal area of the STN (From Aström et al., 2010). 
5.2 OPTIMAL STIMULATION SITE FOR STN DBS IN PARKINSON’S 
DISEASE 
Since the introduction of STN DBS as a surgical treatment for 
Parkinson’s disease, several studies have reported significant benefits on PD 
motor symptoms both in the short and long term (Limousin et al., 1998; Krack et 
al., 2003; Fasano et al., 2010). High frequency stimulation mimics some effects 
induced by lesions in the same target (Aziz et al., 1992).  However, despite the 
similitude, the mechanism of action of DBS is poorly understood. Subthalamic 
nucleus is the most commonly used target for PD.  Nevertheless there is 
substantial debate regarding the optimal anatomical stimulation site within the 
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subthalamic area. The areas most frequently proposed are the dorsolateral 
segment of the STN (known to be its sensorimotor territory) (figure 2), and the 
region dorsally adjacent to it, in the region of pallidofugal fibres and rostral zona 
incerta (table 1). Some groups had found that although stimulation of both areas 
are equally effective, active contacts located in the fibres tracks require less 
stimulation power (Voges et al., 2002; Hamel et al., 2003).   Yet other groups 
have proposed other areas, such as caudal zona incerta (Plaha et al., 2006) 
and prelemniscal radiation (Velasco et al., 2001).   
Even though the mechanism of action of DBS remains controversial it is 
well known that stimulation does not only affect cell bodies but also fibre tracks 
“en passant” along the stimulation area. Since excitability of axons is greater 
than that of the soma, modulation of subthalamic projections is very likely to 
occur (Hamel et al., 2003). Taking into account that electrical stimulation driven 
through the surface of each contact of the quadripolar electrode is capable to 
affect a tissue area of 2-3 mm  (Ranck, 1975) and, given the small size of the 
STN and its close relationship with surrounding fibres; stimulation through 
contacts located at both dorsolateral segment of the STN or just dorsal to it 
would most likely affect both regions.  
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Figure 2. The three functional territories of the subthalamic nucleus. The 
sensorimotor territory is in green, the associative territory in purple, and the 
limbic territory in yellow. Anterior view (A), lateral view (B) and superior view (C) 
with the red nucleus (in orange) and substantia nigra (in grey) (From Yelnik et 
al., 2007). 
Table 1. Optimal stimulation sites proposed for STN DBS in PD  
Stimulation sites References 
Dorsolateral STN Lanotte et al., 2002 
Saint-Cyr et al., 2002 
Yelnik et al., 2003 
Hamel et al., 2003 
Zonenshayn et al., 2004 
Dorsolateral border 
zone
Lanotte et al., 2002 
Saint-Cyr et al., 2002 
Voges et al., 2002 
Hamel et al., 2003 
Herzog et al., 2004 
Godinho et al., 2006 
Caudal ZI Kitagawa et al., 2005 
Plaha et al., 2006 
Prelemniscal radiation Velasco et al., 2001 
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Active contact of the DBS electrode for chronic stimulation is selected on 
based of its clinical efficacy. Therefore its position reflects the optimal 
anatomical site as its efficacy is systematically compared with that of the other 
contacts. Most of the studies reported above have used this approach to define 
the optimal stimulation site. With current guidelines for stimulation 
programming, selection of the optimal contact is performed based on the acute 
effect and usually without objective quantification of symptoms. Furthermore it is 
assumed that stimulation parameters and stimulated contact remained stable 
after the first year after surgery. However Moro and co-workers demonstrated 
substantial improvement with reprogramming in otherwise STN DBS chronic 
stable patients (Moro et al., 2006).  In the subgroup of patients that experienced 
improvement in motor symptoms, active contact change in 68% of the 
electrodes. A previous study performed at our institution (N=22, restropective 
data from time to surgery until six months after) (Odenkerken et al., 2005 
unpublished) showed that active contact moved to a more dorsal, posterior and, 
right position in some patients while in others, remained unchanged.  Therefore 
as stimulation site may change over time, probably reflecting suboptimal 
selection of the active contact in previous programming sessions; its seems 
rational to asses the optimal stimulation site taking into account previous 
changes in the stimulation parameters with objective quantification of 
symptoms. This is one of the points that this study tried to address. Evolution of 
the stimulation site was studied throughout three consecutive adjustment 
sessions, evaluating both acute and chronic effect. Final electrode position 
would represent the optimal stimulation site. Site of stimulation was determined 
by visualizing electrode’s artefact on postoperative MRI. Electrode’s contacts 
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coordinates were transposed onto preoperative MRI and site of stimulation was 
defined based on anatomical criteria.  This certainly represents a more accurate 
approach than to transpose coordinates onto stereotactic brain atlases given 
the interindividual variability (Ashkan et al., 2007).  However one limitation of 
this method is to define the rostro-caudal axis, as MRI slices used in this study 
had 2 mm thickness. Furthermore, we investigated the relation of the number of 
electrode’s contacts considered to be optimally located with clinical outcome, 
types of adjustment required and efficiency of stimulation.  
 
5.3 THE VALUE OF MAGNETIC RESONANCE IMAGING FOR SELECTION 
OF THE OPTIMAL THERAPEUTIC CONTACT 
As previously stated, the best electrode’s contact is selected based on its 
clinical efficacy (the best contact will be the most effective at lowest voltage and 
highest threshold for side effects). Selection of the optimal stimulation 
parameters requires well-trained neurologists and collaboration from patient. 
Several difficulties are encountered when programming stimulation parameters. 
First stimulation parameters should be programmed in the condition off 
medication in order to be able to test the effect of the stimulation on 
parkinsonian symptoms. Even when dopaminergic medication is withdrawn for 
12 hours patients may not be in a complete off-state and therefore off-
symptoms become difficult to assess. In addition, withdrawal of dopaminergic 
medication may cause discomfort and may difficult transfer of patients to clinic. 
Besides it is a time consuming procedure and frequently the response from 
stimulating each contact serially at several-minute intervals can be confounded 
by the carry over effects of the previously stimulated contact. Adequate patient 
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cooperation, which can be easily affected by patient’s motivation, is essential. 
This renders the outcome of DBS programming highly dependent on the 
neurologist capability and patient state and cooperation.  
A more rational and objective approach for selection of the active contact 
may be to select the contact based on its anatomical location. Although most 
favourable site of stimulation remains controversial it is quite likely that 
dorsolateral segment of STN or the area just rostral to it may represent the 
optimal stimulation site. Given the dimensions of the 3389 Medtronic DBS 
electrode used for STN DBS (7.5 mm length with four platinum/iridium contacts 
of 1.5 mm each separated by 0.5 mm gaps) and surgical targeting methods, at 
least one or two contacts will lay within the STN (one in the sensorimotor part of 
the STN) and one in the rostral area above it. Therefore, selection process for 
active contact could be limited to two contacts. This approach may simplify 
current strategies of stimulation parameters selection and would be in benefit of 
the patients and health system costs. In this direction we explored the 
concordance of active contact and best MRI contact. Best MRI contact was 
defined as the one to be located within the STN (central or superior segment) or 
just rostral to the superior segment. A good concordance would support the 
hypothesis that active contact can be selected based on its anatomical location.  
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6. SUBTHALAMIC NUCLEUS LOCAL FIELD POTENTIALS RECORDINGS IN 
STN DBS IN PARKINSON’S DISEASE
Therapeutic efficacy in STN DBS is limited by difficulties in consistently and 
correctly targeting the STN. Misplaced electrodes might result in poor outcome 
of STN DBS and side effects. Besides direct targeting on MR images, 
microelectrode recordings are often performed to verify localization of the 
functional sensorimotor STN during surgery (Gross et al., 2006). However, this 
technique prolongs surgery time and has been associated with increased risk of 
intraoperative haemorrhage (Binder et al., 2005).  In addition, microelectrodes 
must be withdrawn prior to introduction of the DBS electrode, which may 
introduce further errors, especially in the rostro-caudal plane. Local field 
potentials (LFP), which translated the activity of aggregate activity of neuronal 
populations, can be easy and quickly recorded from the DBS macroelectrode. 
Although a clear connection between LFP beta activity and symptoms of PD still 
remains uncertain (Kühn et al., 2009), oscillatory activity in this frequency range 
can be considered a hallmark of parkinsonian STN, in particular of its 
dorsolateral part (Kühn et al., 2005; Zaidel et al., 2010). Pathological oscillations 
are suppressed by volitional movement (Amirnovin et al., 2004; Zaidel et al., 
2010), dopaminergic treatment (Brown et al., 2001; Levy et al., 2002; Priori et 
al., 2004; Weinberger et al., 2006) and STN DBS in some studies, but not 
others (Foffani et al 2006; Wingeier et al., 2006; Kühn et al., 2008; Rossi et al., 
2008; Bronte-Stewart et al., 2009). Moreover, the degree of suppression of the 
beta oscillations by antiparkinsonian treatment correlates with improvement of 
the parkinsonian symptoms, bradykinesia and rigidity, although not tremor 
(Kühn et al., 2006; Kühn et al., 2009). Dorsolateral STN is considered the 
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sensorimotor part of the STN  (Kühn et al., 2005; Weinberger et al., 2006) and 
implantation of electrodes within this area seems to provide optimal benefits 
(Herzog et al., 2004; Godinho et al., 2006; Maks et al., 2010).  Therefore it 
seems plausible to suggest that beta oscillatory activity would mark the 
sensorimotor territory of the STN and that stimulation within this area would 
provide a favourable outcome on STN DBS. In this line, Chen and coworkers 
(2006) found that power in the beta band recorded from the DBS electrode 
intraoperatively showed excellent correlation with the clinical improvement 
occurring immediately after the implantation of the DBS electrode (stun effect) 
and with its accurate location within the STN as judged by postoperative 
stereotactic MRI.  
One of the hypotheses of this thesis derived from this work and postulate that 
the presence of a peak in the beta activity along the trajectory of the DBS will 
predict a good outcome of STN DBS and optimal stimulation site would 
correspond to the level of maximum intraoperative beta activity recorded. 
Hence, coincidence of the level for chronic stimulation and the beta activity level 
would provide further support for the clinical relevance of the beta oscillatory 
region within the STN.  
II. OBJECTIVES 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives  
67 
OBJECTIVES 
The aim of this research is to evaluate means to optimise the selection of the 
stimulation parameters in patients with Parkinson’s disease treated with STN 
DBS. For this purpose several studies were performed pursuing the following 
objectives:  
Study 1: Longitudinal assessment of the impact of consecutive sessions 
for adjustment of stimulation parameters of STN DBS in PD patients:
evaluation of the acute and chronic effects of stimulation parameters 
1. To evaluate the acute and sustained effect of adjustment of stimulation 
parameters on motor symptoms  
2. To evaluate the acute and sustained effect on motor symptoms of the 
different types of adjustment of stimulation parameters.  
3. To identify which factors involved in the programming of the stimulation 
parameters will be predictive of the best clinical outcome in 
reprogramming STN DBS.  
Study 2: Clinical outcome of STN DBS with reprogramming in PD 
1. To assess whether intensive programming of stimulation can lead to 
additional benefits in STN DBS for PD. 
Study 3: Analysis of the anatomical stimulation site in STN DBS for PD 
1. To study the evolution of the stimulation site throughout consecutive 
programming sessions in STN DBS  
2. To study the optimal stimulation site in STN DBS after intensive 
programming of stimulation parameters in STN DBS 
3. To evaluate whether anatomical information can help in the selection of 
the therapeutic contact. 
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Study 4: Analysis of type of adjustment “change in contact”
1. To study the behaviour of the type of adjustment “change in contact” 
throughout consecutive adjustment sessions 
Study 5: The value of the intraoperative LFP recordings in DBS targeting 
of the STN and optimization of stimulation parameters 
1. To evaluate the role of LFP recordings in predicting stimulation 
parameters in STN DBS for PD 
 
 
III. METHODS   
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1. GENERAL METHODOLOGY 
PATIENTS 
Patients with Parkinson’s Disease (PD) treated with subthalamic nucleus 
(STN) deep brain stimulation (DBS) for at least 6 (for the local field potential 
study) or 12 months (for the remaining studies) were recruited from the Unit of 
Functional Neurosurgery, Sobell Department, National Hospital for Neurology 
and Neurosurgery, University College of London. All patients had surgery at the 
National Hospital for Neurology and Neurosurgery but two who were operated 
elsewhere. Follow up visits took place at the Unit of Functional Neurosurgery 
and were part of the routine evaluation of implanted patients.  
SURGICAL PROCEDURE  
Implantation of bilateral STN DBS electrodes (Model 3389 DBS lead, 
Medtronic®, Minneapolis) was performed sequentially in the same operative 
session under local anaesthesia after overnight withdrawal of antiparkinsonian 
medication. All patients received bilateral STN DBS stimulation.  
Pre-operative stereotactic MRI and target planning
Fast acquisition T2 weighted axial and coronal stereotactic MRI scans 
(1.5 Tesla) using Leksell Coordinate Frame Model G (Elekta Instrument AB, 
Stockholm, Sweden) were performed with contiguous slices of 2 mm. This 
visualized the STN and especially its medial border (Hariz et al., 2003). The 
anatomical target point within the center of STN visualized at the MRI was 
selected at a level or 1 mm in front of the anterior border of the red nuclei on the 
axial image showing the largest diameter of the red nucleus (Bejjani et al., 
2000). Contact 1 was intended to reach this point. A double oblique trajectory to 
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the target was calculated on coronal images during planning to avoid sulci and 
ventricular system as this has been shown to reduce complications and improve 
targeting accuracy (Elias et al., 2009; Zrinzo et al., 2009). In addition, the 
trajectory was modified to maximise the number of quadripolar electrode 
contacts within the three-dimensional structure of the nucleus. Calculations of 
Cartesian coordinates of the target point were achieved both manually on 
enlarged MRI film copies and on Framelink software (Medtronic, Minneapolis).    
This is performed to ensure that optimal target selection is reviewed in detail for 
every patient and the possibility of human error or miscalculation is minimised. 
Surgical procedure and intra-operative assessments 
Impedance monitoring was performed while introducing a 1.5 mm blunt-tip 
radiofrequency (RF) electrode to the target (Leksell RF electrodes, Elekta, 
Stockholm). After withdrawal of the RF electrode, a quadripolar DBS electrode 
(Model 3389 DBS lead, Medtronic®, Minneapolis) was soft-passed down the 
same track. The DBS electrode was advanced in steps of 2 mm from 4 or 6 mm 
above to 4 mm below the intended target point.  
At each descending step, wrist rigidity and finger tapping contralateral to the 
brain side were assessed and scored using the corresponding items of the 
motor part of the Unified Parkinson’s Disease Rating Scale. The intraoperative 
stun-effect (lesion like effect) was determined by a sustained reduction of 
rigidity and/or bradykinesia and/or onset of dyskinesias.  
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Local field potentials recordings  
Local Field Potentials (LFP) recordings were made in every 2 mm steps 
with the patient awake, eyes open and at rest.  Detailed description of LFP 
recording methodology is described later in this chapter. 
Intraoperative macrostimulatio 
Intra-operative high-frequency test stimulation for therapeutic effect and 
to rule out side effects (dysarthria, oculomotor deviation, sensory or capsular 
responses) was performed monopolarly at each electrode’s contact after LFP 
recordings. Frequency was set at 130 Hz, pulse width at 60 microseconds and 
voltage was progressively increased from 0 to 3.0 volts.  
Once the optimum target point for stimulation was identified, the electrode was 
advanced in 1-3 mm, in order for the contacts to “encompass” the optimal target 
point before it was fixed in the position with the Medtronic burr hole cap or the 
Stimloc system (Medtronic®, Minneapolis). 
Postoperative MRI   
Immediate post-operative stereotactic MRI (in the same manner as 
preoperatively: contiguous slices of 2 mm thickness but less number of slices) 
with the Leksell Frame still on the head of the patient was completed. This 
allowed us to confirm the correct position of the DBS electrode.  
For safety reasons the specific absorption rate was kept below 0.4 W/Kg. 
Implantation of the neurostimulator 
The neurostimulator (Kinetra, Medtronic®, Minneapolis) was implanted under 
general anaesthesia, either the same day or few days later according to theatre 
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availability. Patients stayed in the ward about 10 days after battery implantation 
to allow the initial adjustment of medications and stimulation parameters (SP).  
 
CLINICAL SCALES USED THROUGHTOUT THE STUDY 
Clinical evaluations were based on the Core Assessment Program for 
Surgical Interventional Therapies in Parkinson’s disease (Defer et al., 1999). 
The following scales were used throughout the study: 
- Unified Parkinson’s Disease Rating Scale (UPDRS) from part 1 to 4 (UPDRS 
I, II, III, IV) 
-  Dyskinesia Rating scale (DRS) 
 
UPDRS
 The UPDRS is the most widely used scale for measuring symptoms and 
signs of patients with PD in clinical practice (Siderowf et al., 2002). The UPDRS 
consists of 42 items in four sections assessing (I) mentation and mood (4 
items), (II) activities of daily living based on historical information (13 items), (III) 
motor function based on clinical examination (14 items) and (IV) complications 
in patients on dopaminergic therapy based on historical information (11 items).  
UPDRS II  
Historical information regarding activities of the daily living were taken 
considering the on-medication and off-medication states (items 5 to 17). 
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UPDRS III (motor part) 
Each of the 14 items of the motor part (III) is given a rate between 0 – no 
abnormality and 4 – severe abnormality. Some of the items (symptoms) are 
rated for the different body parts, for example tremor at rest (item 20) is rated 
for the head and neck, right and left upper and lower limbs respectively. As a 
consequence, the maximum score (all items rated as severe) is 108. Maximum 
points for the different parkinsonian symptoms are as follows: speech (4), facial 
expression (4), tremor (28), rigidity (20), akinesia (32), axial symptoms and gait 
(20). High internal consistency (Martinez-Martin et al, 1994), inter-rater reliability 
(Richards et al, 1994) and test-retest reliability (Siderowf et al., 2002) have been 
shown for the part III UPDRS.  
UPDRS III hemibody scores 
Hemibody scores were calculated from the UPDRS III subscores for upper and 
lower limb tremor (items 20 and 21; range 0-12), upper and lower limb rigidity 
(item 22; range 0-8), upper and lower limbs bradykineisia (items 23-26; range 0-
16): finger tapping (item 23), hand movements (item 24), arm movements (item 
25) and leg movements (items 26). Maximum score for hemibody scores (all 
items rate as severe – 4 -) is 36. 
UPDRS III axial scores 
Axial scores were calculated from the UPDRS III subscores for arise from chair, 
gait and postural stability (items 27, 29, 30; range  0-12).  
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UPDRS IV  
Motor fluctuations and dyskinesia were assessed using UPDRS IV. This part of 
the scale was subdivided in: 1) UPDRS IV dyskinesia comprising items 32, 33 
and 34 (duration, disability and pain) and; 2) UPDRS IV off time comprising item 
39 (offs duration). 
Dyskinesia Rating scale (DRS) 
Dyskinesias were rated in the on-medication/on-stimulation condition. For 
quantification, the patient was sitting in a chair and observed at rest. Then the 
patient was asked to perform the tests in the UPDRS motor part (speaking, 
hand grips, finger taps, pronation/supination, leg ability, standing, walking). DRS 
is a five-graded scale (0=non observed; 1= mild, no interference with voluntary 
motor acts involved in the rated task; 2= moderate, there is interference with 
voluntary motor acts involved in the rated task but it can be completed; 3= 
severe, there is intense interference with voluntary motor acts involved in the 
rated task, and completion is greatly limited; 4= extreme, no completion of the 
voluntary motor acts involved in the rated task is possible). The following 
anatomic regions are rated: 1= face (including jaws, lips, tongue, and other 
components of the face); 2= neck, involving complete head nods, and rotations 
and tilts; 3= trunk, including abdomen, back, and hips; 4= right upper limb 
(includes shoulder, upper and lower arm and hand); 5= left upper limb; 6= right 
lower limb (includes overshooting of the legs when walking, rotations and foot 
movements); 7= left lower limb. Each of this body part is rated from 0 to 4. 
Maximum rating is 28. Hemibody and axial subscores were as well classified as 
follows: 
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- Dyskinesia hemibody scores: total rating for upper and lower limbs for 
the same hemibody (maximum score 8). 
- Dyskinesia axial scores: total rating for face, neck and trunk (maximum 
score 12). 
 
STATISTICAL ANALYSIS
Statistical analysis was performed on SPSS version 17 for Windows (SPSS, 
Chicago, IL) in collaboration with a statistician (Mr. Juan Luis Gómez, St Halley 
Statistics). Specific statistical methodology is described later on in this chapter 
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2. STUDY DESIGN 
This work is design as prospective longitudinal assessments and comprises five 
different studies: 
1. Longitudinal assessment of the impact of consecutive adjustment 
sessions of stimulation parameters in STN DBS in PD: evaluation of the 
acute and chronic effects of stimulation parameters 
2. Clinical outcome of STN DBS with reprogramming 
3. Optimal stimulation site in STN DBS for PD 
4. Study of type of adjustment “change in contact” 
5. The value of the LFP recordings in STN DBS intraoperative targeting and 
optimization of stimulation parameters 
 
2.1 LONGITUDINAL ASSESSMENT OF THE IMPACT OF CONSECUTIVE 
SESSIONS FOR ADJUSTMENT OF STIMULATION PARAMETERS OF STN 
DBS IN PD PATIENTS: EVALUATION OF THE ACUTE AND CHRONIC 
EFFECTS OF STIMULATION PARAMETERS 
CLINICAL ASSESSMENTS 
Patients with DBS therapy duration for at least 12 months were included in this 
part of the study. Evaluations took placed at the time of enrolment (visit 1) and, 
1 (visit 2), 3 (visit 3) and 6 (visit 4) months later. Patients attended the visits 
after an overnight withdrawal of dopaminergic medication (off-medication/on-
stimulation condition).  At each visit, patients were assessed before and after 
adjustment of stimulation parameters with UPDRS III scale in the off-
medication/on-stimulation condition. Later, patients took their morning doses of 
dopaminergic medication and UPDRS III and dyskinesia rating scale were used 
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for evaluation when the patient was considered to have achieved the most 
functional benefits from drugs (on-medication/on-stimulation condition).  
Once clinical evaluations were concluded, UPDRS part I, II and IV were 
recorded. 
At visit 1, patients were assessed as well in the off-medication/off-stimulation 
condition (for practical purposes this took place after around 15 minutes of 
having switched the stimulation off).  
ADJUSTMENT SESSIONS
At each visit patients were assessed before and after adjustment of stimulation 
parameter. Adjustment sessions comprised a total of three different time points 
with clinical evaluations performed in the off-medication/on-stimulation 
condition: 
- Baseline evaluation: corresponds to time point prior to adjustment of the 
stimulation  
- Acute evaluation: performed immediately after adjustment of stimulation 
parameters 
- Chronic evaluation: performed at the following visit before adjustment of 
stimulation. This time point corresponds as well to baseline evaluation of 
the following adjustment sessions. 
The study included a total of three adjustment sessions (Adjustment 1 (A1), A2 
and A3).  
As an example, for A1, baseline evaluation was performed at visit 1 before 
adjustment of the stimulation; acute evaluation was performed at visit 1 
immediately after adjusting the stimulation parameters; and chronic evaluation 
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of A1 was performed at visit 2 (before adjustment of SP) and was at the same 
time the baseline evaluation of A2 (before adjusting the SP at V2) (figure 2.1).  
The time from acute and chronic evaluation varied for the different adjustments. 
For A1 it was of 1 month, for A2 two months (3 months from enrolment) and for 
A3 3 months (6 months from enrolment). 
 
Figure 2.1 Adjustment sessions’ time points for A1 and A2. Abbreviations: 
A1: adjustment 1; A2: adjustment 2; A3: adjustment 3; SP: stimulation 
parameters. Figure shows the different time points of the adjustment sessions 
A1 and A2. Baseline time point corresponds to clinical evaluation before any 
adjustment of stimulation parameters were performed at that visit. Acute time 
point corresponds to clinical evaluations performed immediately after 
adjustment of stimulation parameters. For chronic time point, evaluations were 
performed at the following visit. This time point is at the same time the baseline 
time point of the following adjustment session.  
 
Minimal clinical important changes in UPDRS III 
Minimal clinical important changes in UPDRS III correspond to 2.5 points as 
estimated by Shulman (2010). We used this cut off value in order to define 
improvement, deterioration or no clinical changes for the different effects of the 
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adjustment. For this purpose, raw differences between UPDRS III scores were 
recalculated into qualitative variables.  UPDRS III hemibody scores cut off value 
was estimated from total UPDRS III cut off value and set as 0.825. 
 
Adjustment of stimulation parameters (SP)
Each electrode’s contact was screened to assess both therapeutic 
efficacy and unwanted side effects. Monopolar stimulation with increasing 
voltage was used with a note made of effectiveness at stepwise intervals 
(improvement on rigidity and/or bradykinesia and/or tremor and gait). A pulse 
width of 60 microseconds and frequency of 130 Hz was used. The contact with 
the greatest efficacy at the lowest voltage and a wider window for side effects 
was chosen for each hemibody. Each hemibody was assessed independently. 
A poor stimulation efficacy on symptoms prompted exploration of wider pulse 
widths and higher frequencies. In case of persistent side effects bipolar 
electrode’s configuration was used. At the following visit, if the benefit obtained 
immediately after the previous adjustment was maintained or even a further 
improvement was detected (chronic UPDRS III- acute UPDRS III ≤ 2.5), no 
rescreening of the SP was performed.  If the acute benefit of an adjustment was 
not maintained or deterioration was detected, SP were rescreened (figure 2.2).   
The physician performing clinical evaluations and the patient remained blinded 
to the adjustment of the SP. Clinical evaluations were performed by the same 
neurologist all throughout the study. A neurologist with a wide expertise in DBS 
adjusted stimulation parameters. 
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Figure 2.2. Time points evaluations for each adjustment sessions and 
adjustment of stimulation parameters algorithm. Abbreviations: A1: 
adjustment 1; A2: adjustment 2; A3: adjustment 3; Off M: Off medication; On S: 
On stimulation; SP: stimulation parameters; UPDRS: Unified Parkinson’s 
Disease Rating Scale
 
Type of adjustments of stimulation parameters 
The different possibilities of adjustment of SP were resumed in four groups:  
- “No changes”: parameters are screened but finally no changes of SP are 
performed. 
- “Change in voltage”: consisted in changing the voltage of the stimulation 
keeping the same stimulated contact.  Pulse width and frequency could 
also be modified.  Voltage, pulse width and frequency could be increased 
or decreased.  
- “Change in contact”:  when the stimulated contact was changed, 
including change in electrode configuration (monopolar, double 
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monopolar or bipolar). Voltage, pulse width and frequency could also be 
modified (increased or decreased).  
- “No adjustment needed”: this type of adjustment was applied when no 
rescreening of SP was necessary as the benefit of the acute effect of the 
adjustment was maintained or a further improvement was observed in 
the chronic effect. In these cases no acute effect of the adjustment was 
measured. 
Types of adjustment were considered by DBS electrodes and, therefore for a 
single patient two different type of adjustment could occur during the same visit 
(one for each DBS electrode or brain side). The impact of each type of 
adjustment was measure by changes in the UPDRS III contralateral hemibody 
scores. Each patient’s hemibody side was analysed independently.   
Stimulation Parameters
Electrode’s configuration
Medtronic 3389 DBS electrodes were used in all patients. Electrode 
geometries include monopolar and bipolar configurations. In each configuration 
there is a cathode, or negative electric potential (sink of current), and an anode, 
or positive electric potential (source of current). In monopolar configuration the 
pulse generator is set as an anode and at least one contact of the electrode as 
a cathode. Two or more contacts can be set as cathodes if desired (double, 
triple monopolar). In bipolar configuration, two or more contacts of the electrode 
are activated, one as anode and one or more as cathodes.  
Stimulation parameters 
Besides electrode’s configuration, stimulation parameters that can be 
programmed are: voltage, pulse width and frequency. The neurostimulator used 
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in all patients was the dual channel Kinetra (Medtronic Inc., Minneapolis, MN) 
that provides a finite range of voltage (0-9.50 V), pulse width (60 to 450 μsec) 
and frequency (3 to 250 Hz). While voltage and pulse width can be set 
independently for each channel, frequency has to be set at the same range for 
both channels.   
Total electrical energy delivered (TEED) was calculated using the following 
equation (Koss et al., 2005): 
 
As Kinetra neurostimulator impedance measure accuracy is poor, for TEED 
calculation impedance was assumed to be of 1 kΩ (Moreau et al., 2008).  
Medication 
Patients received a combination of different antiparkinsonian medications 
drugs depending on individual needs. This included: levodopa/carbidopa, 
levodopa/benserazide, dopamine agonists (pergolide, cabergoline, pramipexole 
ropinirole, rotigotine, apomorphine), COMT inhibitors (entacapone) MAO 
inhibitors (rasagiline or selegiline), amantadine. Antiparkinsonian medications, 
number of doses and dosage of each drug were recorded at each visit. Total 
dopaminergic dosage was recalculated into Levodopa Equivalent Daily Dose 
(LEDD) on basis of the following correspondences: 100 mg standard Levodopa 
= 130 mg of controlled-released Levodopa = 10 mg bromocriptine = 1mg 
pergolide = 1 mg lisuride = 1.5 mg pramipexole = 6 mg ropinirole = 2.25 mg 
cabergoline = 10 mg apomorphine (Reichmann et al., 2003; Thobois, 2006).  
Medications were modified when required.  
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ADDITIONAL VISITS 
Additional visits between the study fixed visits were available if the 
patient suffered deterioration. In those visits patients were assessed in the 
same manner as in regular visits. To allow statistical analysis these patients 
were excluded from the analysis of the impact of adjustment of SP on clinical 
scores. We were aware that this decision might have introduced a selection 
bias. However, this approach allowed us to carry on with the analysis of 
repeated measures of ANOVA that was consider to be the most appropriate.  
STATISTICAL ANALYSIS 
All variables were checked for normality with Kolmogorov-Smirnoff test or 
Shaphiro-Wilks test when n<15. When normality assumption was satisfied 
parametric tests were used for the analysis. Otherwise non-parametric tests 
were performed.  
Impact of adjustment session on clinical scores
General lineal model (GLM) of repeated measures of ANOVA with within-
subjects variable (time point of adjustment: baseline, acute or chronic) was 
used to analyse the impact of adjustment of stimulation parameters on clinical 
scores. The significance level was set at 0.05. When assumption of sphericity 
could not be satisfied (Mauchly’s test p<0.05) a multivariate test, Pillai’s trace, 
was used. Pairwise comparisons were performed using Bonferroni correction.  
To assess the impact of the type of adjustment on UPDRS III hemibody scores 
a GLM of repeated measures of ANOVA with within-subjects variable (time 
point of adjustment: baseline, acute or chronic) and between-subjects variable 
type of adjustment (no change, change in voltage, change in contact, no 
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adjustment needed) was used. When assumption of sphericity could not be 
satisfied (Mauchly’s test p<0.05) a multivariate test, Pillai’s trace, was used. 
Pairwise comparisons were performed using Bonferroni correction for within-
subjects test. For between-subject test, homogeneity of variances was required 
for the analysis (Levene test, p>0.05). Pairwise comparisons using Bonferroni 
correction were used to assess differences between types of adjustment. For 
variables not following a normal distribution Friedman test was used.  
Predictive factors for global improvement at each adjustment session 
The effect of certain factors on global outcome of total and hemibody 
UPDRS III scores at each adjustment session was analysed using multivariate 
regression (backwards-stepwise method). Global outcome for each adjustment 
session was defined as the difference between chronic and baseline time 
points. Variables with multicollinearity problems were excluded. Regression 
model was checked for independence of the residuals (Durbin-Watson statistic), 
collinearity, normality and homoscedasticity of the residuals.  
For analysis of total body UPDRS III scores, type of adjustment was reclassified 
taking into account the type of adjustment performed at both DBS electrodes: 
- No change in any of the DBS electrodes 
- Change in voltage in at least one of the DBS electrodes and no change 
in contact  
- Change in contact in at least one of the DBS electrodes 
 
Methods 
87 
2.2 CLINICAL OUTCOME OF STN DBS WITH REPROGRAMMING  
IMPACT OF SUCESSIVE ADJUSTMENT SESSIONS ON CLINICAL 
OUTCOME 
Same patients as in the previous study were included (PD with STN DBS for at 
least 12 months). Final UPDRS III scores were compared to scores at baseline. 
Baseline time point of the study was defined as baseline scores at A1. Final 
time point corresponds to chronic time point of A3. All scores were performed 
off-medication/on-stimulation. Patients were included regardless the need of 
additional visits between adjustment sessions.  
To analyse the impact of this type of adjustment on final outcome after three 
consecutive adjustment sessions, patients (by hemibody sides) were grouped 
according to the following classification “Adjustment of stimulation parameters 
throughout the study”: 
- “No changes” of stimulation parameters (includes no changes and no 
adjustment needed) along the study  
- “One or more change in voltage” but no changes of stimulated contact 
during the study  
- “One change of stimulated contact” during the study  
- “Two or three changes of the stimulated contact” 
Repeated measures analysis (ANOVA) with main factor TIME (2 levels: 
baseline and final time point) and between-subjects factor “adjustment of 
stimulation parameters throughout the study” was performed. 
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PREDICTIVE FACTOR FOR IMPROVEMENT 
Final outcome variable was defined as the differences between chronic time 
point of A3 and baseline scores of the study (baseline time point of A1).  
 
       A minimal clinical important difference was established on 2.5 points for 
total UPDRS III based on the study by Shulman (2010). Final outcome variable 
was recodified into a qualitative variable where differences equal or below -2.5 
points were defined as improvement and equal or above +2.5 points as 
deterioration. Values in between were considered as stable scores. For logistic 
regression analysis the variable was dichotomized into improvement or no 
improvement (includes stable and deterioration). For hemibody scores cut-off 
value was calculated at 0.825 points. Final outcome variable was recodified into 
a qualitative variable. Differences equal or below -0.825 points were defined as 
improvement and equal or above +0.825 as deterioration. Global outcome 
variable for each adjustment session was categorized into improvement 
(differences equal or below -0.825) and deterioration (equal or above 0.825). 
The probability for global improvement was study using logistic regression 
analysis (stepwise method or user-controlled backward stepwise method) for 
both, total and hemibody UPDRS III scores. Model was checked for Hosmer 
test, normality of the residuals and Nagelkerke coefficient.  
Final outcome variable = chronic scores of A3 - baseline scores of A1
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2.3 OPTIMAL STIMULATION SITE IN STN DBS FOR PARKINSON’S 
DISEASE 
ANALYSIS OF THE ANATOMICAL POSITION OF THE DBS ELECTRODE 
AND ACTIVE CONTACTS OF THE DBS ELECTRODE 
PD patients treated with STN DBS for at least 12 months were included in this 
study. Pre and postoperative stereotactic MRI were examined. Post-operative 
stereotactic MRI data and Framelink software (Medtronic) were used to localize 
the position of the contacts. Coordinates of DBS electrode contacts were 
calculated from the centre of the electrode artefact on post-operative MRI. The 
software allows reconstruction of the imaging data in multiple planes, including 
trajectory views along the centre of the electrode contacts. The centre of each 
electrode contact was calculated by superimposing a template of the 
quadripolar electrode. To avoid artefact from the electrode the coordinates of 
each contact were transposed onto the pre-operative MRI. Two neurosurgeons 
blinded to the clinical outcome and stimulation parameters independently 
assessed and agreed on the anatomical position of each electrode’s contacts in 
relation to the visualized STN on the axial and coronal MRI planes. The 
visualized STN was divided into five segments: superior (A), anterior-medial (B), 
central (C), postero-lateral (D) and inferior (E) (figure 2.3). The centre of each 
contact was localized in relation to the closest STN segment and classified as 
being inside, superior, medial, inferior or lateral to that segment. A contact 
located within 1 mm from the STN was considered to be adjacent to the 
corresponding STN segment. Final anatomical position for each DBS 
electrode’s contact was defined by the anatomical localization around the STN 
and its surrounding structures and the STN segment.  
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The optimal stimulation area was considered to be the central, superior, 
posterolateral segment of the STN or the area adjacent to the superior border of 
the STN (located less than 1 mm from the border of the nucleus). 
Position of the DBS electrode was classified into two groups 
- Group I electrode’s position (Group Ie, good location), when at least one 
the four contacts of the electrode was within the defined optimal area.   
- Group II electrode’s position (Group IIe), when none of the contacts was 
within the defined optimal area.  
Active/stimulated contact position was as well resumed into two groups:  
- Group I contact’s position  (Group Ic, good location) the active contact is 
within the defined optimal area  
- Group II contact’s position (Group IIc) consisted of those active contacts 
not fulfilling the above criteria.  
 
Differences between group I and II for electrode’s position (group Ie, group IIe) 
and active contact position (group Ic, group IIc) were examined using univariate 
analysis. Dependent variables were: DBS efficacy, TEED and voltage, type of 
adjustment throughout the study and, LEDD. Analysis was performed on total 
and hemibody scores.  
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Figure 2.3 Division of STN into different segments viewed on plates from 
Schalthenbrand atlas. A) Axial view adapted from plate 55, H.v 4.5: antero-
medial (B), central (C), postero-lateral (D) segments of the STN. B) Coronal 
view adapted from plate 27, f.p 3.0: Superior (A) and inferior (E) segments of 
the STN. 
 
THE VALUE POSTOPERATIVE IMAGING IN THE SELECTION OF THE 
OPTIMAL THERAPEUTIC CONTACT  
One neurosurgeon blinded to the stimulation parameters and clinical 
outcome determined on MRI which contact had the best location in the STN. If 
no contact was found to lie within the nucleus proper, the best contact was 
considered that being closest to the STN or its superior tip. Contacts were 
classified in two groups based on concordance between clinical/MRI contact: 
“no concordance” and “concordance”. Anatomical position of the active contact, 
clinical and stimulation parameters variables and type of adjustment during the 
study were compared between both groups using univariate analysis.  
 
2.4. STUDY OF TYPE OF ADJUSTMENT “CHANGE IN CONTACT”
In this part of the study a description of those hemibody sides that 
underwent “change in the stimulated contact” at any time during the study was 
carried out. Due to a progressive reduction of the sample mainly descriptive 
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statistics were used. Non-parametric tests were applied when appropriated. 
Clinical and anatomical description of the position of the active contact was 
provided. 
2.5 THE VALUE OF THE INTRAOPERATIVE LOCAL FIELD POTENTIAL 
(LFP) RECORDINGS IN DBS TARGETING OF THE STN AND 
OPTIMIZATION OF STIMULATION PARAMETERS 
Patients with STN DBS for at least 6 months and in whom LFP data was 
available were included in this study. Implantation of bilateral DBS electrodes 
was performed as previously described.  
LFP RECORDINGS 
Recordings were made from every 2 mm steps in the electrode descent 
while patients were awake, with eyes open and at rest. Each depth was 
recorded for 60-65 s. STN LFPs were recorded bipolarly from the four adjacent 
contacts of each DBS electrode (contact pairs 01, 12, 23). Signals were 
amplified, pass band filtered between 1 and 80 Hz and sampled at 184 Hz in 23 
patients, 500 Hz in two patients and 1600 Hz in three patients (Biopotential 
Analyser Diana, St Petersburg, Russia) or pass band filtered between 1 and 80 
Hz and sampled at 1024 Hz in three patients (Porti Amplifier; TMSI 
International, Enschede, The Netherlands). The optimum sampling rate was 
184 Hz, as higher rates do not afford any advantage given that the pass band of 
interest was under 35 Hz. Purpose written software saved the original time 
series on a portable PC and displayed online the evolving patterns of beta band 
power from contact pairs 01, 12, 23 as the DBS electrode was advanced (figure 
2.4). Thereafter, LFP were interpolated to a sampling rate of 184 Hz, where 
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necessary, and examined offline in Spike2 software (Cambridge Electronics 
Design, Cambridge, UK). Spectra of LFP power were estimated in Spike2 using 
the discrete Fourier transform. Spectral resolution was 0.72 Hz. Analysis 
excluded periods of recording while the electrode was moved.  
A beta frequency band peak in the power spectra was operationally defined as 
a local maximum between 11 and 35 Hz in which the mean power over the five 
contiguous frequency bins centred on the peak frequency exceed 180% of the 
mean power over the five contiguous bins of lower and higher frequency. 
Recordings from contact 01 at all depths were considered and the depth with 
the highest peak power over the frequency band of interest was used to define 
the centre frequency of the peak. The mean (absolute rather than relative) 
power over the five frequency bins centred on this peak was then estimated for 
each recording depth of the electrode. Five bins were chosen to allow for any 
minor change in peak frequency between depths. A discrete peak between 11 
and 35 Hz in power spectra of contact 01 was identified in all but two sides. A 
step change in peak beta power was operationally defined as at least a 100% 
increase in mean beta power at contact 01 between successive depths as the 
electrode was advanced in 2 mm steps or, where the maximum peak lay at the 
most superficial depth tested (four sides), there was at least a 100% drop in 
mean beta power at contact 01 when it was advanced a further 2 mm. For 
example, if the mean power of the peak doubled when the electrode was moved 
from 4 mm to 2 mm above the anatomical target point, then the step change 
and site of the local beta generator were considered to be at 2 mm. The beta 
generator was defined as the local electrical source of beta activity, 
acknowledging that this may be driven by input from elsewhere. If there was 
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more than on step change in the beta power between depths, then only the step 
involving the highest mean beta power was considered. For example if the 
mean power of the peak doubled when the electrode was moved from 4 mm to 
2 mm above the anatomical target point, but then doubled again when the 
electrode was moved from 2 mm to 0 mm, then the step change and site of the 
local beta generator were considered to be at 0 mm, the depth with the highest 
peak mean power. We elected to focus on peak power, rather than on LFP 
power across the beta band, as previously used (Chen et al., 2006) as this 
afforded a better signal to noise ratio and given the recent emphasis on spectral 
peaks rather that broad band power changes in correlation between LFP power 
and clinical state (Kühn et al., 2009). Absolute and not relative or normalised 
power was analysed. The beta generator depth was described with reference to 
the surgical target point.  
CLINICAL ASSESSMENTS OF EFFICACY OF CHRONIC DBS 
A Neurologist blinded to the intraoperative recordings performed 
postoperatively clinical assessments and programming of the stimulation 
parameters. Stimulation parameters and UPDRS motor scores were determined 
a minimum of 6 months after surgery. Stimulation parameters were selected as 
previously described.  
ELECTRODE’S CONTACT ANATOMICAL POSITION
The contact from each electrode with the best anatomical position was 
determined and classified into one of two groups (Goup Ic and Group IIc). In 
group Ic, the contact was inside or adjacent to the most superior part of the 
STN. Group IIc essentially consisted of the contact that was closest to the 
superior part of the STN in those electrodes not fulfilling the above criteria. The 
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depth of the contact of each electrode used for chronic stimulation was also 
described with reference to the surgical target point  (the same reference as 
used for the depth of the beta generator). In case of bipolar stimulation, 
stimulation depth was assumed to lie midway between the respective contacts.  
STATISTICAL ANALYSIS 
Correlations were performed using Spearman’s rho so as to 
accommodate the non-parametric distribution of our data and to avoid any 
spurious correlations due to outlying values, although this has the disadvantage 
that correlation coefficients cannot be used to estimate the proportion of the 
variance of one signal linearly predicted by another. 
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Figure 2.4 On-line displays of spectral change in LFP as DBS electrode 
descends through the target, obtained intra-operatively. The intended 
target at 0 mm was the center of the SNT. DBS electrodes were introduced in 2 
mm steps from (+) 4 mm above target to (-) 4 mm below.  Recordings were 
made for 60 seconds after each step. The x-axes are the distance of contact 0 
along the electrode trajectory with respect to the intended target. The depth at 
which the intra-operative stun effect was obtained is shown by vertical black 
arrows. The highest level of beta activity is seen in contact 01 first and then 
recorded in more rostral contact pairs after further descent (A and D). Power is 
in arbitrary units and its range is independently optimized for each channel by 
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the software. The depth of contact pair 01 with maximal power in the 13-35 Hz 
band corresponded to (A, B) or was adjacent to (D) the depth of the intra-
operative stun effect, except in panel C where a step in power was recorded at 
contact pair 01 without an accompanying stun effect (From Chen et al., 2006). 
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1. LONGITUDINAL ASSESSMENT OF THE IMPACT OF CONSECUTIVE 
SESSIONS FOR ADJUSTMENT OF STIMULATION PARAMETERS OF STN 
DBS IN PD PATIENTS: EVALUATION OF THE ACUTE AND CHRONIC 
EFFECTS OF STIMULATION PARAMETERS 
 
The present study sought to carefully assess the acute and long-term impact of 
the adjustment of the stimulation parameters of STN DBS in patients with 
Parkinson’s disease.  
 
1.1 DESCRIPTION OF THE STUDY POPULATION 
Thirty-one consecutive PD patients (19 male) treated with STN DBS for at least 
one year were enrolled in the study. All but two patients underwent surgery at 
the National Hospital for Neurology and Neurosurgery (London, United 
Kingdom). Mean age was 56.356.8 years (range 41-66), age at onset of PD 
was 44.266.1 years-old (range 32-61), duration of PD at time of surgery was 
12.39  5.3 years (range 5-24), duration of DBS therapy was 29.94 months 
(range 12-86) and age at DBS was 56.35 years-old (42-66).  
To determine the benefit obtained with STN DBS, preoperative UPDRS III 
motor scores were compared to postoperative scores (baseline of the study, 
which corresponds to the first evaluation at visit 1). Preoperative data was 
available only for 20 patients.  
At the baseline of the study, STN DBS provided an improvement on UPDRS III 
scores of 49.53% (off medication/on stimulation at baseline of the study vs off 
medication pre-DBS) and an improvement of 44.63% when compared to the off 
medication/off stimulation condition, both at baseline of the study. On 
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medication UPDRS III scores deteriorated after DBS (from 8.956.1 to 
12.855.6, p=0.01, two-tailed paired t-test) (figure 1.1). UPDRS III score and 
subscores are shown at table 1.1 and figure 1.1 and 1.2.   
 
Table 1.1 UPDRS III total, axial and hemibody scores pre-DBS and at 
baseline of the study 
UPDRS III SCORES n Mean (SD) Range
UPDRS III off M pre-DBS 20 46.45 (17.31) 18-78 
UPDRS III on M pre-DBS 20 8.95 (6.16) 0-20 
UPDRS III off M/on S at baseline 31 27.16 (14.33) 11-79 
UPDRS III off M/off S at baseline 28 49.14 (18.35) 26-88 
UPDRS III on M/on S at baseline 31 14.52 (8.37) 3-40 
UPDRS III axial off M/on S at baseline 31 2.65 (2.48) 0-10 
UPDRS III axial off M/off S at baseline 28 4.50 (2.51) 2-12 
UPDRS III axial on M/on S at baseline 31 1.26 (1.61) 0-8 
UPDRS III hemibody off M/on S at baseline 62 8.03 (5.03) 0-29 
UPDRS III hemibody off M/off S at baseline 56 16.11 (7.18) 3-31 
UPDRS III hemibody on M/on S at baseline  62 3.95 (2.90) 0-13 
Abbreviations off M: off Medication; off S: off stimulation; on M: on Medication; on S: on 
stimulation; pre-DBS: before deep brain stimulation; SD: standard deviation; UPDRS: Unified 
Parkinson’s Disease Rating Scale.  
 
 
Results 
103 
 
 
Figure 1.1 UPDRS III scores before DBS and at baseline of the study (off 
M/on S, off M/off S and on M/on S) 
Abbreviations off M: off Medication; off S: off stimulation; on M: on Medication; 
on S: on stimulation. Dark grey columns correspond to UPDRS III off M 
preDBS, UPDRS III Off M/off S and UPDRS III On M pre DBS respectively. 
Ligth grey columns correspond to OffM/On S, Off M/OnS  and On M/On S at 
baseline. 
* two-tailed t-test  
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Figure 1.2 UPDRS III subscores (axial and hemibody) at baseline of the 
study (off M/off S, off M/on S and on M/on S) 
Abbreviations off M: off Medication; off S: off stimulation; on M: on Medication; 
on S: on stimulation. 
* two-tailed t-test  
 
Patients attended a total of four visits. As described in the methodology section, 
three adjustment sessions were performed and named as adjustment 1 (A1), 
adjustment 2 (A2) and adjustment 3 (A3). Mean time between baseline 
assessment and chronic effect was 38.29 days (SD 16.536, range 17-99), 70.77 
days (SD 25.426, range 25-164) and 87.46 days (SD 23.930, range 47-170) for 
A1, A2 and A3, respectively.  
At the final time point of the study, 5 patients withdrew. All patients completed 
the A1 and A2 time points. A3 time points were completed by 28 patients 
(baseline and acute time point) and by 26 for the chronic time point. Reasons 
for discontinuation were: the development of a cardiac condition that prevented 
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the patient attending the planned visits (1), and personal decision to discontinue 
the assessments (4). Six patients required additional visits because of 
deterioration in parkinsonian symptoms (2 at A1, 1 at A2 and 3 at A3).  
 
1.2 EVALUATION OF ACUTE AND CHRONIC EFFECTS OF STIMULATION 
PARAMETERS DURING THREE CONSECUTIVE ADJUSTMENT SESSIONS 
This part of the study will focus on the impact of each adjustment session 
(acute and chronic effect) on UPDRS III total, hemibody and axial scores. The 
impact of the new stimulation setting was assessed in the clinical condition off-
medication/on-stimulation. Changes in stimulation parameters were classified in 
four different groups:  
TYPE OF ADJUSTMENT OF STIMULATION PARAMETERS
No changes Stimulation parameters are tested for clinical effect but no changes 
are performed 
Change in voltage Change of stimulation voltage that could also include variations on 
pulse width and/or frequency 
Change in contact Change of the stimulated electrode’s contact. Variations on voltage, 
pulse width and/or frequency were also possible 
No adjustment needed After A1, some patients did not require further evaluation of the 
stimulation parameters as a clinically stable benefit was achieved in 
the previous adjustment session. Clinical acute assessments were 
not performed for this group 
 
Therapeutic outcome was quantified using contralateral motor scores (referred 
in the text as UPDRS III hemibody scores) rather than total UPDRS III scores. 
This is because each DBS electrode programme is independent. This 
necessarily excludes axial scores, which result from the combined effect of 
stimulation of both brain sides. 
Results 
106 
Patients requiring additional adjustment sessions were excluded from this part 
of the study and will be discussed separately. 
Stimulation parameters at each time point of the study are provided in appendix 
I.  
 
Statistical considerations 
Statistical comparisons were made using parametric or non-parametric tests 
where appropriate, and after checking assumptions of normality (Shapiro-Wilk 
test; p < 0.05 to reject) and homogeneity of variance (Levene test, p < 0.05 to 
reject). Pillai’s Trace multivariate test was used when sphericity could not be 
assumed. With normality assumption repeated measures ANOVA with the time 
point of the adjustment (baseline, acute, chronic) as the main factor was used to 
compare baseline, acute and chronic scores of adjustment sessions. To assess 
the interaction of the type of adjustment, this variable was included in the model 
as a between-subjects factor. A Bonferroni correction was applied for post hoc 
pairwise comparisons. For variables not following a normal distribution 
(Shapiro-Wilk test), non-parametric Friedman´s test was used and post-hoc 
analysis with Wilcoxon signed-rank test was conducted with a Bonferroni 
correction applied, resulting in a significance level set at p>0.016 (three 
samples). 
 
OVERVIEW OF THE IMPACT OF ADJUSTMENT SESSIONS ON MOTOR 
SCORES 
Thirty-one patients completed all A1 time points. Two patients required 
an additional visit between A1 and A2 and were therefore excluded. Analysis 
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was performed on the data of twenty-nine patients (58 hemibody sides). Thirty 
patients completed all A2 time points. One patient required an additional visit 
between A2 and A3 and was therefore excluded from this part of the study. 
Data was therefore available for 29 patients (58 hemibody sides). Twenty-six 
patients completed all A3 time points. Three patients required an additional visit 
before the chronic time point of A3 and were therefore excluded. Analysis was 
performed on the data of twenty-three patients (46 hemibody sides).   
The impact of the adjustment session was similar for UPDRS III total and 
hemibody scores. A statistically significant acute benefit was found in A1, A2 
and A3; however, the acute improvement was only maintained at A3. Thus, a 
positive global effect of the adjustment was only seen in the last adjustment 
session. The impact on axial scores was more variable. A1 produced a 
significant acute benefit followed by deterioration. A2 did not have any impact 
on axial subscores and A3 produced an acute and additional chronic benefit.  
For total UPDRS III scores and analysis see tables 1.2 and 1.3 and figure 1.3.  
For hemibody and axial subscores and analysis see tables 1.4 to 1.10. 
IMPACT OF TYPE OF ADJUSTMENT ON HEMIBODY MOTOR SCORES 
The interaction of the variable “type of adjustment” was statistically significant in 
all of the adjustment sessions (A1 p=0.013, A2 p=0.008 and A3 p<0.001; Pillai’s 
Trace).  
Type of adjustment “no change” did not have an impact on UPDRS III hemibody 
scores in either acute or chronic time points at A1 and A2. At A3, a chronic and 
global improvement was observed.  
Type of adjustment “change in voltage” did not vary UPDRS III hemibody 
scores at A1 and A2. At A3, an acute sustained improvement was found.  
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Type of adjustment “change in contact” was the adjustment producing greater 
variations on UPDRS III hemibody scores. At A1, it produced an acute 
improvement followed by deterioration. At A2 and A3, the acute benefit was 
maintained over time, leading to a global improvement in both programming 
sessions.  
“No adjustment needed” condition did not produce variations on motor scores, 
as expected.  
The behaviour of UPDRS III hemibody scores at each adjustment session is 
displayed in figures 1.4 to 1.6 and for each type of adjustment in figure 1.7
No differences were found for UPDRS III hemibody scores among the different 
types of adjustment (F=1.366, p=0.264) at A1. At A2, hemibody sides in the 
group of “no adjustment needed” had significantly lower scores (F=4.309, 
p=0.009; “no change” (p=0.033), “change in contact” (p=0.043) and “change in 
voltage” (p=0.056). At A3, hemibody sides included in the group “no adjustment 
needed” had lower UPDRS III hemibody scores compared with “change in 
contact” (F=4.984, P=0.005, mean difference 5.62 points, p=0.004).
Table 1.2 UPDRS III scores at different time points of A1, A2 and A3 
A1 A2 A3
UPDRS III BL A C BL A C BL A C
N 29 29 29 29 29 29 23 23 23 
Mean 28.00 22.41 26.59 25.55 23.31 26.03 26.22 24.17 22.39 
SD 14.41 9.59 12.13 12.53 10.96 12.48 13.06 10.64 8.91 
Range 11-79 7-48 10-50 9-50 9-49 7-66 7-66 7-52 7-45 
Pillai’s 
trace
< 0.001   < 0.001   < 0.027   
Abbreviations: A1, A2, A3 adjustment 1, 2 and 3; A: acute time point; BL: baseline; C: chronic 
time point; SD standard deviation.  
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Table 1.3 Differences of UPDRS III scores for A1, A2 and A3  
 A1 A2 A3
UPDRS III 
differences
Mean 
difference 
p Mean 
difference 
p Mean 
difference 
p 
BL-A 5.59 <0.001 2.24 0.002 2.04 0.035 
A-C -4.17 0.011 -2.72 0.032 1.78 0.325 
BL-C 1.41 1.000 -0.45 1.000 3.83 0.036 
 
Abbreviations: A: Acute scores; A1, A2, A3 adjustment 1, 2 and 3; BL: baseline scores; 
C: Chronic scores; P: p value. A minus sign indicates deterioration on UPDRS III 
scores. P values adjusted according to Bonferroni correction. Acute effect: baseline-
acute scores; chronic effect: acute-chronic scores; general effect: baseline-chronic 
scores.  
 
Figure 1.3. UPDRD III scores along the different time points of A1, A2 and 
A3 (baseline, acute and chronic). Mean values of UPDRS III scores are 
represented by rhombus, squares and triangles for A1, A2 and A3, respectively.  
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Table 1.4. UPDRS III hemibody scores at the different time points of A1 
(baseline, acute and chronic) by type of adjustment  
A1 Total No Change Change 
Voltage
Change 
Contact
BASELINE n 58 11 19 28 
Mean 8.22 7.46 6.90 9.43 
SD 5.13 3.27 4.33 6.00 
Range 0-29 3-14 0-17 3-29 
ACUTE n 58 11 19 28 
Mean 6.29 6.64 5.84 6.46 
SD 3.66 3.01 3,91 3.82 
Range 0-18 3-13 0-16 0-18 
CHRONIC n 58 11 19 28 
Mean 7.69 7.55 5.95 8.93 
SD 5.00 2.98 4.70 5.58 
Range 0-21 1-12 0-19 2-21 
Abbreviations: SD standard deviation. Baseline: evaluation before adjustment of the stimulation 
parameters (SP); acute time point: evaluation immediately after adjustment of the SP; chronic 
time point: chronic evaluation after adjustment of SP (for A1: 1 month).  
Table 1.5. Mean differences of UPDRS III hemibody scores at the different 
time points of A1 by type of adjustment  
UPDRS III 
hemibody 
differences
Total   
Mean (p 
value) 
No change
Mean (p value) 
Change in voltage
Mean (p value) 
Change in contact
Mean (p value) 
Baseline-acute
Mean
P value
1.61 
(<0.001) 
0.82 
(1.000) 
1.05 
(0.317) 
2.96 
(<0.001) 
Acute-chronic
Mean
P value
-1.16 
(0.024) 
-0.91 
(0.947) 
-0.11 
(1.000) 
-2.46 
(<0.001) 
Baseline-chronic
Mean
P value
0.45 
(1.000) 
-0.09 
(1.000) 
0.95 
(0.949) 
0.50 
(1.000) 
A minus sign means deterioration. For each column, the first value represents the mean 
difference in UPDRS III hemibody scores and the p value is shown in brackets. P values were 
corrected according to Bonferroni adjustment. 
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Figure 1.4. UPDRS III hemibody scores along A1 time points grouped by 
type of adjustment. Rhombus, square, triangle and cross represent mean 
values of UPDRS III hemibody scores at each time point of the adjustment 
session. Blue line indicates total scores, red line shows no change, green line 
denotes change in voltage, and purple line shows change in contact.  
Table 1.6. UPDRS III axial scores at A1, A2 and A3 
A1* A2§ A3**
Mean SD Mean SD Mean SD
Baseline 2.83 2.47 2.76 1.50 2.43 2.02 
Acute 2.10 1.93 2.31 1.44 2.22 1.78 
Chronic 2.83 1.42 2.55 1.86 1.91 1.73 
Abbreviations: A: adjustment session; SD standard deviation.  
*A1 [p=0.003, Friedman test; pairwise comparisons: baseline vs. acute (p=0.003), acute vs. 
chronic (p=0.018), baseline vs. chronic (p=0.527)]. 
§A2 (p=0.093, Friedman test) 
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**A3 [p=0.010, Friedman test); pairwise comparisons: baseline vs. acute (p=0.059), acute vs. 
chronic (p=0.083), baseline vs. chronic (p=0.013)]. 
 
Table 1.7. UPDRS III hemibody scores at the different time points of A2 
(baseline, acute and chronic) by type of adjustment   
A2 Total No change Change 
voltage
Change 
contact
NAN
BASELINE n 58 19 13 8 18 
Mean 7.38 8.11 8.43 11.11 4.00 
SD 5.06 5.09 4.27 5.07 2.54 
Range 0-21 1-21 3-19 5-21 0-11 
ACUTE n 58 19 13 8 18 
Mean 6.72 7.84 7.71 8.22 NA 
SD 4.27 4.66 3.80 4.47 NA 
Range 0-19 1-19 4-16 4-18 NA 
CHRONIC n 58 19 13 8 18 
Mean 7.83 9.21 9.23 8.25 5.17 
SD 4.93 6.08 4.17 5.37 2.64 
Range 2-27 2-27 2-19 4-19 2-11 
Abbreviations: NA: not applied; NAN: no adjustment needed. Baseline: evaluation before 
adjustment of the stimulation parameters (SP); acute time point: evaluation immediately after 
adjustment of the SP; chronic time point: chronic evaluation after adjustment of SP (for A2: 2 
months). 
For “no adjustment needed”, the acute time point was not measured and therefore no values 
are given.  
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Table 1.8. Differences of UPDRS III hemibody scores at the different time 
points of A2 by type of adjustment  
UPDRS III hemibody 
differences
Total No change Change in 
voltage 
Change in 
contact 
NAN
Baseline-acute 
Mean
P value
0.98 
(<0.001) 
0.26 
(1.000) 
0.77 
(0.295) 
2.88 
(<0.001) 
NA 
Acute-chronic      
Mean
P value
-0.94 
(0.009) 
-1.37 
(0.023) 
-1.46 
(0.054)
0.25  
(1.000)
NA 
Baseline-chronic 
Mean
P value
0.04 
(1.000) 
-1.11 
(0.265) 
-0.69  
(1.000)
3.13 
(0.007)
-1.17 
(0.240) 
Abbreviations: NA:  not applied; NAN: no adjustment needed. 
A minus sign means deterioration. For each column, the first value represents the mean 
difference on UPDRS III hemibody scores and the p value is shown in brackets. P values were 
corrected according to Bonferroni adjustment. 
 
Figure 1.5. UPDRS III hemibody scores along A2 time points grouped by 
type of adjustment. Rhombus, square, triangle, cross and asterisk represent 
mean values of UPDRS III hemibody scores at each time point of the 
adjustment session. Blue line denotes total scores, red line shows no change, 
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green line indicates change in voltage, purple line shows change in contact and 
light blue line indicates no adjustment needed. 
Table 1.9. UPDRSIII hemibody scores at the different time points of 3 
(baseline, acute and chronic) by type of adjustment  
A3 Total No change Change 
voltage
Change 
contact 
NAN
BASELINE n 46 11 6 7 22 
Mean 7.93 9.08 8.88 12.75 5.18 
SD 5.08 4.38 4.32 6.43 2.79 
Range 2-27 3-17 5-19 5-27 2-11 
ACUTE n 46 11 6 7 22 
Mean 7.02 8.42 7.25 9.75 5.18 
SD 3.95 3.78 3.99 4.13 2.79 
Range 2-18 3-14 2-16 4-18 2-11 
CHRONIC n 46 11 6 7 22 
Mean 6.35 6.27 5.83 9.571 5.50 
SD 3.52 2.37 2.56 4.99 3.29 
Range 1-19 3-10 4-11 3-19 1-13 
Abbreviations: NAN: no adjustment needed. Baseline: evaluation before adjustment of the 
stimulation parameters (SP); acute time point: evaluation immediately after adjustment of the 
SP; chronic time point: chronic evaluation after adjustment of SP (for A3: 3 months). 
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Table 1.10 Differences of UPDRS III hemibody scores at the different time 
points of A3 by type of adjustment  
UPDRS III hemibody 
differences
Total No change Change in 
voltage 
Change in 
contact 
NAN
Baseline-acute 
Mean
P value
1.48 
(<0.001) 
0.64 
(0.478) 
1.83 
(0.012) 
3.43 
(<0.001) 
NA 
Acute-chronic 
Mean
P value
1.02 
(0.052) 
2.27 
(0.012) 
1.83 
(0.227) 
0.29 
(0.932) 
NA 
Baseline-chronic 
Mean
P value
2.49 
(<0.001) 
2.91 
(0.002) 
3.68 
(0.005)
3.71 
(0.002) 
-0.32  
(1.000) 
Abbreviations: NA:  not applied; NAN: no adjustment needed.  
A minus sign means deterioration. For each column, the first value represents mean difference 
on UPDRS III hemibody scores and p value is shown in brackets. P values were corrected 
according to Bonferroni test. 
 
 
Figure 1.6. UPDRS III hemibody scores along A3 time points grouped by 
type of adjustment. Rhombus, square, triangle, cross and asterisk represent 
mean values of UPDRS III hemibody scores at each time point of the 
adjustment session. Blue line indicates total scores, red line denotes no 
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change, green line shows change in voltage, purple line indicates change in 
contact and light blue line shows no adjustment needed. 
 
Figure 1.7 UPDRS III hemibody scores for each type of adjustment at A1, 
A2 and A3. Abbreviations: A: adjustment session; UPDRS III: motor part of 
Unified Parkinson’s Disease Rating Scale. 
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1.3 IMPACT OF ADJUSTMENT SESSIONS ON “ON MEDICATION/ON 
STIMULATION” SCORES 
Statistical considerations 
None of the variables analysed followed a normal distribution (Shapiro-Wilk test, 
p<0.05); therefore, non-parametric tests were used: comparisons for related 
samples were carried out using Friedman test and Wilcoxon signed ranks test 
with Bonferroni correction for pairwise comparisons (p value set at 0.016 for 
three samples comparison). 
 
UPDRS III SCORES, UPDRS III AXIAL SCORES AND TOTAL AND AXIAL 
DYSKINESIAS SCORES ON-MEDICATION/ON STIMULATION 
UPDRSIII scores on medication/on stimulation (onM/onS) varied throughout the 
study (Friedman test, p=0.017) experiencing a significant deterioration between 
A1 and A2 (p=0.009, Wilcoxon test) and a tendency to deteriorate between A1 
and A3 (p=0.054, Wilcoxon test); however, there were no differences between 
A2 and A3 scores.  
No differences were found for UPDRS III axial scores among adjustment 
sessions (p=0.137, p=0.0886 and p=0.690 respectively). 
Neither total dyskinesia nor axial dyskinesia scores varied during the study 
(Friedman test, p=0.861 and p=0.788) (table 1.11).  
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Table 1.11 ON medication/On stimulation scores 
A1 A2 A3
Mean (SD) Mean (SD) Mean (SD)
UPDRS III 14.48 (8.64) 17.56 (9.59) 17.11 (9.23) 
UPDRS III axial 1.30 (1.71) 1.44 (1.31) 1.52 (1.22) 
UPDRS III hemibody 4.10 (2.93) 4.91 (3.68) 4.35 (3.09) 
Dyskinesia total 4.52 (3.19) 3.59 (3.41) 3.37 (2.55) 
Dyskinesia axial 1.81 (2.30) 1.30 (1.96) 1.26 (1.70) 
Dyskinesia hemibody 1.52 (1.07) 1.13 (1.15) 0.90 (0.85) 
Abbreviations: A: adjustment session; SD standard deviation  
 
UPDRS III HEMIBODY SCORES AND HEMIBODY DYSKINESIAS SCORES 
ON-MEDICATION/ON-STIMULATION  
Variations of UPDRS III hemibody scores were found for the three adjustment 
sessions (Friedman test, p=0.02): a tendency to deteriorate from A1 to A2 
(p=0.02, Wilcoxon test) and no differences for A2 vs. A3 (p=0.12) and A1 vs. A3 
(p=0.28) (table 1.11). A tendency towards an improvement was observed for 
hemibody dyskinesia (Friedman test, p=0.08; hemibody dyskinesia at A1 vs. 
hemibody dyskinesia at A3 p=0.03, Wilcoxon test) (table 1.11) 
 
1.4 ADDITIONAL VISITS 
Six patients required one additional visit. Two patients had an additional visit 
between adjustment 1 and 2 (2 hemibody sides), one between adjustment 2 
and 3 (one hemibody side) and 3 after adjustment 3 (5 hemibody sides). Type 
of adjustment that prompted the additional visit was “change in contact” in all 
cases. Type of adjustment performed at the additional visit was “change in 
contact” in all but two sides where only voltage was adjusted. Hemibody motor 
scores deteriorated in 5 sides, whereas in three it was the presence of 
dyskinesia what prompted the additional adjustment.  
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1.5 PREDICTIVE FACTORS FOR GLOBAL IMPROVEMENT AT EACH 
ADJUSTMENT SESSION 
Predictive variables for global outcome at each adjustment session were 
studied using multivariate regression. Global outcome for each adjustment 
session was defined as the difference on UPDRS III total and hemibody scores 
between chronic and baseline time points. The regression model (backward 
method) was checked for independence of the residuals (Durbin-Watson 
statistic), co-linearity, normality and homoscedasticity of the residuals. The 
independent variables analysed are shown in table 1.12.  
Table 1.12. Variables considered for the multiple regression analysis  
Dependent variable Global outcome for each Adjustment session 
Independent variables for UPDRS III 
total scores
Acute total UPDRS III effect  
Acute axial UPDRS III effect  
Acute total dyskinesia 
UPDRS IV total, off and dyskinesia 
Global effect on axial UPDRS III  
Global effect on total dyskinesia 
Type of adjustment 
Independent variables for UPDRS III 
hemibody scores
Acute UPDRS III hemibody effect  
Acute limb dyskinesia 
Difference in voltage* 
TEED 
LEDD 
Change in contact** 
Time between visits 
* difference  in voltage between baseline and final time point of the adjustment 
** Change in contact was redefined as an ordinal variable taking into consideration the depth of 
the change (change towards a more inferior or superficial position).  
 
For total body analysis, “type of adjustment” was reclassified taking into account 
the type of adjustment performed at both DBS electrodes: 
- No change in any of the DBS electrodes 
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- Change in voltage in at least one of the DBS electrodes and no change 
in contact  
- Change in contact in at least one of the DBS electrodes 
- No adjustment needed in any of the DBS electrodes 
 
1.5.1 TOTAL UPDRS III  
Thirty-one patients were included in this part of the study. Patients with 
additional visits were excluded from the analysis. Two patients required 
additional visits at A1, one at A2 and, 3 at A3.  
IMPACT OF TYPE OF ADJUSTMENT ON GLOBAL OUTCOME AT EACH 
ADJUSTMENT SESSION 
No impact of type of adjustment on global effect of the adjustment was 
seen at A1. At A2, there was a strong tendency towards a total UPDRS III 
global improvement for those patients that had at least one change in the 
stimulated contact and towards stable scores for those with at least one change 
in voltage. At A3, there was a total UPDRS III global improvement of 
approximately 8 points for those patients who had at least one change in 
voltage or one change in contact. Those not requiring additional adjustments at 
A3 had steady scores (table 1.13 and figure 1.8). 
MULITIVARIATE REGRESION ANALYSIS 
At A1, the global effect of axial UPDRS III scores predicted the global 
effect (R2 = 0.69). For each unit of improvement on axial UPDRS III global 
scores there was a 3.22 improvement on total UPDRS III global scores. At A2 
and A3, a strong association between total acute effect and global outcome was 
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found [(R2 = 0.59 (A2); R2 = 0.63 (A3)]. Acute effect had a direct impact on 
global outcome (for each unit of improvement on acute UPDRS III scores there 
was approximately 0.8 points improvement on global scores) (table 1.14).  
 
Table 1.13 Global outcomes of adjustment sessions on total UPDRS III 
scores according to type of adjustment  
Total No
change
At least one 
change in 
voltage
At least on 
change in 
contact 
NAN p*
Global 
outcome at 
A1
n 29 2 5 22 NA  
Mean -1.41 -2.00 -2.00 -1.23 NA 0.816 
SD 9.55 2.83 1.58 10.98 NA  
Global 
outcome at 
A2
n 29 3 10 7 9  
Mean 0.48 5.33 0.90 -5.29 2.89 0.070 
SD 6.89 9.29 5.11 8.30 4.34  
Global 
outcome at 
A3
n 23 2 4 6 11  
Mean -3.83 -5.00 -8.00 -8.83 0.66 0.009 
SD 6.17 2.83 5.16 6.24 5.16  
Abbreviations: A: adjustment session; NA: not applicable; NAN: no adjustment needed; SD 
standard deviation. A minus sign means improvement.  
* Kruskal Wallis Test 
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Figure 1.8. Global outcome of adjustment sessions on total UPDRS III 
scores according to type of adjustment. Type of adjustment by adjustment 
sessions were re-codified as: no change in any of the electrodes, at least one 
change in voltage, at least one change in contact and no adjustment needed. 
Negative values show an improvement in global UPDRS III scores.  
 
Table 1.14 Multivariate regression analysis of total UPDRS III global 
outcome at each adjustment session 
B coefficient Beta p-value
A1 Axial UPDRS III global scores 3.225 0.664 0.001 
A2 Total UPDRS III acute effect 0.782 0.360 0.053 
A3 Total UPDRS III acute effect 0.766 0.406 0.018 
Abbreviations: A: adjustment session 1, 2 and 3.  
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1.5.2 HEMIBODY UPDRS III  
Patients with additional visits were excluded from the analysis. At A1, 
one hemibody side with a bipolar electrode geometry configuration at baseline 
was also excluded. A total of 55, 58 and 46 hemibody sides were included for 
the analysis at A1, A2 and A3, respectively.  
Acute effect on UPDRS III hemibody scores predicted global outcome in all the 
adjustment sessions (table 1.15). There was a linear relationship between acute 
UPDRS III hemibody effect and global effect (figure 1.9). For each unit of 
improvement on the acute effect on UPDRS III hemibody scores, there was a 
global hemibody improvement of 0.91 points at A1, 1.17 points at A2 and 0.66 
points at A3.  
The magnitude of the acute effect necessary to ensure improvement/stability or 
improvement on global effect decreased as stimulation was optimised 
throughout the adjustment sessions. At A1, at least 3 points of acute 
improvement were needed to provide a global improvement or stability (95% 
confidence interval (CI) ranging from -2.65 to 0.14). All of the hemibody sides 
that experienced an acute improvement of at least 5 points did show global 
improvement (95%CI ranging from -5.47 to -2.43). At A2, at least 2 points of 
acute improvement were needed to provide a global improvement or stability 
and 3 points to guarantee a global improvement (95%CI ranging from -1.84 to -
0.43 and from -3.23 to -1.39 respectively). At A3, at least 1 point of 
improvement on the acute effect was necessary to provide a global 
improvement (95%CI ranging from -3.28 to -1.50). 
At A1, an increase in the depth of the active contact produced deterioration on 
the global effect of 5.06 points. Conversely, at A2 change contact towards a 
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more superficial position showed a tendency towards a global improvement  
(2.305 points) (table 1.15).  
Time between visits had a negative impact on motor scores only at the third 
adjustment session. This session had a longer interval between acute and 
chronic evaluations (3 months). For each day of delay, there was an increment 
of 0.063 points on the UPDRS III hemibody scores.  
Table 1.15. Multivariate regression analysis of global hemibody outcome 
at each adjustment session 
PREDICTIVE VARIABLE B Coefficient Beta p value
A1*
Acute effect UPDRS III hemibody scores 0.908 0.623 <0.001 
Increase contact depth 5.058 0.479 <0.001 
A2 §
Acute effect UPDRS III hemibody scores 1.177 0.714 <0.001 
Decrease contact depth -2.0305 -0.231 0.087 
A3**
Acute effect UPDRS III hemibody scores 0.665 0.395 0.001 
Time between visits (days) 0.063 0.463 <0.001 
Abbreviations A: adjustment session. 
*A1: R2=0.504; F=13.215, p<0.001. 
A2§: R2=0.509; F=58.121, p<0.001. 
**A3: R2=0.497; F=21.225, p<0.001.  
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Figure 1.9 Correlation between acute effect and global effect for each 
adjustment session. A) Adjustment 1; B) Adjustment 2; and C) Adjustment 3. 
Global effect:  chronic-baseline UPDRS III hemibody scores; acute effect: 
acute-baseline UPDRS III hemibody scores. 
 
In view of these results, global outcome at each adjustment session seemed 
mainly dependent of the acute effect. However, we aimed to explore whether 
the type of adjustment acted as a confounding factor distorting the global 
outcome scores regardless of the acute effect. For this purpose, a new 
regression model was run considering the global outcome for each session as a 
dependent variable and the acute effect and type of adjustment as independent 
variables. Later on the same model was operated, excluding the type of 
adjustment, and the B coefficients compared.   
At A1 and A2, only the acute effect had an impact on global outcome (A1: B 
coefficient 1.002; beta 0.726; p<0.001 when type of adjustment was considered 
in the model and B coefficient 0.881; beta 0.639; p<0.001 when type of 
adjustment was excluded; A2: B coefficient 1.059; beta 0.642; p<0.001 when 
type of adjustment was considered in the model and B coefficient 1.177; beta 
0.714; p<0.001 when type of adjustment was excluded). 
At A3, global outcome was influenced by the acute effect and by the type of 
adjustment (change in voltage). For each unit of improvement on the acute 
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effect there was a global improvement of 0.726 units on UPDRS III hemibody 
scores. However, when the type of adjustment corresponded to “change in 
voltage” there was a further benefit beyond the acute effect of 2.6 points. 
Therefore, there is a good proportion of the global effect that cannot be 
explained by acute effect. When a “change in contact” was applied no further 
benefit from the acute effect was observed (figure 1.6).  
 
SUMMARY 
Stimulation parameters of STN DBS were reprogrammed in 31 patients (62 
DBS electrodes; 19 male, mean age 56.356.8 years old; mean disease 
duration 12.395.3 years) during three consecutive adjustment sessions. STN 
DBS produced a 49.53% improvement in UPDRS III scores (off-medication) at 
baseline of the study (comparison with pre-DBS). The impact of SP adjustment 
was similar for total and hemibody UPDRS III scores and subscores. 
Reprogramming produced an acute benefit in all of the adjustment sessions 
(A1, A2 and A3); however, this benefit was only maintained at A3. The type of 
adjustment influenced the response of hemibody UPDRS III subscores to SP 
adjustment. “No changes” in SP produced neither an acute nor sustained 
benefit except for at A3, where a chronic improvement was detected. “Change 
in voltage” did not produce either an acute or sustained benefit at A1 or A2. At 
A3, an immediate maintained benefit was achieved. “Change in contact” was 
the type of adjustment producing a major impact on SP. In all of the adjustment 
sessions, this type of adjustment produced an immediate benefit; however, it 
was only maintained at A2 and A3. For those hemibody sides not requiring any 
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adjustment of the stimulation parameters, motor scores were significantly lower 
and were kept stable throughout the study.  
The best predictive factor for a global improvement at each adjustment 
session was an acute improvement on total and hemibody UPDRS III. A linear 
relationship was found between the acute and global effect on hemibody 
UPDRS III. The magnitude of the acute effect necessary to ensure a sustained 
benefit decreased with progressive adjustment of SP [A1: 5 points (range -5.47 
to -2.43, 95% CI); A2: 3 points (range -3.23 a -1.39, 95% CI) and A3: 1 point 
(range -3.28 a – 1.50, 95% CI)]. At A1, stimulating a more caudal contact 
predicted a global deterioration, while, at A2, stimulating a more rostral area 
showed a tendency towards an improvement. 
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2. CLINICALOUTCOME OF STN DBS WITH REPROGRAMMING 
2.1 IMPACT OF SUCCESSIVE ADJUSTMENT SESSIONS ON CLINICAL 
OUTCOME  
Final UPDRS III scores were compared to scores at baseline. Baseline and final 
time point of the study corresponded to baseline scores at A1 and chronic time 
points of A3, respectively. All scores were performed off-medication/on-
stimulation. Patients were included regardless of the need for additional visits 
between adjustment sessions. A total of 26 patients (52 hemibody sides) were 
included in this part of the analysis. 
A significant improvement in UPDRS III total and hemibody scores and a 
tendency towards improvement on axial subscores was observed at the final 
time point compared to baseline. UPDRS I and activities of daily living (UPDRS 
II) off-medication improved as well. LEDD was significantly reduced after 6 
months. However there was no further benefit on motor complications or in 
activities of daily living on-medication (table 2.1).  
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Table 2.1 Comparison of UPDRS scores at baseline and final time point of 
the study  
Baseline Final P value*
UPDRS III 27.85 (15.31) 22.96 (10.06) <0.001 
UPDRS III hemibody subscores 8.38 (5.33) 6.63 (4.04) <0.001 
UPDRS III axial subscores 2.54 (2.63) 1.92 (1.65) 0.08 
UPDRS I 2.27 (1.39) 1.55 (1.41) 0.017 
UPDRS II OnM/OnS 10.41 (5.15) 10.68 (4.86) 0.683 
UPDRS II OffM/OnS 16.41 (7.39) 13.36 (4.49) 0.003 
UPDRS IV dyskinesia 2.00 (1.85) 1.41 (1.79) 0.158 
UPDRS IV off-time 1.68 (1.64) 1.05 (1.21) 0.125 
LEDD 660.15 (403.98) 454.77 (224.18) 0.016 
Abbreviations A: adjustment session; OffM: off-medication condition; OnM: on-medication 
condition; OnS: on-stimulation condition; SD: standard deviation. Values of UPDRS scores and 
subscores are given as means (SD). UPDRS IV dyskinesia comprises items 32, 33, and 34; 
UPDRS IV off-time comprises item 39. *Two-tailed t test. 
Multivariate regression analysis at each adjustment session highlighted the 
importance of changing the stimulated contact. To analyse the impact of this 
type of adjustment on final outcome, patients (by hemibody sides) were 
grouped according to the following classification “Adjustment of stimulation 
parameters throughout the study” (table 2.2): 
- “No changes”: No changes of stimulation parameters (includes “no 
changes” and “no adjustment needed”) throughout the study. 
- “Change in voltage”: One or more change in voltage (or pulse width or 
frequency) but no changes of stimulated contact. 
- “One change in contact”: One change of stimulated contact.  
- “≥ 2 change in contact”: Two or three changes of the stimulated contact. 
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Table 2.2. UPDRS III hemibody scores by type of adjustment of stimulation 
parameters throughout the study (comparison baseline time point of A1 
and chronic time point of A3) 
UPDRS III 
hemibody
Total No
change 
Change in 
voltage
One
change in 
contact
≥ 2 
changes 
in contact
N 52 6 13 21 12 
Baseline Mean
(SD)
8.385 
(5.33) 
5.50  
(2.07) 
7.923 
(4.63) 
8.619 
(5.38) 
9.917 
(6.82) 
Final Mean
(SD)
6.635 
(4.04) 
4.50 
(3.08) 
6.385 
(3.45) 
5.857 
(2.67) 
9.333 
(5.80) 
Abbreviations: SD: standard deviation. 
 
Repeated measures analysis with main factor TIME (2 levels baseline and final 
time point) and between-subjects factor “adjustment of stimulation parameters 
throughout the study” was performed. The analysis revealed a significant effect 
for Time (Pillai’s Trace, p=0.019) but not for adjustment (Pillai’s Trace, p=0.457; 
F=1.789; p=0.162). Post-hoc tests showed a significant improvement of UPDRS 
III hemibody scores for “one change of stimulated contact” (p=0.003), while 
“change in voltage” showed a tendency towards improvement (p=0.068). The 
remaining types of adjustment led to stable UPDRS III hemibody scores. 
Multiple comparisons did not show any significant differences among groups of 
type of adjustment. However, those included in “more than one change of 
stimulated contact” seemed to have higher baseline and final scores, especially 
when compared to “no changes” (figure 2.2).  
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Figure 2.2. UPDRS III hemibody scores at baseline and final time point by 
type of adjustment throughout the study. Mean UPDRS III hemibody scores 
are represented by rhombus, squares, triangles, crosses and stars.  
 
2.2 PREDICTIVE FACTORS FOR  FINAL IMPROVEMENT  
Final outcome variable was defined as the differences between chronic time 
point of A3 and baseline scores of the study (baseline time point of A1).  
 
       A minimal clinical important difference was established on 2.5 points for 
total UPDRS III based on the study by Shulman (2010). Final outcome variable 
was re-codified into a qualitative variable where differences equal or below -2.5 
points were defined as improvement and equal to or above +2.5 points as 
deterioration. Values in between were considered stable scores. For logistic 
regression analysis, the variable was dichotomised into improvement or no 
improvement (including stable and deterioration). For hemibody scores, the cut-
off value was calculated at 0.825 points. Final outcome variable was re-codified 
Final outcome variable = chronic scores of A3 - baseline scores of A1
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into a qualitative variable. Differences equal or below -0.825 points were 
defined as improvement and equal to or above +0.825 as deterioration. The 
global outcome variable for each adjustment session was categorised into 
improvement (differences equal or below -0.825) and deterioration (equal or 
above 0.825).  
 
IMPROVEMENT OF UPDRS III SCORES ALONG THE STUDY 
Twenty-six patients (52 hemibody sides) completed all adjustment sessions. 
Eleven patients (42.3%) had a global improvement, eleven remained stable and 
four (15.4%) deteriorated. For hemibody side: 31 (59.6%) improved, 7 (13.4%) 
remained clinically stable and 14 (26.92%) deteriorated. At A1, half of these 
hemibody sides improved (51.1%). At A2 only 30% improved. At A3 most of the 
hemibody sides improved (68.9%). 
 
Figure 2.3. Final outcome for total and hemibody UPDRS III global 
outcome. Area in the circles represents the percentage of patients and 
hemibody sides, respectively.  
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LOGISTIC REGRESSION OF GLOBAL OUTCOME AND OUTCOME AT 
ADJUSTMENT SESSIONS  
The probability of a global improvement on hemibody motor scores was studied 
using logistic regression analysis (stepwise method). The dependent variable 
was the final outcome defined as improvement or deterioration (cut-off value 
0.825 points). The independent variables considered for the analysis were: 
improvement at A1, improvement at A2 and improvement at A3, as well as 
interactions between them.  
The best predictive factor for a global improvement was improvement at 
A3 on hemibody UPDRS III scores (Exp (B) = 22.455, p=0.006) followed by 
improvement at A1 (Exp (B) 13.598, p=0.021) (table 2.3). Improvement at A2 
and interactions between adjustment sessions were not significant and were left 
out of the equation. Thus, the probability to improve after improvement at A3 or 
improvement at A1 was of the same magnitude regardless of whether there was 
an additional improvement at A1 or A3, respectively. 
The percentage of cases predicted by the model was of 73.1% (for total 
UPDRS III) and 77.8% (for hemobidy UPDRS III) 
The models were checked for Hosmer test (p=0.86 and 0.65), normality of the 
residuals (p=0,073 and 0.077) and Nagelkerke coefficient (0.32 and 0.44).  
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Table 2.3. Logistic regression for global outcome by outcome at each 
adjustment session 
B Exp (B) p-value
Total UPDRS III
Improvement at A1 2.065 7.888 0.064 
Improvement at A2 2.106 8.212 0.072 
Hemibody UPDRS III
Improvement at A1 2.610 13.598 0.021 
Improvement at A3 3.111 22.455 0.006 
Abbreviations: A: adjustment session (1, 2 and 3) 
 
LOGISTIC REGRESSION ANALYSIS OF GLOBAL OUTCOME AND SOCIO-
DEMOGRAPHIC VARIABLES  
The impact of sex, age at DBS and duration of DBS therapy on global outcome 
UPDRS III total and hemibody scores (final time point – baseline time point of 
the study) were studied using logistic regression (user-controlled backward 
stepwise method). 
For UPDRS III total scores, none of these variables predicted global outcome 
(p-values: 0.581, 0.519 and 0.157).  
For UPDRS III hemibody scores, there was a tendency towards an influence on 
final outcome for sex and, to a lesser degree, for age at DBS (table 2.4). 
Women presented a higher probability for improvement than men (Odds ratio 
5.412) (table 2.5). There was a tendency as well for older patients to present a 
decreased probability to improve compared to younger patients (Odds ratio 
0.892). For each year of age difference at the time of DBS, the probability of 
improvement decreased by 11%. 
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Table 2.4. Logistic regression analysis of sociodemographic variables on 
final outcome on hemibody UPDRS III scores 
B Exp (B) p
Sex 1.689 5.412 0.058 
Age at DBS -0.114 0.892 0.077 
Abbreviations: DBS: deep brain stimulation; p: p value 
 
 
Table 2.5. Final outcome on hemibody UPDRS III scores according to sex 
Final outcome Total Male Female 
Total  45 30 15 
Deterioration 14 12 2 
Improvement  31 18 13 
 
 
ANALYSIS OF GLOBAL OUTCOME AND TEED, LEDD AND UPDRS III AT 
BASELINE 
Total UPDRS III scores 
Univariate analysis for change in TEED from baseline to final time point (mean 
difference for both hemibodies) and for change LEDD did not showed 
differences between those patients that improved and those that did not (Mann-
Whitney U test p=0.357 and p=0.157, respectively). However, those with higher 
UPDRS III scores at baseline (off-medication/on-stimulation) had a higher 
probability of a final improvement (logistic regression: B=0.141, Exp(B)=1.151, 
p=0.024). For each unit of increment in UPDRS III baseline scores, the odds 
probability for global improvement increased by 11.51% (95%CI, 1.018-1.301) 
(table 2.6).  
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Table 2.6 Global outcome according to UPDRS III at baseline of the study 
Global outcome
UPDRS III scores at BL  Total Improvement No improvement
n 26 11 15 
Mean (SD) 27.8 (15.3) 37.6 (18.5) 20.7 (6.7) 
Abbreviation: BL: baseline of the studySD standard deviation; UPDRS III: motor part of Unified 
Parkinson’s Disease Rating Scale. 
Mann-Whitney U test p=0.004. 
Hemibody UPDRS III scores 
Logistic regression analysis was used (user-controlled backward stepwise 
methods for main effects and stepwise for interactions) with independent 
variables: change in TEED from baseline to final time point, change in LEDD 
from basal to final time points, UPDRS III hemibody scores at baseline of the 
study and type of adjustment throughout the study.  
Only UPDRS III hemibody scores at baseline were significant (B=0.291, Exp 
(B)= 1.337, p=0.030 (95%CI 1.029-1.738)). For one point of increment in 
UPDRS III hemibody scores at baseline, the probability for improvement 
increased by 33.7% (odds ratio 1.337) (table 2.7). 
Table 2.7 Global outcome according to UPDRS III hemibody scores at 
baseline of the study 
Global outcome
Hemibody UPDRS III BL Total Improvement Deterioration
n 45 31 14 
Mean (SD) 8.6 (5.58) 10.1 (5.92) 5.29 (2.70) 
Abbreviation: BL: baseline of the study; SD standard deviation; UPDRS III: motor part of Unified 
Parkinson’s Disease Rating Scale. 
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SUMMARY 
Forty-two per cent of the patients (59.6% of hemibody sides) showed a motor 
improvement with reprogramming at the end of the study. A significant 
improvement was found for total (p <0.001; two-tailed t test) and hemibody 
UPDRS III (p <0.001; two-tailed t test), UPDRS I and activities of daily living off-
medication (p=0.017 and 0.003 respectively, two-tailed t test). Dopaminergic 
medication requirements were reduced by 30% (p=0.016, two-tailed t test). DBS 
electrodes where a single change in the stimulated contact during the study 
period was conducted showed a statistically significant final improvement 
(p=0.003), while those undergoing “change in voltage” showed a tendency
towards improvement (p=0.068). “No changes” or “two or more changes in 
active contact” did not produce any final effect. 
Younger patients (B=-0.114, p=0.077), women (B=1.689, p=0.058) or higher 
UPDRS III scores at baseline (total: B=0.141, p=0.024; hemibody: B=0.291, 
p=0.030) showed a higher probability for final improvement.  
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3. OPTIMAL STIMULATION SITE IN STN DBS FOR PARKINSON’S 
DISEASE 
 
The position of the DBS electrode and therapeutic contact (active 
contact) was evaluated in 31 patients. Demographic data are described in part 1 
of the results. All patients underwent bilateral STN DBS for at least 12 months. 
Stimulation parameters were optimised after three consecutive adjustment 
sessions with objective quantification of symptoms. This ensures that final 
active contact represents the optimal stimulation site for a given electrode.  
Pre- and postoperative stereotactic MR image acquisition and electrode 
contacts positions were obtained as previously described in methodology. Two 
neurosurgeons blinded to the clinical outcome and stimulation parameters 
independently assessed and agreed on the anatomical position of each contact 
in relation to the visualised STN on the axial and coronal MRI planes. The 
visualised STN was divided into five segments: superior (A), anterior-medial (B), 
central (C), postero-lateral (D) and inferior (E). Each contact was localised in 
relation to the closest STN segment and classified as being inside, superior, 
medial, inferior or lateral to that segment. Final anatomical position for each 
DBS electrode’s contact was defined by the anatomical localisation around the 
STN and its surrounding structures and the STN segment. The optimal 
stimulation area was considered to be the central, superior, posterolateral 
segment of the STN or the area adjacent to the superior border of the STN 
(located less than 1 mm from the border of the nucleus).  
This study will analyse three points: 
Results 
139 
1) Analysis of the anatomical position of the DBS electrode. This part will 
focus on the position of the DBS electrode (regardless the position of the 
stimulated contact). Electrode’s position will be resumed in two groups: 
a. Group I electrode’s position (Group Ie, good location), when at 
least one of the four contacts of the electrode was within the 
defined optimal area (not necessarily corresponds to the active 
contact).   
b. Group II electrode’s position (Group IIe), when none of the 
contacts was within the defined optimal area.  
2) Analysis of the anatomical position of the active (therapeutic) contact. 
This part will define the optimal stimulation site. Active contact position 
will be classified as:  
a. Group I contact’s position  (Group Ic, good location) the active 
contact is within the defined optimal area - the central, superior, 
posterolateral segment of the STN or the area adjacent to the 
superior border of the STN. 
b. Group II contact’s position (Group IIc) consisted of those active 
contacts not fulfilling the above criteria.  
3) The value of postoperative imaging in the selection of the optimal 
therapeutic contact. This part of the study will investigate the usefulness 
of an image-guided selection of the active contact. One of the 
neurosurgeon, blinded to the stimulation parameters and clinical 
outcome, selected one or two contacts considered to be optimally placed 
according to MRI data (MRI contact), assuming that the best site of 
stimulation is the STN nucleus and not the surrounding tracks. If no 
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contact was found within the nucleus, the best contact was considered to 
be the one closest to the superior tip of the STN. Concordance of the 
best located contact (MRI contact) with active contact (clinical contact) 
was evaluated. Contacts were classified into two groups: “no 
concordance clinical/MRI contact” and “concordance clinical/MRI 
contact”.
3.1 ANALYSIS OF ANATOMICAL POSITION OF THE DBS ELECTRODE  
Data regarding electrode’s position was available for 50 electrodes (24 patients 
information available for both DBS electrodes and in 2 patients, for one DBS 
electrode). Figure 3.1 shows number of electrode contacts within (group I) and 
outside the optimal stimulation area (group II): eighty-eight per cent of the 
electrodes had one or more contacts within the optimal stimulation area and; 
60% had two or more contacts. In 12% of the electrodes, all contacts were 
outside the defined optimal area. This accounts for nineteen patients (79%) 
having both electrodes (right and left brain sides) with at least one contact 
within the optimal area and, 5 patients with one of the DBS electrodes sub-
optimally placed. No differences were found for right or left hemisphere (table 
3.1).  
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Figure 3.1.  Number of electrode’s contacts within (group I) and outside 
(group II) the optimal stimulation area for patients included in the clinical 
study.  
 
Table 3.1. Electrodes classification in group Ie by brain hemisphere for 
patients of the study  
Group Ie Right hemisphere Left hemisphere Total
0 contacts 3 3 6 (12%) 
1 contact 5 9 14 (28%) 
2 contacts 11 6 17 (35%) 
3 contacts 5 6 11 (22%) 
4 contacts 1 1 2 (4%) 
Total 25 25 50 (100%) 
TYPE OF ADJUSTMENT AND ELECTRODE’S POSITION 
From a descriptive point of view, electrodes sub-optimally placed required more 
frequently multiple changes in the active contact, whereas “no changes” in the 
SP only occurred in those electrodes with a good location (Chi-square test 
p=0.988; figure 3.2). No statistically significant differences were found for 
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number of contacts per electrode classified as group Ie and either type of 
adjustment performed at the different adjustment sessions (Kruskal Wallis test 
A1 p=0.880; A2 p=0.774; A3 p=0.122).  
DBS EFFICACY AND ELECTRODE’S POSITION
There was a strong tendency towards lower UPDRS III hemibody scores at 
baseline and final time point when the electrode has one or more contacts 
optimally placed. Both groups (Ie and IIe) obtained similar benefits on UPDRS 
III hemibody scores at the end of the study. No statistically significant 
differences were found for DBS efficacy at baseline (compared to preoperative 
scores) and number of contacts classified as group I (table 3.2). 
TEED, VOLTAGE, LEDD AND ELECTRODE’S POSITION
TEED at baseline (statistically significant) and final time point (nearly significant) 
was lower for those electrodes classified as group Ie (table 3.2, figure 3.3). 
Lower values were also found for voltage at baseline in this group (table 3.2, 
figure 3.4).  
Considering both DBS electrodes, LEDD was significantly lower for those 
patients having both electrodes at group Ie at the final time point but not at 
baseline. No differences were found for reduction of LEDD at the end of the 
study within or between groups (table 3.3). 
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Figure 3.2 Percentage of electrodes with 0 or ≥ 1 or more contacts of the 
DBS electrode at group Ie by type of adjustment during the study. Y axis: 
percentages respect to the total number of electrodes with 0 contacts at group I 
or ≥ 1 more contacts at group I. 
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Table 3.2 Comparison of DBS efficacy, global outcome, TEED and voltage 
by number of contacts at group Ie at baseline and final time point 
0 contacts at group Ie
Mean (SD)
1 contacts at group Ie
Mean (SD)
P value
N at BL 6 44  
N at final 6 37  
DBS efficacy at BL (%) 54.52% (14.60) 54.63% (17.84) 0.744* 
DBS efficacy at final (%) 60.01% (16.50) 58.17% (15.47) 0.744* 
UPDRS III hemibody BL 7.90 (3.28) 7.43 (4.68)  0.082** 
UPDRS III hemibody final 6.33 (3.03)  5.46 (2.86)  0.062** 
Global outcome -1.60 (2.34) -0.54 (2.96) 0.44** 
TEED BL 138235.5 (41651.47) 93247.94 (50801.28) 0.044** 
TEED final 157351.0 (91661.11) 102.503.7 (56206.65) 0.075** 
Change TEED 19115.75 (72860.35) 8929.95 (26612.26) 0.55** 
Voltage BL 3.73 (0.41) 3.13 (0.75) 0.060* 
Voltage final 3.73 (0.39) 3.22 (0.76) 0.113* 
Change voltage 0.00 (0.46) 0.10 (0.36) 0.54* 
Abbreviations: BL: baseline; SD: standard deviation; TEED: total electrical energy delivered 
DBS efficacy: [(UPDRS III off medication pre DBS – UPDRS III off medication/on stimulation at 
baseline)/UPDRS III off medication pre DBS] x 100. 
Global efficacy: UPDRS III final time point of the study - UPDRS III baseline time point of the 
study (both off medication/on stimulation). A minus sign means improvement. 
* T-test. 
** Mann-Whitney U test. 
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Figure 3.3. TEED at baseline by number of contacts per electrode 
classified as group Ie. Inside horizontal line: median TEED value; whiskers: 
first and third quartile.   
 
Figure 3.4. Voltage (in volts) at baseline by number of contacts per 
electrode classified as group Ie. Inside horizontal line: median voltage value; 
whiskers: first and third quartile.   
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Table 3.3 LEDD at baseline and final time point classified by number of 
electrodes having at least one contact at group Ie 
One electrode with at 
least one contact at 
group I
Two electrodes with at 
least one contact at group 
I each
P*
n 5 19  
LEDD baseline 864.71 (144.73) 667.77 (476.86) 0.430 
LEDD final  735.00 (114.74) 373.63 (213.39) 0.005 
Change LEDD -129.71 (112.13) -105.21 (180.95) 0.80 
Abbreviations: LEDD: Levodopa equivalent daily dose; SD: standard deviation. Change LEDD: 
difference between final and baseline LEDD 
* T- test. 
3.2. ANALYSIS OF THE ANATOMICAL POSITION OF THE ACTIVE 
CONTACT
Contact location information was available for 50 electrodes at baseline 
and 43 at final time point. At baseline, 54% of active contacts (stimulated 
contacts) lay inside the STN, 40% were medial and the remaining 6% were 
located lateral, superior or inferior to the STN. Those active contacts inside the 
nucleus were mainly at its centre (55.5%) or its superior part (30%). Those 
located medial to the nucleus were mainly medial to the centre (30%) or to the 
superior part (60%), i.e. in the zona incerta that stretches from just above the 
STN and along its medial border and terminates medial and posteromedial to 
the STN’s posterior tail (figure 3.5).  
At the final time point, 58.1% of the active contacts projected inside the STN 
and 30.2% were medially located. The remaining 11.6% were positioned lateral, 
superior or inferior to the nucleus. Active contacts located inside the nucleus 
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were placed at its centre (40%) or at its superior part (52%); those located 
medially were more frequently located medially to the superior part (46%) and 
to the centre of the nucleus (30%). A description of the active contacts 
according to the Schaltenbrand atlas is given in figures 3.5 and 3.6.  Figure 3.7 
shows the evolution of the active contact towards a more rostral position.   
 
Figure 3.5. Location of active contacts at baseline as transposed onto the 
Schaltenbrand atlas. A) Axial view adapted from plate 55, H.v 4.5. Contacts 
related to the antero-medial (light blue dots), central (green dots) and postero-
lateral (dark blue) segments of the STN. B) Coronal view adapted from plate 27, 
f.p 3.0. Contacts related to the superior (red dots) and inferior segments (pink 
dots) of the STN.  
 
Figure 3.6. Location of active contacts at final time point as transposed 
onto the Schaltenbrand atlas. A) Axial view adapted from plate 55, H.v 4.5.   
Contacts related to the antero-medial (light blue dots), central (green dots) and 
postero-lateral (dark blue) segments of the STN. B) Coronal view adapted from 
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plate 27, f.p 3.0. Contacts related to the superior (red dots) and inferior 
segments (pink dots) of the STN.  
 
Figure 3.7 Evolution of the active contact of the quadripolar DBS electrode 
from baseline to final time point. The DBS electrode has four contacts named 
from 0 to 3 (contact 3 being the upper most and contact 0 the lowest most). 
Contact 0, 1, 2, 3 refers to single monopolar stimulation (carcase of the 
neurostimulator as anode and contact as cathode). Contact 01, 12 and 23 
refers to double monopolar stimulation. Bipolar refers to bipolar configuration 
with one or more contacts as the cathode and one contact as the anode. 
Numbers in the y-axis represent percentages. 
Figure 3.8 and table 3.4 shows distribution of active contacts to group Ic or IIc at 
different time points. Nearly 12% of the active contacts moved to a more optimal 
anatomical position at the end of the study.  
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Figure 3.8 Anatomical location group of active contact at baseline and 
final time point. Group Ic (good location): the contact was inside the STN or at 
least adjacent the superior border of the STN. Group IIc: contacts not fulfilling 
the above criteria.  
 
Table 3.4 Anatomical location group of the active contact at different time 
points of the study 
Total (%) Group Ic (%) Group IIc (%)
Baseline time point 50 (100%) 28 (56%) 22 (44%) 
Chronic time point A1 50 (100%) 30 (60%) 20 (40%) 
Chronic time point A2 49 (100%) 30 (61.2%) 19 (38.8%) 
Final time point 43 (100%) 29 (67.4%) 14 (32.6%) 
Abbreviations: A: adjustment session. 
 
 
 
CLINICAL AND STIMULATION PARAMETER VARIABLES  
A tendency towards a larger STN DBS induced improvement and lower UPDRS 
III hemibody scores were observed when the stimulated contact was at group 
Ic. In this group, stimulation was also more efficient, as lower TEED was 
required. TEED increased in both groups (change in TEED group Ic and IIc 
p=0.74, Mann-Whitney U test) and both groups showed a similar improvement 
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at the end of the study (global outcome). LEDD requirements were lower for 
group Ic at baseline, although no differences were found at the final time point 
as medication was reduced in both (change in LEDD final–basal, Mann-Whitney 
U test, p=0.23) (table 3.5).  
It is worth mentioning that 11 patients (13 hemibody sides) had stimulation-
induced dyskinesia at one or both hemibodies at some points of the study 
(dyskinesia rating scale for arm, leg scoring 2 or more points). Dyskinesia 
scores did not change from baseline to final time point [mean (SD), baseline 
0.89 (1.125) and final time point 1.21 (1.478); Wilcoxon test, p=0.49]. In 8 sides, 
dyskinesia appeared or was aggravated readily after the adjustment of the 
stimulation. In none of the patients, dyskinesia was disabling enough to prevent 
stimulation. Active contacts were located inside the STN in all but two, where 
the contact was adjacent to the rostral border of the superior segment (1 side 
missing). Therapeutic contact position distribution at the final time point was as 
follows: central segment of STN (6 sides), superior segment of STN (4), rostral 
to superior segment of STN (2) and, inferior segment of STN (1). Stimulation-
induced dyskinesia did not differ between baseline and final time point. 
Contacts eliciting dyskinesia were more frequently inside the nucleus at both 
basal and final time points compared to the group without dyskinesia. Hemibody 
sides with stimulation-induced dyskinesia had significantly lower hemibody 
motor scores both at baseline and final time points, lower TEED at baseline and 
lower LEDD at final time points. Both groups improved with reprogramming to a 
similar extent (table 3.6).  
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Table 3.5 Differences between contacts at group Ic and IIc for clinical and 
stimulation parameters variables and LEDD 
Group Ic
Mean (SD)
Group IIc
Mean (SD)
p value†
DBS improvement* 52.737 (14.155) 48.122 (12.532) 0.08 
Normalized DBS improvement^ 0.0010 (0.0012) 0.0005 (0.0002) 0.06 
UPDRS III hemibody BL 5.878 (2.035) 7.891 (2.102) 0.07 
UPDRS III hemibody final 5.707 (2.763) 6.629 (2.656) 0.13 
Global outcome (hemibody)** -0.79 (3.256)  -0.50 (1.990) 0.548 
TEED BL 89919.53 (30510.11) 119753.78 (31610.23) 0.07 
TEED final  99649.65 (40698.02) 141921.67 (52598.58) 0.08 
LEDD BL 634.07 (221.54) 773.86 (357.55) 0.07 
LEDD final  430.07 (212.15) 509.23 (280.84) 0.12 
Abbreviations: BL: baseline; DBS deep brain stimulation; LEDD: levodopa equivalent daily 
dose; SD: standard deviation; TEED total electrical energy delivered; UPDRS: Unified 
Parkinson’s Disease Rating Scale. 
*Calculated respect to the off medication/on stimulation versus off medication/off stimulation 
condition at baseline for UPDRS III hemibody scores. 
^ Percentage of DBS improvement on UPDRS III hemibody scores (respect to off medication/off 
stimulation) divided by TEED at baseline. 
** Global outcome of UPDRS III hemibody scores: UPDRS III hemibody scores at final time 
point - UPDRS III hemibody scores at baseline time point  (a minus sign means improvement). 
† Mann Whitney U test 
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Table 3.6. Comparison between group with stimulation-induced 
dyskinesia and group without dyskinesia
Dyskinesia + Dyskinesia - p
UPDRS III hemibody BL 6.43 (3.13) 8.55 (5.45) 0.073* 
UPDRS III hemibody final 4.54 (2.73) 7.34 (4.24) 0.031* 
Global outcome (hemibody)** -1.85 (2.70) -1.79 (4.36) 0.965* 
Voltage BL 2.90 (0.63) 3.22 (0.80) 0.171* 
Voltage final 3.00 (0.70) 3.26 (0.83) 0.297* 
TEED BL 79499.04 (39700.80) 10.3596.83 (53392.53) 0.078* 
TEED final  87714.69 (48274.25) 114330.32 (67994.52) 0.200* 
LEDD BL 548.75 (331.21) 690.87 (411.33) 0.258* 
LEDD final  346.72 (217.83) 490.45 (217.73) 0.064* 
Active contact in/outside the 
STN at baseline (%) 
92.3/7.7 44.7/55.3 0.003** 
Active contact in/outside the 
STN at final (%) 
91.7/8.3 54.8/45.2 0.023** 
Abbreviations: BL: baseline; LEDD: levodopa equivalent daily dose; SD: standard deviation; 
STN: subthalamic nucleus; TEED total electrical energy delivered; UPDRS: Unified Parkinson’s 
Disease Rating Scale. Dyskinesia + refers to the group displaying stimulation induced 
dyskinesia. Values are expressed as means (SD). 
* T-test. 
** Fisher’s exact test. 
 
TYPE OF ADJUSTMENT THROUGHOUT THE STUDY AND ACTIVE 
CONTACT ANATOMICAL GROUP 
At final time point, those electrodes requiring only “one change in contact 
throughout the study” belonged more frequently to group Ic [48.3% (group I) 
versus 14.28% (group II)]. On the other hand, those electrodes requiring “more 
than one change in contact” belonged more frequently to group IIc [13.7% 
(group I) vs. 42.85% (group II)] (table 3.7 and figure 3.8).   
In terms of evolution of the active contact, those electrodes requiring only “one 
change in contact” did not change the anatomical group in 81.3% of the cases 
(68.8% remained in group Ic and 12.5% in group IIc), while anatomical position 
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moved from group IIc to Ic in 18.8% of the cases. In the same way “2 or more 
changes in the active contact” did not change contact location in 90% of the 
cases but did improve contact position in 10% (table 3.8).  
 
Table 3.7. Type of adjustment throughout the study by DBS electrode 
according to anatomical contact location group at baseline and final time 
point
Time point Group Total
N (%)
No
changes
Change 
voltage
One change 
in contact
>1 change 
in contact
Baseline Total 50 (100) 6 (100) 16 (100) 17 (100) 11 (100)
 Ic 28 (56) 3 (50) 10 (62.5) 11 (64.7) 4 (36.4) 
 IIc 22 (44) 3 (50) 6 (37.5) 6 (35.3) 7 (63.6) 
Final Total 43 (100) 6 (100) 11 (100) 16 (100) 10 (100)
 Ic 29 (67.4) 3 (50) 8 (72.7) 14 (87.5) 4 (40) 
 IIc 14 (32.6)  3 (50) 3 (27.3) 2 (12.5) 6 (60) 
 
 
Figure 3.8 Percentage of active contacts by type of adjustment and 
anatomical group at final time point.  
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Table 3.8 Type of adjustment performed and evolution of anatomical 
group from baseline to final time point 
Group Total
N (%)
No change in 
contact
One change in 
contact
>1 change in 
contact
Total 43 (100) 17 (100) 16 (100) 10 (100) 
Ic (stable) 25 (58.1) 11 (64.7) 11 (68.8) 3 (30) 
IIc (stable) 14 (32.6) 6 (35.3) 2 (12.5) 6 (60) 
IIcIc 4 (9.3) 0 (0.00) 3 (18.8) 1 (10) 
The term stable refers to those contacts that did not change anatomical group and IIcIc 
applies for those contacts that moved from group IIc to Ic. No contact moved from group Ic to 
IIc. 
 
Results 
155 
3.3 THE VALUE OF POSTOPERATIVE IMAGING IN THE SELECTION OF 
THE OPTIMAL THERAPEUTIC CONTACT 
 Anatomical data were available for 50 contacts at baseline and 43 at final 
time point. Concordance between clinically selected contact and MRI selected 
contact was seen for 33 contacts (66%) at baseline and increased up to 70% at 
the final time point (figure 3.10). 
 
Figure 3.9 Distribution of concordance clinical/MRI contact at baseline 
and final time point 
CONCORDANCE BETWEEN CLINICAL/MRI CONTACT AND CLINICAL, 
STIMULATION PARAMETERS AND LEDD VARIABLES 
No clinical significant differences were found between “concordance” and 
“no concordance” groups for UPDRS III hemibody at baseline and final time 
points (p=0.509, p=0.339; Mann-Whitney U test), DBS efficacy, normalised DBS 
efficacy by hemibody (p=0.519, p=0.952; Mann-Whitney U test) or global effect 
of adjustments (p=0.927; Mann-Whitney U test). 
Increases in voltage and TEED at the end of the study were larger when no 
concordance existed between clinical/MRI contact (table 3.9).  
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CONCORDANCE BETWEEN CLINICAL AND MRI CONTACT ACCORDING 
TO ANATOMICAL GROUP 
There was a statistically significant higher degree of concordance for those 
contacts located in group Ic than in group IIc at the final time point (p=0.049; 
Fisher’s exact test; table 3.10).  
However, 4 active contacts at group Ic showed a discrepancy with MRI contact. 
In two of them, a contact located rostral to the superior segment of the STN was 
deliberately selected because of stimulation-induced dyskinesia with stimulation 
within the STN. In 2 cases, the MRI contact was inside the central segment of 
the STN, while the therapeutic contact was inside the superior segment; 
therefore, the selection of contact based on MRI data for these two cases may 
have been imprecise. 
 
CONCORDANCE BETWEEN CLINICAL AND MRI CONTACT AND TYPE OF 
ADJUSTMENT DURING THE STUDY 
Those contacts requiring more than one change in the active contact during the 
study had a higher frequency of discrepancy clinical/MRI contact (p 0.052, Chi-
square test) (figure 3.11). 
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Table 3.9 Stimulation parameters variables and LEDD for concordance 
and no concordance groups 
Concordance No concordance P
Voltage baseline 3.11 (0.82) 3.37 (0.54) 0.365* 
Voltage final 3.23 (0.78) 3.42 (0.66) 0.515* 
Change Voltage 0.01 (0.35) 0.26 (0.35) 0.051* 
TEED BASELINE 96818.32 (50947.81) 102195.176 (54168.32) 0.886* 
TEED final 100208.90 (48385.48) 133113.578 (88295.42) 0.432* 
Change TEED 53.80 (19630.48) 34114.50 (50725.57) 0.013* 
LEDD baseline 636.78 (293.52) 801.79 (600.76) 0.292** 
LEDD final 429.92 (232.14) 523.98 (260.87) 0.285** 
Change LEDD -104.28 (192.43) -97.47 (99.14) 0.92** 
Abbreviations: LEDD: levodopa equivalent daily dose; TEED total electrical energy delivered. 
Values are expressed as means (SD) 
* Mann-Whitney U test. 
** T-test 
Table 3.10 Concordance between clinical and MRI contact in relation to 
anatomical group at final time point  
Total
N (%)
Group I
N (%)
Group II 
N (%)
Total 43 (100) 29 (100) 14 (100) 
No concordance 13 (30.2) 4 (13.8) 7 (50.0) 
Concordance 30 (69.8) 25 (86.2) 7 (50.0) 
p value (Fisher’s exact test) 0.049. 
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Figure 3.10 Concordance between clinical and MRI contact according to 
type of adjustment during the study. Numbers of therapeutic contacts are 
represented at y-axis. 
 
SUMMARY 
Postoperative anatomical information about the position of the four contacts of 
the DBS electrode was available for 50 electrodes. Eighty-eight per cent of the 
electrodes had at least one contact within the defined optimal stimulation area. 
Lower hemibody UPDRS III subscores were found at baseline and the final time 
point (p=0.082 and p=0.062; Mann-Whitney U test), TEED at baseline and the 
final time point (p=0.044 and p=0.075; Mann-Whitney U test) and voltage at 
baseline (p=0.60, two-tailed t test) for those electrodes that were optimally 
placed. LEDD at the final time point was significantly lower when both 
electrodes were optimally located (p=0.005, two-tailed t test).  
Active contact evolved towards a more rostral position during the study (from 
central to superior STN segment). Reprogramming led to a more optimal active 
contact position in 12% of the electrodes. Larger DBS benefit (p=0.06, Mann 
Whitney U test) and lower hemibody UPDRS III subscores (P=0.07 Mann 
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Whitney U test) and TEED (baseline: p=0.07 Mann Whitney U test) were found 
for active contacts that were optimally placed. Nevertheless, reprogramming led 
to a similar improvement and allowed a similar reduction of dopaminergic 
medication, regardless the position of the active contact, but at the expense of 
higher TEED in sub-optimally located contacts (p=0.08 Mann Whitney U test). 
Stimulation-induced dyskinesia occurred more frequently with stimulation of 
contacts inside the STN. 
Increases in TEED and voltage were higher when no concordance 
existed between clinical and MRI contact (p=0.013 and p=0.051, respectively, 
Mann-Whitney U test). Concordance was significantly higher when active 
contact was optimally placed (0=0.049, Fisher’s exact test)
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4. ANALYSIS OF TYPE OF ADJUSTMENT “CHANGE IN CONTACT” 
 
This part of the study sought to describe the evolution of those sides that 
underwent “change in contact” from a clinical and anatomical point of view. Due 
to a progressive reduction of the sample, descriptive statistics were mainly 
used. Non-parametric tests were applied when appropriate.  
 
4.1 CHANGES IN CONTACT AT ADJUSTMENT 1 
At A1, the type of adjustment “change in contact” was performed on 28 
hemibody sides (48.3%). Nearly all of them moved towards a contiguous 
contact (93%), and usually to the immediate rostral contact (64%). One contact 
changed from contact 1 to contact 3, and another changed from bipolar (contact 
1 as cathode and 2 as anode) to monopolar configuration (contact 2 as 
cathode). In the remaining 8, the change was towards the immediate caudal 
contact.   
Twenty-one of these contacts did not require a second change of contact at A2 
(figure 4.1); These contacts evolved more frequently towards the immediate 
superior contact (76%). In 4 of these 21 contacts, active contact moved towards 
the immediate caudal contact (in three of these, active contact was changed 
again at A3) (figure 4.1). These 21 hemibody sides had a global motor 
improvement at A1 of 2.45 points. Type of adjustment performed at A2 was: no 
change (9), change of voltage (6), no adjustment needed (6). Anatomical 
position (available for 17 electrodes) before and after A1 is shown in figure 4.2. 
At the baseline of A1, 7 active contacts (41%) were close to the superior 
segment of the STN (inside, medial) and 8 (47%) were inside the central 
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segment. After A1, the number of active contacts adjoining the superior 
segment increased to 12 (70%), while only 3 contacts (17.5%) were located 
close to the central segment. 
4.2 CHANGES IN CONTACT AT ADJUSTMENT 2 
Of the 28 electrodes that had a change in contact at A1, 7 required a new 
change in contact at A2 despite showing an acute improvement after A1. 
Nevertheless, the acute benefit was significantly smaller and they suffered a 
larger deterioration afterwards compared to those not requiring a new “change 
in contact” (table 4.1). Most of these contacts (71.4%) corresponded to those 
moved caudally at A1. The newly stimulated contact at A2 corresponded to the 
same contact used at baseline in 85.7% of the electrodes. Anatomical position 
was available for 4 contacts (figure 4.3). One contact changed towards a new 
contact (different to that use at baseline). In this case, anatomical position 
evolved from the medial to the central segment of the STN (A1 before 
adjustment) to medial to the superior segment (A1 after adjustment) to inside 
the superior segment (A2 after adjustment).  
Two contacts changed only at A2 (figure 4.4); however, anatomical data 
was available only for one of the electrodes. Contact moved to the immediate 
inferior contact (from contact 1 to contact 0). Both anatomical positions were 
considered to be inside the central segment of the STN.   
 
4.3 CHANGES IN CONTACT AT ADJUSTMENT 3 
Three electrodes underwent “change in contact” at all the adjustment sessions. 
Active contacts and their anatomical positions are outlined in table 4.2.  
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Five electrodes had a change in contact at A1 and A3 (prior type of adjustment 
at A2 was “no change” in 2, “change in voltage” in 1 and; “no adjustment 
needed” in 2). Three returned to the contact used at the baseline time point of 
A1. All of these sides experienced an improvement with respect to baseline of 
the study (mean global UPDRS III hemibody scores (final time point of the 
study-baseline time point of the study)= -5.00 points). Anatomical position was 
available for 4 contacts (table 4.3). 
 
Table 4.1. Effects of adjustment 1 on UPDRS III hemibody scores for those 
contacts that underwent a “change in contact” at A1 classified by 
requirement of change of contact at A2 
Type of adjustment at A2
A1 effect hemibody No change in contact Change in contact p
N 21 7  
Acute - 3.68 (3.71) - 0.50 (2.00) 0.027* 
Chronic 1.22 (2.86) 5.25 (4.59) 0.007** 
Global  - 2.45 (4.13) 4.75 (4.71) 0.024* 
Abbreviations: A adjustment session.  
Values are expressed as means (standard deviation). A minus sign means improvement.  
Acute effect: acute – baseline UPDRS III hemibody scores; Chronic effect: chronic - acute 
UPDRS III hemibody scores; global: chronic – baseline  UPDRS III hemibody scores.  
* Mann-Whitney U test. 
** T-test. 
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Figure 4.1 Flow chart of hemibody sides that underwent a “change in 
contact” at A1. Abbreviations A1: adjustment 1; A2: adjustment 2; A3: 
adjustment 3. The numbers refer to the number of electrodes. “Same contact” is 
used when a contact was changed towards the same contact used in the 
previous adjustment session. “New contact” is used when a different contact is 
selected. “Other changes” includes no changes, change in voltage and no 
adjustment needed.  
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Figure 4.2 Anatomical positions of active contacts before (A) and after (B) 
adjustment 1 for those contacts that changed at A1 but not at A2. Number 
of active contacts are displayed on the y-axis and anatomical position related to 
the STN on the x-axis. Location with respect to STN segment is codified in 
different colours, as shown in the legend. 
 
 
Figure 4.3 Anatomical position of active contacts that underwent “change 
in contact at A1 and A2: before (A) and after (B) adjustment 1. Number of 
active contacts are displayed on the y-axis and anatomical position related to 
the STN on the x-axis. Location respect to STN segment is codified in different 
colours, as shown in the legend. At A2, active contact was changed again to the 
contact used at the baseline of A1.  
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Figure 4.4 Flow chart of hemibody sides that did not underwent “change 
in contact” at A1. Abbreviations A1: adjustment 1; A2: adjustment 2; A3: 
adjustment 3. The numbers mean number of electrodes. “Same contact” is used 
when a contact was changed towards the same contact used in the previous 
adjustment session. “New contact” is used when a different contact is selected. 
“Other changes” includes no changes, change in voltage and no adjustment 
needed.  
 
Table 4.2. Active contact and its anatomical position for those contacts 
that changed at A1, A2, A3 
Active contact Anatomical position of active contact
A1b A1a A2a A3a A1b A3a
Case 1 1 12 1 0 Medial to superior 
segment 
Medial to anteromedial 
segment 
Case 2 1 3 1 0 Inside central 
segment 
Inside central segment 
Case 3 2 1 2 1 Medial to superior 
segment 
Inside central segment 
Abbreviations: A1a: adjustment 1 after adjustment of stimulation parameters; A1b: adjustment 1 
before adjustment of stimulation parameters; A2a: adjustment 2 after adjustment of stimulation 
parameters; A3a: adjustment 3 after adjustment of stimulation parameters.  
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Table 4.3. Active contact and its anatomical position for those contacts 
that changed at A1 and A3 
Active contact Active contact position
A1b A1a A3a A1b/A3a A1a
Case 1 1 0 1 Inside inferior segment Caudal to inferior segment 
Case 2 1 0 1 Medial to dorsolateral 
segment 
Medial to dorsolateral segment  
Case 3 1 2 1 Inside superior 
segment 
Rostral to superior segment  
Case 4 2 3 23 NA NA 
Case 5 2 1 12 Medial to superior 
segment 
Medial to superior segment  
Abbreviations: A1a: adjustment 1 after adjustment of stimulation parameters; A1b: adjustment 1 
before adjustment of stimulation parameters; A3a: adjustment 3 after adjustment of stimulation 
parameters; NA: not available.  
SUMMARY 
Twenty-eight electrodes underwent a “change in contact” at A1. Acute effect 
produced by the adjustment was significantly higher for those contacts in which 
the acute benefit was maintained compared to those that deteriorated and 
required a second change in the active contact at A2 (p=0.027, Mann Whitney 
U test). In the latter, most contacts moved caudally, while those not requiring a 
second change in contact moved rostrally. At A2, the new active contact 
selected corresponded to the contact stimulated at the baseline of A1.  
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5. THE VALUE OF THE INTRAOPERATIVE LFP RECORDINGS IN DBS 
TARGETING OF THE STN AND OPTIMIZATION OF STIMULATION 
PARAMETERS 
  Thirty-one patients (17 males) were included in this part of the study. Mean 
age at time of DBS was 57.0 years (SD 7.4; range 38-68). All patients had 
advanced PD with motor fluctuations and/or dyskinesias. Mean disease 
duration was 11.7 years (range 5-28). Before surgery, the mean UPDRS III 
scores off medication was 44.8 (SD 14.5) and on medication 13.9 (SD10.0) 
(p<0.001, two-tailed paired t-test). Clinical assessment of efficacy of chronic 
DBS could not be performed in 2 of the 31 patients. One patient developed 
unexplained confusion postoperatively and the DBS electrodes were removed 
in the immediate postoperative period. One patient succumbed to cancer a few 
months after surgery. Mean time of DBS treatment at time of clinical 
assessments was 19 months (range 6-51 months). UPDRS III scores fell from 
44.7 (SEM 2.9) off-medication/off-stimulation to 21.2  1.5 off-medication/on-
stimulation. Electrode’s contact configuration was monopolar in all but 5 sides 
where it was set as bipolar. Pulse with was set at 60 seconds (90 in 4 sides) 
and frequency at 130 Hz (145 Hz in four sides, 150 Hz on two sides, 160 Hz on 
two sides, 180 Hz on five sides and 185 Hz on two sides).  
A discrete peak between 11 and 35 Hz in power spectra of the LFP activity 
recorded at contact 01 was identified in all but two sides (both on the left). The 
power of this peak was clearly modulated during electrode descent, except on 
one side. Thus, three (5%) out of 57 sides did not have an obvious peak or step 
change in LFP activity along the electrode trajectory. There was no difference in 
the efficacy of DBS between the 54 sides, with evidence of a local beta 
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generator [improvement in contralateral UPDRS III hemibody score off-
medication 8.2 (SD 0.7) points or 51.3% (SD 4.2) of preoperative score] and, 
those three sides without such evidence [improvement in contralateral UPDRS 
III hemibody score off-medication 13 points (97%), 3 (50%), 10 (62%), 
respectively] although the latter group was very small. No differences between 
stimulation parameters were found between both groups [evidence of beta 
generator: mean stimulation voltage 2.8  (SD 0.1) volts, pulse width 60 (90 on 
four sides) microseconds, frequency 139 (SD 2) Hz; no evidence of beta 
generator (3 sides):  stimulation voltage 1.7, 3.8 and 1.9 v, pulse width 60 
microseconds, frequency 130 Hz]. However, those sides with evidence of a 
local beta generator tended to have more optimal anatomical targeting (88% in 
group I) than those without evidence of a local beta generator (33% (1 side) in 
group I; Fisher’s exact test, p=0.054). 
Among the 54 sides in whom there was a focal beta peak, the subthalamic LFP 
peaks were distributed across 14-34 Hz (figure 5.1). The median power of the 
peak LFP activity recorded at the initial step in the beta activity (ie, the depth 
considered to be that of the local beta generator) was 3.3 V (IQR 1.1 to 7.2 
V; Kolmogorov-Smirnov test for normal distribution, p=0.004); 2 mm above 
(below in four sides) this, the median power over the frequencies of the peak 
was 0.5 V (IQR 0.1 to 1.2 V; Kolmogorov-Smirnov test for normal distribution, 
p=0.003). The median percentage change between the two levels was 500% 
(z=6.393, p<0.001). There was no difference between the depth of the local 
beta generator recorded intraoperatively (mean 0.83 mm and median 0 mm 
above the surgical target point) and the depth of the contact independently 
chosen for chronic DBS (mean 1.01 and median 0.5 mm above the surgical 
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target point; Wilcoxon signed ranks test, z=-0.571, p=0.568). However, both 
differed from the depth of the target point aimed at during surgery (Wilcoxon 
signed ranks tests, z=-2.973, p=0.003 and z=-4.161, p<0.001, respectively).  
There was a correlation between the depth of the local beta generator recorded 
intraoperatively and the depth of the electrode contact independently chosen for 
chronic DBS (Spearman’s rho=0.35, p=0.01, n=54; figure 5.2). A potential 
association between the depth of the beta generator and the optimal site for 
amelioration of parkinsonism was strengthened by considering those sides in 
which there was a disparity between the depth of the generator and that of the 
contact chosen for chronic stimulation. There was a weak correlation between 
the absolute disparity in millimetres and the stimulation voltage used for chronic 
stimulation, such that a bigger difference between depths was associated with a 
higher stimulation voltage or TEED (rho=0.322, p=0.017, n=54 and rho=0.308, 
p=0.024, respectively). There was no such tendency between the stimulation 
voltage or TEED employed for chronic stimulation and the absolute difference 
between the surgical target point depth and that of the contact chosen for 
chronic stimulation (rho=0.103, p=0.468, n=54 and rho=0.127, p=0.368, 
respectively). This suggests more stimulation voltage had to be employed if a 
depth was selected for chronic stimulation that differed from that of the local 
beta generator but not if it differed in depth from the surgical target point. This 
relationship between the depth of the generator and the stimulation intensity 
was maintained even if we controlled for clinical effect of DBS. To this end we 
derived a measure of the normalised efficacy of DBS by dividing the DBS 
induced improvement in contralateral hemibody UPDRS III scores by TEED. 
There was a negative correlation between the normalised chronic DBS efficacy 
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and the absolute difference between the depth of the local beta generator and 
that of the contact chosen for chronic stimulation (rho=-0.315, p=0.021), so that 
chronic stimulation at the depth of the intraoperatively defined generator was 
associated with more effective long-term stimulation. As before, however, there 
was no correlation between the normalised chronic DBS efficacy and the 
absolute difference between the surgical target point depth and that of the 
contact chosen for chronic stimulation (rho=-0.116, p=0.411), so that the depth 
of the surgical target point was a relatively poor predictor of stimulation efficacy. 
Figure 5.3 highlights the scale of the effect of disparity between the depths of 
the generator and contact chosen for chronic stimulation. The normalised 
efficacy of DBS was more than halved when the contact was 2mm from the 
depth of the generator. 
Finally, there was a positive correlation between the depth of the local beta 
generator and that of the optimally anatomically placed contact on those 46 
sides (group I) in which a contact was inside or adjacent to the most superior 
part of the STN (rho=0.379, p=0.011). As expected, there was no such 
correlation in the remaining sides where the best situated contact was neither 
inside nor abutted the superior part of the STN (group II) although the numbers 
were much smaller (n=8, rho=0.226, p=0.55).  
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Figure 5.1. Distribution of spectral peaks, as recorded intraoperatively 
from the deep brain stimulation electrode (n=54. One peak per side).  
Abbreviations: LFP local field potentials 
 
Figure 5.2. Correlation between the depth of the local beta generator 
recorded intraoperatively and the depth of the contact independently 
chosen for chronic deep brain stimulation (DBS). The size of the circle 
indicates the number of sides that shared these graphical coordinates. Depths 
are relative to the surgical target point. Spearman’s rho=0.35, p=0.01, n=54. 
Abbreviations LFP: local field potentials 
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Figure 5.3. The effect of any difference between the depth of the local beta 
generator identified intraoperatively and the depth of the contact chosen 
for chronic stimulation on normalised DBS efficacy (DBS induced 
improvement in contralateral UPDRS III hemibody scores/total electrical energy 
delivered (in μJ). Chronic stimulation at the depth of the intraoperatively defined 
beta generator was associated with more effective long term stimulation. (p 
value is given following a t test for independent samples with unequal 
variances). Note that depths that differed by 1 mm occurred because the 
neurosurgeon advanced the electrode 1 or 3 mm beyond the target point before 
fixation.  
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SUMMARY 
LFPs were recorded from the contacts of 57 DBS electrodes as the latter were 
advanced in 2 mm steps from above to below the intended surgical target point 
in STN.  
A spectral peak in the bipolar LFP was recorded in the 11-35 Hz band at the 
lowest contact pair that underwent a steep but focal change during electrode 
descent in all but three sides. The depth of the initial intraoperative step 
increase in beta correlated with the depth of the contact independently chosen 
for chronic DBS (Spearman’s rho=0.35, p=0.01). In addition, the absolute 
difference between the depths of the initial increase in beta and the contact
chosen for chronic DBS correlated with the voltage used for chronic stimulation 
(rho=0.322, p=0.017). Thus, more voltage had to be employed if a depth was 
selected for chronic stimulation that differed from that of the beta generator.  
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1. LONGITUDINAL ASSESSMENT OF THE IMPACT OF CONSECUTIVE 
SESSIONS FOR ADJUSTMENT OF STIMULATION PARAMETERS OF STN 
DBS IN PD PATIENTS: EVALUATION OF THE ACUTE AND CHRONIC 
EFFECTS OF STIMULATION PARAMETERS 
This study was designed to evaluate the acute and sustained effect on 
motor symptoms of three consecutive sessions of programming of stimulation 
parameters in chronically STN DBS-treated PD patients. The objective was to 
establish whether the acute effect consistently predicted a sustained benefit. 
  Our general results on DBS efficacy are in line with previously published 
studies (Krack et al., 2003, Fasano et al., 2010; Castrioto et al., 2011). In the 
present study, an improvement of almost 50% on motor UPDRS III scores was 
found after a mean time of DBS treatment of 30 months in the off-medication 
condition (compared to pre-DBS scores). This improvement was corroborated 
for total scores as well as for hemibody and axial UPDRS III subscores. 
However on-medication scores deteriorated when compared to pre-DBS 
scores, probably reflecting both a progression of PD with development of 
dopamine-resistant symptoms and stimulation induced-desensitisation in the 
dopaminergic system (Moro et al., 2002; Bejjani et al., 2000).  
Currently, guidelines for selection of optimal stimulation parameters are 
based on the acute improvement produced by the combination of stimulation 
parameters. In routine practice, the improvement is subjectively assessed 
without proper quantification. The acute effect of stimulation parameters 
adjustment is firstly influenced by the complexity of the response to stimulation 
of Parkinsonian symptoms (Kuncel et al., 2004), need of cooperation from the 
patient and possible placebo effect (Mercado et al., 2006). This renders 
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programming of DBS dependent on several variables and there is no guarantee 
that a new setting will be optimal in the long-term.  
There is not a specific pattern of behaviour for the different types of 
adjustment, as the outcome of one setting would necessarily be influenced by 
the preceding ones. In line with this, minor changes in the stimulation 
parameters, such as “change in voltage”, did not produce either an acute or 
sustained benefit at A1 and A2 sessions. However, at the third adjustment 
session (A3), adjustment of voltage produced an acute benefit that was 
maintained over time. “Change in the active contact” – and therefore in the 
stimulated area – showed a more complex response. This type of adjustment 
always produced a significant acute benefit, but the chronic response showed 
more variability. Under this condition, while a chronic deterioration was seen at 
A1, a sustained benefit occurred at A2 and A3. The behaviour of this type of 
adjustment will be discussed later, as it is closely linked to the anatomical site of 
stimulation. “No change” in the stimulation parameters, as expected, did not 
produce either an acute or sustained benefit at A1 and A2 adjustments. 
However, at A3 a long-term improvement was seen. Whether this could be 
related to optimisation throughout previous adjustment sessions is not clear. 
Those sides where no adjustment of the stimulation was needed had lower 
motor scores, reflecting that the clinical decision to not modify the stimulation in 
this group was correct.  
Our findings lead us to conclude that subjective assessment of the acute 
impact of stimulation parameters is not always translated into an objective acute 
effect and, moreover, long-term deterioration can occur even after an acute 
benefit, particularly when the new setting involves a change in the active 
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contact. Previous studies have shown a similar behaviour when the 
programming setup involved a change in the active contact. Fasano et al. 
(2010), in their long-term study, found that changes in the stimulated contact 
beyond the fifth year of DBS led to an improvement in motor signs in 52% of the 
patients while it produced deterioration in the remaining 48%. Moro et al. (2006) 
conducted a study with the aim to evaluate the evolution of chronically 
implanted patients after reprogramming. This study demonstrated an 
improvement of symptoms with reprogramming of the stimulation settings in the 
majority of patients. In those who improved, the most frequent type of 
adjustment was a change in the electrode’s geometry. However, half of the 
patients who deteriorated also underwent a change in the electrode’s geometry. 
In this study, evaluations were not blinded and although some clinical 
assessments were performed for selection of the optimal setting, the acute 
effect was not clearly quantified. Neither did they determine the anatomical 
position of the electrode’s contacts.  
It has been shown that the stimulation effect might take up to 3 hours to 
vanish once the stimulation is switched off (Temperli et al., 2003). Tremor 
returns first, followed by rigidity and bradykinesia. Impact on axial signs may 
take even longer to fade away. In the same way, improvement of Parkinsonian 
signs after switching the stimulation on follows a similar pattern with tremor 
improving first, followed by rigidity and bradykinesia, and later on by axial signs 
(Temperli et al., 2003). Even more, a two-step process for bradykinesia 
washout has been described (Cooper et al., 2011).  This is most relevant for 
DBS programming. In fact, the acute effect observed during a programming 
session will represent just a part of the total stimulation effect for a given 
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contact, which may explain the additional sustained benefit observed at A3. 
More important for DBS programming is that the “carry over” effects of previous 
stimulation parameters may still be present when assessing a new setting. This 
might be of relevance when changing the stimulated contact and thus the 
stimulation area, and explains the delayed deterioration in Parkinsonian 
symptoms observed in our study.  
Sustained benefit was only achieved after two consecutive adjustment 
sessions, reflecting the complexity of DBS optimisation even in expert hands.  
Finally, PD is a disorder in which the placebo effect can play a significant 
role (De la Fuente-Fernandez et al., 2002). DBS therapy is not exempt from this 
effect (Mercado 2006; De la Fuente-Fernandez et al., 2004). Therefore, 
although patients were blinded to the new stimulation setting, they were familiar 
with the beneficial effect of STN DBS. Thus, we cannot rule out that patient 
expectations may have magnified the acute response to the new stimulation 
parameters. Furthermore, hemibody UPDRS III subscores comprise several 
items evaluating bradykinesia, which is one of the Parkinsonian symptoms more 
susceptible to the placebo effect (Mercado et al., 2006).  
On-medication/on-stimulation total UPDRS III scores showed a tendency 
towards deterioration (18% deterioration), while hemibody dyskinesia showed a 
tendency towards an improvement. This could be explained by a statistically 
significant reduction of dopaminergic medication at the end of the study.  
In this study we have demonstrated that the variable that most 
consistently predicts global motor outcome is the acute effect on motor 
symptoms produced by adjustment of the stimulation parameters. The 
magnitude of the chronic effect was directly related to the magnitude of the 
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acute effect. Interestingly, as optimisation of the stimulation progressed through 
consecutive adjustment sessions, smaller improvements in the acute effect 
were necessary to ensure a global benefit.  
“Change in contact“ also influenced motor outcome. Changing the contact 
towards a more caudal position predicted a global deterioration at A1, while 
reversing this situation at A2 showed a tendency towards a global improvement. 
Change in active contact did not predict global outcome at A3, most likely 
because optimal contact was already established at previous adjustment 
sessions. Nevertheless, this capacity of “change in contact” to impact global 
outcome is mainly through its acute effect. In contrast, “change in voltage” 
added a further benefit on global outcome, which might reflect how optimisation 
is achieved through consecutive programming sessions.  
In our study, the presence of acute dyskinesia did not predict global 
outcome of the adjustment. This aspect contrasts with previous studies where 
this sign seemed to be a good predictor for DBS outcome. Moro et al. (2006) 
found that more than half of the patients that improved after reprogramming of 
DBS settings had stimulation-induced dyskinesia after a mean time of 9.9 
hours. Our acute evaluation did not extend that long, thus it is probable that mild 
and non-disabling dyskinesia may have occurred and not been eve perceived  
by the patient. Smaller increments of voltage at the programming session might 
be another factor. At A3, which had the longest interval between acute and 
chronic evaluations, time between visits had a negative impact on motor scores, 
which raise the question about a possible tolerance effect in DBS, a matter that 
has been widely discussed, in particular for essential tremor (Hariz et al., 1999; 
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Pilitsis et al., 2008; Zhang et al., 2010; Favilla et al., 2012). Nevertheless 
worsening due to natural disease progression cannot be completely rule out. 
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2. FINAL OUTCOME OF ADJUSTMENT SESSIONS 
Consecutive adjustment sessions of stimulation parameters led to an 
additional benefit of DBS therapy of 17.5% on total UPDRS III scores and of 
20.9% on hemibody subscores in the condition of off-medication/on-stimulation 
(comparison baseline vs final time point of the study). UPDRS III axial 
subscores showed a tendency towards improvement. Activities of daily living 
off-medication/on-stimulation improved as well, whereas on-medication/on-
stimulation UPDRS II did not. Forty-two per cent of the patients experienced a 
motor improvement with reprogramming and 42% remained stable at the end of 
the study. Only 15% of the patients had a motor deterioration from their 
baseline situation. Furthermore, reprogramming led to a reduction of 
dopaminergic medication by 30%. Our results, along with those from Moro et al. 
(2006) support the fact that reprogramming in chronic implanted patients can 
lead to additional benefits and reduction of dopaminergic dosage, at least in a 
subgroup of patients. 
 Electrodes undergoing only “one change in the active contact” had a 
significant improvement whereas those requiring only adjustment of amplitude 
showed a tendency to improve. Electrodes needing “two or more changes in the 
stimulated contact” did not obtain additional benefits. This last scenario 
probably reflects suboptimal electrode location. Motor scores for electrodes in 
which stimulation parameters were not changed did not significantly vary. This 
implies that although the placebo effect may be present in STN DBS 
adjustments (Mercado et al., 2006), it is not maintained over time.   
As expected, improvement at previous adjustment sessions predicted global 
outcome. This was the case for A1 and A3, which were the adjustment sessions 
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that showed a global benefit. At A2, sides that improved corresponded mainly to 
those that underwent a change in contact at A1 and A2. The new contact 
selected at A2 matched the contact used at baseline of A1, and therefore the 
adjustment at A2 consisted mainly of reversing an unsuccessful adjustment at 
A1.  
In our series, there was a male preponderance, as it has been the case 
in other DBS populations (Hariz G-M et al., 2003) where women are under-
represented and seem to be referred to surgery later on in the course of the 
disease. Interestingly, we observed a lower probability for men to improve with 
reprogramming. In general, benefits obtained after STN DBS are similar in both 
sexes (Hariz G-M et al., 2003, Accolla et al., 2007) although women 
experienced greater benefits in activities of daily living (Accolla et al., 2007; 
Hariz G-M et al., 2003) despite showing a poorer response in bradykinesia 
(Accolla et al, 2007). Differences in response to DBS for women and men are 
not easily explained. The fact that, in our study, these differences were seen 
only for hemibody motor subscores and not for total motor scores may imply a 
different behaviour between sexes for tremor, rigidity and bradykinesia but not 
for axial symptoms. 
In general, our results showed that patients who improved with 
reprogramming were younger. This finding is in line with the study of Moro et al. 
(2006). A worse outcome after STN DBS has been described in elderly patients 
and related to the presence of less responsive axial symptoms (Derost et al., 
2007; Welter et al., 2002). However, in our study, the reduced probability for 
improvement was only seen on motor UPDRS III hemibody scores. Thus, it is 
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possible that rigidity, tremor and bradykinesia also had a more limited response 
to DBS in the elderly population.   
Patients with a worse motor performance at baseline of the study 
showed a greater probability of improvement. This could be explained by a 
suboptimal optimisation of DBS therapy prior to inclusion in the study.  
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3. OPTIMAL STIMULATION SITE IN STN DBS FOR PARKINSON’S 
DISEASE 
DBS of the STN is nowadays a well-established treatment for advanced 
Parkinson’s disease. Since its introduction, several studies have reported long-
term benefits of this procedure for selected patients with advanced PD. 
However, although DBS mimics several clinical effects induced by therapeutic 
lesions, the precise mechanisms of action are poorly understood. Furthermore, 
it remains unclear which locus within the subthalamic area is optimal to obtain 
the best efficacy with lower stimulation consumption. Two sites have been more 
frequently proposed: the dorsal part of the STN, known to be its sensorimotor 
part  (Herzog et al. 2004; Yelnik et al., 2003; Saint-Cyr et al., 2002); and the 
dorsal area adjacent to it, containing pallidofugal fibres and the rostral zona 
incerta (ZI) (Voges et al., 2002; Hamel et al., 2003; Godinho et al., 2006). Most 
studies have addressed this question through determination of the anatomical 
location of the active contacts at one time point of the follow-up, regardless of 
previous changes in the electrode’s active contact and thus of the stimulation 
site. In this regard, we sought to study the evolution of the stimulation site 
through consecutive programming sessions with objective quantification of 
symptoms. The final position of the active contact will most likely represent the 
optimal stimulation site. Finally, we investigated whether an image-guided 
approach for selection of the optimal contact could complement and simplify the 
programming of stimulation.  
Our optimal defined area comprised the central/superior STN segments 
and the rostral area adjacent to it, as long as the contact was adjacent to the 
rostral border of the STN. Almost 90% of the DBS electrodes had at least one 
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contact within the optimal stimulation site, which accounts for nearly 80% of the 
patients having both DBS electrodes with at least one contact lying on the 
optimal stimulation site. None of the patients had both electrodes outside the 
optimal stimulation site.  
STN DBS-induced improvement was similar in both groups of electrodes. 
However, stimulation was more efficient, in terms of TEED consumption, when 
the electrode was optimally placed. UPDRS III hemibody scores showed a 
tendency towards lower values in this group both at baseline and final time 
point. Adjustment of the stimulation led to a similar improvement in both groups. 
Nevertheless, for those electrodes suboptimally placed, TEED requirement was 
larger at the end of the study. As voltage did not change for these electrodes, 
augmentation of TEED might be explained by increased pulse width or 
frequency, stimulation parameters that are usually modified when improvement 
cannot be achieved by increasing voltage. Intensive programming allowed a 
reduction of dopaminergic medication in both groups. Nevertheless, LEDD at 
the final time point was significantly lower for the electrodes that were 
accurately implanted. Optimisation of stimulation parameters were more easily 
achieved for optimally located electrodes. Indeed, no changes of the stimulation 
parameters only occurred in this group, whereas multiple changes in the 
stimulated contact were needed more frequently for suboptimally placed 
electrodes.  
Accuracy of electrode implantation is a crucial factor to ensure a good 
clinical response and to avoid side effects (Guehl et al., 2007; Richardson et al., 
2009; Hamid et al., 2005). Our findings support this vision but highlight how 
improvement can still be achieved for suboptimally placed electrodes, as a 
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benefit can be obtained as long as the contact is within 2-3 mm diameter from 
the optimal stimulation site (Richardson et al., 2009; Ellis et al., 2008; Anheim et 
al., 2008). Nevertheless, this improvement is at the expense of higher 
stimulation parameters and dopaminergic medication. Furthermore, 
suboptimally placed electrodes may involve more laborious programming, with 
the consequent discomfort for the patient and time consumption for the 
neurologist.  
The position of active contacts was determined on MR images and 
defined by their position within the STN and surrounding structures, instead of 
using atlas coordinates or microelectrode recording (MER) data. We believe 
that this is a more reliable method than using the inter-commissural point as the 
reference, given the significant intra- and inter-individual variation in the 
relationship of the inter-commissural point with the STN (Littlechild et al., 2003; 
Patel et al., 2003; Richter et al., 2004). Furthermore, the description of the 
anatomical position based on MER findings does not take into account possible 
deviations from the selected MER trajectory that can occur when introducing the 
microelectrodes  or the DBS electrode (Bakay et al., 2011). Basing identification 
and location of the electrodes’ contacts on MR images presupposes that MR 
provides a reliable representation of brain anatomy, a fact that has been 
previously verified (Yelnik et al., 2003). 
At baseline of the study, more than half of the active contacts were inside 
the STN, whereas the remaining contacts were mainly medial to the nucleus. 
Our practice comprises an image-guided approach with routine postoperative 
stereotactic imaging. In a preliminary analysis, a systematic error consisting of a 
medial and posterior deviation of electrode placement was noticed. Accuracy 
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was improved after calibration of this systematic targeting error (Holl et al., 
2010). However, this series of patients belong to the pre-calibration era, which 
may explain why almost half of the contacts were medially located.  
Nevertheless, reprogramming - “change in contact” - reduced the 
percentage of active contacts medially placed by 10%, while those inside the 
nucleus and rostral to the superior segment increased. Contacts located inside 
the STN evolved from the central to the superior segment, the latter being the 
most frequent stimulation site at the final time point. Besides, contacts located 
medially to the nucleus were more frequently medial to the superior segment, 
which corresponds to the ZI, a recognised target for symptoms of PD (Plaha et 
al., 2006).  Our implantation procedure aims to implant contact 1 at the centre of 
the STN, ensuring that there is one contact at the superior segment and the 
next one rostral to it. Thus, these results strongly suggest that the theoretical 
target is the superior segment of the STN in accordance with previous 
publications (Herzog et al., 2004; Yelnik et al., 2003; Godinho et al., 2006). 
Others, however, have concluded that the white-matter area above the STN is 
equally effective but more efficient in terms of energy consumption (Voges et 
al., 2002; Saint Cyr et al., 2002). Specifically, Hamel et al.,  (2003) proposed 
this latter zone to be the optimal area as it was the most frequent stimulation 
site. However, a later publication from the same group, which included 
symptoms quantification, found stimulation to be equally effective in the 
sensorimotor STN and dorsal margin of the nucleus whereas stimulation above 
the dorsolateral border resulted in poorer benefits and higher energy 
consumption (Herzog et al., 2004).  
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These discrepancies may, in part, reflect differences in the accuracy of 
the methods used to localise the electrode’s position. Nonetheless we also 
found that some active contacts evolved towards the rostral white-matter 
subthalamic area, although they only represented 6% of all the contacts 
studied. In any case, if one takes the current spread around the electrode 
contact with monopolar stimulation into account (2–3 mm diameter) (Ranck, 
1975; Ashby et al., 1999; Saint Cyr et al., 2002), it is quite likely that stimulation 
of either the sensorimotor STN or white-matter subthalamic area would 
modulate the contiguous region. A patient-specific model study found greater 
STN DBS-induced improvement when the volume of tissue stimulated spread 
outside the atlas-defined borders of the STN compared to stimulation inside the 
nucleus (Maks et al., 2009).  
One of the advantages of our study design over previous studies 
evaluating the optimal stimulation site is that we assessed stimulation area after 
a careful optimisation of the stimulation parameters while some of these studies 
have assumed that an active contact at a given time should represent the 
appropriate target (Voges et al., 2002; Hamel et al., 2003; Saint Cyr et al., 
2002). This is based on the assumption that stimulation parameters are 
optimised during the first months after surgery and few changes are needed 
afterwards. However, we, along with other authors (Moro et al., 2006; Fasano et 
al., 2010) have probed that reprogramming in otherwise stable patients may 
lead to further benefits, especially when it involves a change in the active 
contact. 
We found that stimulation within our defined optimal area – the 
central/superior segment of the STN or adjacent rostral area – to be more 
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efficient. Stimulation of this region not only provided a larger benefit but required 
less energy of stimulation and lower medication.  
Despite the suboptimal position of some of the active contacts, both 
groups improved with reprograming to a similar extent and medication could be 
further reduced. This improvement may be explained by a change in the 
stimulation area and higher electrical stimulation parameters used at the final 
time-point. Nevertheless, it is important to stress that optimisation was much 
more laborious for suboptimally placed contacts, with multiple changes in the 
stimulated contact required more often in this group. These findings highlight 
how stimulation can be further optimised even for suboptimally placed 
electrodes, although they may require higher stimulation parameters to broaden 
the volume of the tissue stimulated.  
Selection of the active contact by clinical assessment improved 
stimulation site in almost 10% of the electrodes. Our defined optimal site is wide 
enough to cover at least two contacts of the DBS electrode, which explains why 
some changes in contact did not result in a modification of the stimulated area, 
as long as the change is towards a contiguous contact. Some of the active 
contacts located at group Ic underwent a “change in contact”, which explains 
the evolution from central to superior STN segment. 
In our results, in all but two cases, stimulation-induced dyskinesia 
occurred when the active contact was located inside the STN. In these, 
stimulation was applied adjacent to the superior border of the STN, which would 
necessarily have influenced the sensorimotor STN. The presence of 
stimulation-induced dyskinesia has been considered a good predictive factor of 
amelioration of Parkinsonian signs (Houeto et al., 2003; Moro et al., 2006). 
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Indeed, we found this group to have lower UPDRS III scores and TEED and 
medication requirements. These results also support the hypothesis of 
sensorimotor STN as the optimal target. Nevertheless, as not all patients in 
which contacts where located inside the STN had stimulation-induced 
dyskinesia, patient susceptibility factors may also be involved. Conversely, 
stimulation of the subthalamic white matter has been found to have an 
antidyskinetic effect (Herzog et al., 2007; Alterman et al., 2004). Herzog (2007) 
reported three patients in whom stimulation inside the STN induced disabling 
dyskinesia that was reduced with additional stimulation of the rostral white-
matter area. We performed the same approach in one of our patients (not 
included in this study) and, although stimulation of a proximal contact 
suppressed stimulation-induced dyskinesia, Parkinsonian symptoms worsened, 
rendering this approach impracticable.  
Additionally, we would like to stress that electrode implantation was performed 
without microelectrode recordings. A single brain-pass was used in the majority 
of patients. Most teams use three to five MER passes to define the functional 
sensorimotor STN segment with the consequent increase in the risk of 
intracranial haemorrhage and time of surgery (Hariz, 2002). We have 
corroborated that the clinically defined optimal stimulation site corresponds to 
the superior segment of the STN and that this functional segment can 
accurately be targeted using neuroimaging and macrostimulation criteria. 
Additionally the efficacy of our method on Parkinsonian symptom amelioration 
has been previously reported (Foltynie et al., 2011).  
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3.3 THE VALUE POSTOPERATIVE IMAGING IN THE SELECTION OF THE 
OPTIMAL THERAPEUTIC CONTACT 
 
We have shown how anatomical position of the active contact is critical 
for DBS efficiency and optimisation. According to current guidelines for DBS 
programming, the best electrode contact is selected based on its clinical 
efficacy (the best contact will be the most effective at lowest voltage and higher 
threshold for side effects). However, the increased knowledge about the optimal 
stimulation site and advances in neuroimaging techniques may allow selection 
of the optimal contact based on its anatomical location. This approach 
represents a more rational strategy for selection of the therapeutic contact, 
avoiding confounding effects that may arise from traditional strategies of 
programming (patients’ cooperation, neurologist capability, dopaminergic 
medication state, carry-over effects of previous stimulation) and shortening the 
time for programming.   
Selection of the active contact by anatomical criteria matched clinical 
criteria in 66% of the electrodes at baseline. This percentage increased after 
consecutive adjustment sessions to 70%. For a similar global improvement, a 
lower increment in TEED and voltage were required in the concordance group. 
In the same way, optimisation of DBS was more easily achieved for the 
concordance group, where “multiple changes in the stimulated contact” was 
less-often needed. When the active contact was within the defined optimal area, 
a significantly higher degree of concordance was achieved. Yet, four optimally 
placed therapeutic contacts did not match MRI criteria. In two of them, 
stimulation was found to cause disabling dyskinesia and a more rostral contact 
Discussion  
194 
was selected for chronic stimulation. This area contains pallidofugal fibres 
conveying pallidal activity to thalamic nuclei and it is likely that high frequency 
stimulation of this area would modulate signals, which are primarily accountable 
for the emergence of dyskinesia. In the remaining two, MRI contact selection 
was probably inaccurate, assuming that the best contact was the one located 
inside the central segment of the STN (which showed to be inside the STN in 
coronal and axial MRI planes) while the contact in the superior segment was 
shown to be clinically more appropriate (which shown to be inside the STN in 
one of the MRI planes and adjacent in the other plane). Conversely, selection of 
suboptimally placed contacts based on MR data may be more inaccurate – only 
50% of the therapeutic contacts matched MRI criteria.  
Two previous attempts have been made to program DBS parameters 
based on neuroimaging anatomical location of the electrode contacts (Lee et 
al., 2010; Paek et al., 2011). In the former study, patients treated for at least 6 
months with DBS therapy were reprogrammed stimulating as many contacts 
considered to be optimally placed (in the STN or, at worst, at its boundaries) by 
neuroimaging criteria. After reprogramming, most of the electrodes passed from 
a single to a multiple monopolar configuration. An additional improvement in 
motor UPDRS scores off and on medication along with a reduction in TEED and 
LEDD was found. This improvement was observed mainly for those leads 
considered to be well placed; which is in agreement with our findings. However, 
as multiple monopolar stimulation was used after reprogramming, a broader 
area was probably being stimulated, which might in part account for the further 
benefit observed and the reduction of TEED. In the study by Paek (2011), 
patients were programmed one month after surgery using neuroimaging criteria 
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for the selection of the active contact. Even though no control group was used, 
improvement at 3 and 6 months after surgery and reduction of LEDD were 
comparable to those previously described (Limousin et al., 1998; Rodriguez-
Oroz et al., 2005) with the advantage that time of programming was markedly 
shortened.  
Our results, along with those previously published, suggest that 
integration of anatomical contact location information on current strategies of 
programing of DBS may help to select the optimal therapeutic contact. Despite 
the present controversy regarding the optimal stimulation site, selection of 
therapeutic contact by an imaged-based programming may reduce the potential 
therapeutic contacts to two (given the Medtronic 3389 DBS electrode 
dimensions). This methodology would most likely simplify and shorten the 
programming of stimulation parameters, increase stimulation efficiency and 
alleviate patient discomfort. Moreover, this approach may be most valuable for 
future more complex leads and settings available and also for targets and other 
diseases where acute effect is less reliable.  Nevertheless, intensive 
programming may still be necessary for suboptimally placed electrodes. 
Fortunately, these represent a small percentage of electrodes in the majority of 
centres performing DBS.  
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4. STUDY OF TYPE OF ADJUSTMENT “CHANGE IN CONTACT” 
One of the key factors in the programming of stimulation is the selection 
of the optimal contact, as it represents the optimal stimulation site for a given 
electrode. Each contact of the DBS electrode stimulates a different area within 
the subthalamic region in the rostro-caudal axis (with an anterior-posterior and 
latero-medial direction). The optimal contact is selected based on the acute 
effect elicited by the stimulation. Nevertheless, the acute efficacy of one contact 
may be confounded with the carryover effects of a previous setting, as 
stimulation effect can take up to four hours to vanish (Temperli et al., 2003).  
From the 28 electrodes that underwent a change in contact during the first 
adjustment session, 53.7% remained in that new contact at the end of the 
study. In 43% of electrodes, the contact changed again at the second and/or 
third adjustment session. In the majority of these electrodes (75%) the active 
contact returned to the same contact stimulated at baseline; thus, previous 
programming could be considered useless. Moreover, 10% of the electrodes 
required multiple changes in the active contact. For those contacts where the 
first “change in contact” was appropriate, the stimulation site moved mainly from 
the central to the superior segment of the STN or adjacent to it. For the 
remainder, stimulation site at the final time point was more heterogeneous, 
preventing us from drawing any conclusions.  
These results, along with previous findings reported in this study, strongly 
suggest that the superior segment of the STN is the optimal area for stimulation.  
Active contact was selected based on its acute effect. However, although all 
contacts undergoing a “change in contact” at A1 had an acute benefit, this was 
significantly larger for those not requiring additional changes in the stimulated 
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contact at A2. In both groups, the acute effect was attenuated over time, but 
deterioration was only present for those requiring a second change at A2. 
Therefore, the magnitude of the acute effect seems to be closely related to the 
sustained benefit, as was seen in the multivariate regression analysis. The 
acute benefit observed in suboptimal selected contacts can be explained by the 
lasting effect of the stimulation. While tremor may return within minutes after 
switching the stimulation off (Temperli et al., 2003; Blahak et al., 2009), 
bradykinesia (Temperli et al., 2003, Cooper et al., 2013, Cooper et al., 2011, 
Waldau et al., 2011; Lopiano et al., 2003), rigidity and axial symptoms require 
longer washout periods (Temperli et al., 2003). In the same way, tremor readily 
improves after switching stimulation on, while improvements of bradykinesia 
and rigidity may take longer. Thus, when assessing the effects of stimulation of 
a new contact, and therefore, of a new anatomical area, the influence of the 
stimulation over the previous site is still present, unless stimulation has been 
turned off for a few hours. The complex response of symptoms to off and on 
stimulation conditions complicates any acute evaluation. Furthermore, this 
behaviour reflects different mechanisms of action of high frequency stimulation. 
Immediate effects may be related to the direct depolarisation of STN neurons or 
neurotransmission (Krack et al., 1998; Blahak et al., 2009), while other 
mechanisms, such as secondary messengers, long-term potentiation or a long-
lasting modification of the basal ganglia activity by STN DBS, may be involved 
in the prolonged and even sometimes delayed effect of the stimulation 
(Temperli et al., 2003, Cooper et al., 2013). It has been suggested that a period 
of at least 3 hours with the stimulation turned off may be required to assess all 
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Parkinsonian signs (Temperli et al., 2003), which may be not only unbearable 
for patients but also unviable in routine practice.  
Furthermore, some contacts changed at A2 or A3 without a previous change in 
contact. This reflects the difficulty in selection of the optimal contact when only 
clinical assessment is available and how this process may be dependent of 
many factors (i.e. clinician’s expertise, patient cooperation, placebo effect, off-
medication condition).  
When a change in the active contact is involved in the reprogramming, the 
acute effect would comprise both the readily achieved effect of stimulation of a 
new contact and the long-lasting effect of the stimulation of the previous one. 
However, the delay-effects of the stimulation will not be present during the 
acute evaluation. This makes adjustment of the stimulated contact based on the 
acute effect quite unpredictable unless a large enough acute benefit has been 
obtained.  
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5. THE VALUE OF THE INTRAOPERATIVE LFP RECORDINGS IN DBS 
TARGETING OF THE STN AND OPTIMIZATION OF STIMULATION 
PARAMETERS 
Online spectral analysis of LFPs recorded from the DBS electrode may provide 
information that would help to predict optimal stimulation settings during long-
term follow-up. We previously shown that the same signals were quick to record 
and analysed intraoperatively, and correlated with successful targeting with 
respect to intraoperative implantation effect and postoperative imaging (Chen et 
al., 2006). The latter was also confirmed in this larger sample where most of the 
contacts considered to be optimally placed had evidence of a local beta 
generator. Together, these results point to the utility of the intraoperative 
spectral analysis of LFPs recorded from the DBS electrode in aiding the 
functional localisation of the STN. 
No evidence for significant perioperative brain shift was found, in so far as there 
was no difference between the mean depth of the local generator and the depth 
of the contact independently used for chronic stimulation, although some 
individual variability existed. The limited delays introduced by our intraoperative 
functional localisation technique may have helped avoid significant subdural air 
collection. This contrasts with more prolonged microelectrode recording 
techniques where brain shift might be a problem (Miyagi et al., 2007). 
Furthermore, there were no perioperative haemorrhages in our series.   
In this work we studied how well the intraoperative LFP recordings could predict 
the chronic contact and voltages independently selected for chronic stimulation.  
The depth of the surgical target point was a relatively poor predictor of the depth 
of the local beta generator or the contact selected for chronic stimulation. We 
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concluded that although anatomical targeting based on preoperative 
stereotactic MRI may be very good at selecting an appropriate electrode 
trajectory towards and through the nucleus, it is relatively poor in identifying the 
precise rostro-caudal depth of the stimulation target, whether the latter is 
functionally defined as the local generator or clinically defined as the site of the 
best contact for chronic stimulation. There was even evidence that the local 
beta generator may be more indicative of the optimal depth for ameliorating 
parkinsonism than the contact level chosen for therapeutic stimulation over 
long-term follow up, perhaps because the latter represents a compromise 
between efficacy and side effects. Thus, higher stimulation voltage and energy 
tended to be delivered if a depth was selected for chronic stimulation that 
differed from that of the local beta generator. Stimulation efficacy was more 
than halved when the therapeutic contact was ≥ 2 mm from the depth of the 
beta generator; which is further explained by the fact that current spread around 
the electrode contact is of  2-3 mm of diameter (Ranck, 1975; Ashby et al., 
1999; Saint-Cyr et al., 2002). In contrast, disparities in the depth selected for 
chronic stimulation and the depth of the surgical target point had no significant 
effect on stimulation voltage or energy. Further studies have confirmed a high 
concurrence between the center of the site used for chronic stimulation and the 
dorsolateral oscillatory region of the STN (Zaidel et al., 2010; Guo et al., 2013). 
In the same way stimulation of this area was correlated with a good outcome of 
STN DBS.  
Intraoperative recording of local field potential activity directly from the DBS 
electrode may potentially provide an alternative to microelectrode recordings for 
identifying the depth of the STN, with attendant advantages in terms of the 
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duration of the operation and possible reduction in the risks of intraoperative 
haemorrhage and brain shift. Nevertheless, the technique relies on minimal 
error in the anterior-posterior plane, as a single trajectory cannot provide 
information about localisation in these dimensions, and the utility and safety of 
exploration of alternative trajectories with the DBS electrode remains uncertain. 
Thus the technique must be combined with accurate targeting in the anterior-
posterior plane using stereotactic preoperative MRI. Yet, the present data 
provide further support for the clinical relevance of the local beta activity in the 
STN and suggest that the technique whereby LFPs are recorded from the DBS 
electrode also helps predict the optimal stimulation contact for use in chronic 
DBS. Nevertheless, further studies will be needed to assess the role of LFP in 
selection of the optimal stimulation parameters in DBS.  
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1. LONGITUDINAL ASSESSMENT OF THE IMPACT OF CONSECUTIVE 
SESSIONS FOR ADJUSTMENT OF STIMULATION PARAMETERS OF STN 
DBS IN PD PATIENTS: EVALUATION OF THE ACUTE AND CHRONIC 
EFFECTS OF STIMULATION PARAMETERS 
The aim of this study was to improve the current strategies for selection of the 
stimulation parameters. We have shown that the acute effect on motor scores is 
the factor that better predicts a sustained benefit. Nevertheless, although a 
lineal relationship between the acute and global benefit of the adjustment exists, 
the magnitude of the acute effect necessary for the adjustment to provide a 
sustained benefit may vary depending on previous optimisation of the 
stimulation. We can conclude that:  
1. Subjective assessment of the acute effect of the stimulation is not always 
translated into an objective acute effect. 
2. The most consistent predictive factor for a global motor improvement of a 
programming session of the stimulation parameters is the acute effect of 
the new setting on motor scores.   
3. The magnitude of the acute effect necessary to ensure a global 
improvement varies depending on previous optimisation of the 
stimulation parameters. 
4. The impact of the different types of adjustment on global outcome is 
mainly through its acute effect.  
2. CLINICAL OUTCOME OF STN DBS WITH REPROGRAMMING  
In this part of the study we have demonstrated that reprogramming, in otherwise 
stable PD patients treated with STN DBS, can lead to additional benefits; which 
contradicts what has been widely accepted that little changes on stimulation 
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parameters are required after the first six months of stimulation. While some 
patients will improve, others will remain stable and a minority will deteriorate.  
Patients requiring only “one change in the active contact” or “change in voltage” 
will show the greatest benefits. Necessity of “multiple changes in the stimulated 
contact” will not provide additional benefits and it may reflect a suboptimal 
electrode position. Women and younger patients showed the greatest 
probability for improvement. The following conclusions can be extracted from 
this part of the study: 
1. Reprogramming of stimulation parameters in patients with chronic STN 
DBS can lead to additional benefits in terms of improvement on motor 
scores, activities of daily living off-medication and reduction of 
dopaminergic medication.  
2. There is a lower probability for men and older patients to improve with 
reprogramming 
3 and 4. OPTIMAL STIMULATION SITE IN STN DBS FOR PARKINSON’S 
DISEASE AND STUDY OF THE TYPE OF ADJUSTMENT “CHANGE IN 
CONTACT”
Intensive programming of the stimulation led to evolution of the active contact 
towards the superior part of the STN, strongly suggesting that this  area is the 
optimal stimulation site. Accurate implantation of the electrode within the 
optimal area will provide a greater benefit of the stimulation and lead to more 
efficient stimulation parameters. Selection of the optimal therapeutic contact, 
based on its anatomical location, could simplify the programming of stimulation. 
The results of this part of the study lead to conclude that: 
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1. The best area for stimulation within the subthalamic area for STN DBS 
for Parkinson’s disease is the superior segment of the nucleus.   
2. Stimulation of central/superior segment of the STN provides a more 
effective and efficient therapy than stimulation of other regions of the 
subthalamic area.  
 
5. THE VALUE OF THE INTRAOPERATIVE LFP RECORDINGS IN DBS 
TARGETING OF THE STN AND OPTIMIZATION OF STIMULATION 
PARAMETERS 
LFP can be an alternative to microelectrode recordings to electrophysiologically 
define the functional target. Furthermore, we have demonstrated that this 
technique may help in the selection of the optimal therapeutic contact. We 
conclude that:  
1. Online spectral analysis of local field potentials recorded from the DBS 
electrode aids in the functional localization of the STN. 
2. Online spectral analysis of local field potentials recorded from the DBS 
electrode provides information that helps predict the optimal stimulated 
contact. 
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APPENDIX I. STIMULATION PARAMETERS 
 
Table 1.1 Voltage at different time points of the study 
 n Mean SD Range (min-max)
A1 before 62 3,15 0,764 0,90-4,50 
A1 after 62 3,19 0,720 1,00-4,50 
A2 after 62 3,25 0,746 1,20-4,50 
A3 after 56 3,30 0,709 1,25-4,50 
Abbreviations: A: adjustment session; SD: standard deviation.  
Table displays the values of voltage (in volts) before A1, after adjustment of 
stimulation parameters in A1, after adjustment of stimulation parameters in A2 
and after adjustment of stimulation parameters in A3 
 
Table 2.1 Pulse widths at the different time points of the study 
 n Mean SD Range (min-max)
A1 before 62 62,90 8,942 60-90 
A1 after 62 62,42 8,235 60-90 
A2 after 62 63,39 9,572 60-90 
A3 after 56 63,75 10,011 60-90 
Abbreviations: A: adjustment session; SD: standard deviation.  
Table displays the values of pulse width (in microseconds) before A1, after 
adjustment of stimulation parameters in A1, after adjustment of stimulation 
parameters in A2 and after adjustment of stimulation parameters in A3 
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Table 3.1 Frequency at the different time points of the study 
 n Mean SD Range (min-max)
A1 before 62 145,00 20,961 130-185 
A1 after 62 147,90 22,716 130-185 
A2 after 62 147,90 22,716 130-185 
A3 after 56 149,82 23,100 130-185 
 
Abbreviations: A: adjustment session; SD: standard deviation. Table displays 
the values of frequency (in Hertz) before A1, after adjustment of stimulation 
parameters in A1, after adjustment of stimulation parameters in A2 and after 
adjustment of stimulation parameters in A3 
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APPENDIX II. SPANISH SUMMARY
OPTIMIZACION Y CUANTIFICACION DE LOS PARAMETROS DE 
ESTIMULACION EN LA ESTIMULACIÓN CEREBRAL PROFUNDA DEL 
NUCLEO SUBTALAMICO EN LA ENFERMEDAD DE PARKINSON 
A. INTRODUCCION  
La enfermedad de Parkinson (EP) es una de las enfermedades 
neurodegenerativas más prevalentes y discapacitantes. Sus síntomas incluyen 
lentitud de movimientos voluntarios (acinesia), temblor característico, rigidez 
muscular e inestabilidad de la postura y la marcha. Pese a no disponer un 
tratamiento curativo, actualmente existen tratamientos farmacológicos que 
mejoran los síntomas de los pacientes. La levodopa es el fármaco más eficaz; 
sin embargo, con el tiempo la medicación no logra controlar los síntomas y los 
pacientes desarrollan efectos secundarios (fluctuaciones motoras y discinesias) 
muy incapacitantes. En estos estadios de la enfermedad, la estimulación con 
alta frecuencia del núcleo subtalámico (NST), ha demostrado ser un 
tratamiento seguro y eficaz en pacientes seleccionados (Limousin et al., 1998; 
Krack et al., 2003; Fasano et al., 2010).  
La estimulación cerebral profunda consiste en la implantación de un 
electrodo en una región cerebral concreta. Este electrodo es conectado, 
mediante una extensión, a un neuroestimulador que se coloca generalmente en 
la región infraclavicular.  
El éxito de la estimulación cerebral profunda (ECP) del NST depende de 
una correcta selección de los candidatos, una precisa implantación de los 
electrodos y de una cuidadosa programación de los parámetros de 
estimulación y ajustes en la medicación dopaminérgica. Una correcta 
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programación de los parámetros de estimulación permitirá obtener el máximo 
beneficio de la estimulación, disminuir la incidencia de efectos adversos 
inducidos por la estimulación, optimizar el consumo de energía del 
neuroestimulador y disminuir los requerimientos de medicación dopaminérgica. 
Actualmente existen unas guías para la selección de los parámetros de 
estimulación (Moro et al., 2002; Rizzone et al., 2001). Éstas se basan en el 
efecto inmediato de las distintas combinaciones de los parámetros de 
estimulación sobre los síntomas. Sin embargo, hasta la fecha no ha sido 
estudiado si este beneficio inmediato predice una mejoría a largo plazo. Los 
parámetros de estimulación que se pueden programar son el voltaje, la 
duración de pulso y la frecuencia. Además, durante la programación hay que 
seleccionar el contacto del electrodo de ECP más eficaz. El electrodo dispone 
de cuatro contactos en su punta (dispuestos longitudinalmente) que se pueden 
estimular de forma independiente o en combinación. La selección del contacto 
más eficaz consiste en determinar cuál de los cuatro contactos presenta un 
mejor efecto clínico con  menor consumo de energía y mayor ventana para la 
aparición de efectos secundarios. La programación de los parámetros de 
estimulación es un proceso laborioso, que depende de la experiencia del 
neurólogo que realiza los ajustes y de la colaboración del paciente. Además no 
está exenta de un posible efecto placebo (Mercado et al., 2006) y los ajustes 
deben  hacerse con el paciente en la condición de off-medicación, es decir, tras 
retirar su medicación antiparkinsoniana 12 horas antes de la programación, lo 
que en ocasiones causa gran disconfort al paciente.  
La zona óptima de estimulación dentro del área subtalámica (contiene el 
NST y las fibras que lo rodean) ha sido una cuestión ampliamente debatida 
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(Kuncel et al., 2004). Dos regiones son las que se han propuesto con mayor 
frecuencia: la región dorsolateral del NST que corresponde a su territorio 
sensitivo-motor (Lanotte et al., 2002; Saint-Cyr et al., 2002; Yelnik et al., 2003) 
y la región localizada rostralmente a este territorio que contiene la parte rostral 
de la zona incerta y las fibras palidofugales (Voges et al., 2002; Hamel et al., 
2003; Godinho et al., 2006). Algunos grupos han encontrado que ambas zonas 
son igualmente efectivas pero que en la última los requerimientos de energía 
eléctrica suministrada por el neuroestimulador son menores (Voges et al., 
2002; Hamel et al., 2003). El contacto óptimo de estimulación es seleccionado 
en base a sus efectos clínicos, por tanto su posición refleja el sitio más 
adecuado de estimulación. Esta estrategia ha sido utilizada en la mayoría de 
los estudios que han evaluado la zona más óptima de estimulación. Sin 
embargo, con la actuales guías clínicas, el contacto terapéutico es 
seleccionado en base a su efecto agudo y sin una cuantificación objetiva del 
impacto de su estimulación sobre los síntomas. Es más, generalmente se 
asume que los parámetros de estimulación y el contacto estimulado, una vez 
realizados los ajustes de los primeros meses tras la cirugía, no requieren de 
grandes cambios. Sin embargo, algunos estudios han obtenido un beneficio 
adicional con la reprogramación de pacientes crónicamente tratados con ECP 
del NST, especialmente cuando se cambia el contacto de estimulación (Moro et 
al., 2006; Fasano et al., 2010).  
En los últimos años, los avances de la neuroimagen y los programas de 
planificación han permitido poder determinar la localización final de los 
electrodos implantados y por tanto de sus contactos. Sin embargo, no se ha 
desarrollado ninguna guía clínica que incluya estos datos anatómicos para la 
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selección del contacto óptimo para la estimulación. La información anatómica 
puede ser de gran utilidad, disminuyendo el número de contactos del electrodo 
que requieren ser evaluados y por tanto acortando el tiempo de programación y 
reduciendo  la incomodidad que el procedimiento puede causar  al paciente.  
Por último, los potenciales de campo locales (PCL) son una técnica 
electrofisiológica que ayuda a identificar el NST durante la cirugía. Un pico en 
la actividad beta, propia del territorio sensitivo-motor del NST en pacientes 
parkinsonianos, tiene una buena correlación con la el alivio de los síntomas 
durante la implantación del electrodo y con la localización de éste en el NST 
evaluado con resonancia magnética postoperatoria (Chen et al., 2006). Sin 
embargo, se desconoce si los PCL pueden ayudar a seleccionar el contacto de 
estimulación y optimizar los parámetros de estimulación.  
El objetivo fundamental de esta tesis doctoral es la optimización de los 
parámetros de estimulación. Para tal efecto se ha evaluado el efecto agudo y 
sostenido (crónico) de los ajustes de estimulación,  qué variables pueden 
predecir un efecto mantenido tras la programación, el sitio óptimo de 
estimulación tras una optimización clínica y objetiva de los parámetros de 
estimulación y el papel de la información anatómica (RM) y los PCL en la 
selección del contacto más eficaz para la estimulación.  
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B. OBJETIVOS 
1. Evaluar el efecto agudo y mantenido del ajuste de  los parámetros de 
estimulación sobre los síntomas motores de la EP 
2. Evaluar el impacto agudo y crónico de los diferentes tipos de ajuste de los 
parámetros de estimulación sobre los síntomas motores.  
3. Identificar qué factores involucrados en la programación de la ECP predicen 
el mejor efecto clínico a largo plazo en la ECP del NST en la EP.  
4. Determinar si una programación minuciosa e intensiva de los parámetros de 
estimulación puede proporcionar un beneficio clínico adicional. 
5. Estudiar la evolución del sitio de estimulación tras sesiones consecutivas de 
programación de los parámetros de estimulación. 
6. Estudiar el sitio óptimo de estimulación en las ECP del NST tras una 
optimización de los parámetros de estimulación. 
7. Evaluar si la información anatómica de la localización del electrodo y sus 
contactos puede ayudar a la selección de contacto terapéutico. 
8. Estudiar el comportamiento del tipo de ajuste “cambio de contacto” durante 
sesiones consecutivas de programación. 
9.  Evaluar el papel de los potenciales de campo locales intraoperatorios en la 
predicción de los parámetros de estimulación en la estimulación cerebral 
profunda para la Enfermedad de Parkinson.  
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C. METODOLOGIA 
Pacientes 
Pacientes con EP tratados con ECP del NST con una duración mínima del 
tratamiento de 12 meses (6 meses en el estudio de los potenciales de campo 
locales) fueron reclutados para el estudio.  
Se trata de un estudio prospectivo que consta de 5 subapartados: 
1. Estudio longitudinal sobre el  impacto de sesiones consecutivas de 
programación de los parámetros de estimulación en la ECP del NST en 
la EP 
2. Resultado clínico de la reprogramación de la estimulación en la ECP del 
NST   
3. Sitio óptimo de estimulación en la ECP del NST en la EP y papel de la 
información anatómica del electrodo de ECP y sus contactos en la 
selección del contacto terapéutico 
4. Análisis del tipo de ajuste “cambio de contacto” en la ECP del NST en la 
EP 
5. Papel de los potenciales de campo locales (PCL) intraoperatorios en la 
optimización de los parámetros de estimulación en la ECP del NST en la 
EP 
 
1. Estudio longitudinal sobre el  impacto de sesiones consecutivas de 
programación de los parámetros de estimulación en la ECP del NST en la 
EP
Los pacientes fueron evaluados en tres visitas: en el momento de la inclusión 
(visita 1), un mes (visita 2) y tres meses después de la inclusión (visita 3). En 
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cada visita los pacientes fueron evaluados con la parte motora de la escala 
UPDRS (UPDRS III) antes (tiempo basal) e inmediatamente tras el ajuste de 
los parámetros de estimulación (tiempo agudo). En la siguientes visita, la 
primera evaluación corresponde al tiempo crónico del ajuste previo y al basal 
del nuevo ajuste. Las valoraciones se hicieron en la situación off-
medicación/on-estimulación. Tras la valoración “aguda” los pacientes tomaron 
su medicación antiparkinsoniana y fueron valorados on-medicación con la parte 
motora de la UPDRS y con la escala de discinesias. Una vez concluidas las 
valoraciones clínicas se completaron el resto de partes de la UPDRS (I, II y IV). 
El neurólogo que realizó las valoraciones clínicas y el paciente permanecieron 
ciegos a las modificaciones de los parámetros de estimulación. 
El estudio consta por tanto de tres sesiones de ajuste: A1, A2 y A3 y cada una 
de éstas consta de tres tiempos de evaluación: basal, agudo y crónico (figura 
2.1, apartado metodología).  
Los ajustes de los parámetros de estimulación se clasificaron en:  
- “sin cambios”: se valoran nuevos parámetros de estimulación (PE) y 
finalmente no se modifican  
- “cambio en voltaje”: se modifica el voltaje de la estimulación (además se 
puede variar la duración de pulso y/o  la frecuencia) 
- “cambio en contacto”: consiste en la modificación del contacto 
terapéutico. Se puede variar el voltaje, la duración de pulso y/o la 
frecuencia. 
- “no necesidad de ajustes”: tras A1, algunos electrodos presentan un 
beneficio clínico mantenido por lo que no requieren una nueva 
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programación de la estimulación. El efecto agudo por tanto no es 
valorado.  
Los tipos de ajustes de los PE se consideran por electrodos y por tanto las 
valoraciones clínicas se realizan sobre el hemicuerpo contralateral 
utilizando los ítems 20 a 26 de la parte motora de la UPDRS (rango de 
puntuación 0-36). La medicación antiparkinsoniana se ajustó según las 
necesidades.  
En el análisis estadístico se compararon las puntaciones en la UPDRS III 
(total y hemicuerpo)  obtenidas en los tiempos basal, agudo y crónico de 
cada sesión de ajuste (variable intra-sujetos) utilizando el modelo general 
lineal de medidas repetidas ANOVA. En la valoración por hemicuerpos se 
incluyó el  “tipo de ajuste” como variable entre-sujetos. El estudio de 
variables predictoras de beneficio mantenido del ajuste de la estimulación 
se estudió con un modelo de regresión multivariante.  
2. Resultado clínico de la reprogramación de la estimulación en la ECP del 
NST
Se compararon las puntuaciones en las distintas escalas utilizadas en la 
situación basal del estudio (tiempo basal de A1) y final (tiempo crónico del A3) 
en la condición off-medicación/on-estimulación. Para evaluar el impacto de los 
ajustes de estimulación sobre la situación final se definió una nueva variable 
“tipo de ajuste a lo largo del estudio”:  
- sin cambios en los PE (incluye no cambios y no necesidad de ajustes) 
- uno o más ajustes en voltaje pero no en contacto 
- un cambio en contacto  
- dos o más cambios en contacto.  
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El análisis estadístico se realizó utilizando un modelo de medidas repetidas con 
factor principal “tiempo” (UPDRS III total y por hemicuerpos basal y final del 
estudio) y variable entre-sujetos “tipo de ajuste a lo largo del estudio” para el 
análisis por hemicuerpos. Se determinaron las variables predictoras de mejoría  
final mediante un modelo de regresión logística. Para tal efecto, se redefinió 
una nueva variable cualitativa de  “mejoría final”.  
3. Sitio óptimo de estimulación en la ECP del NST en la EP y  papel de la 
información anatómica en la selección del contacto terapéutico 
Las imágenes de RM postoperatoria y el programa Framelink se 
utilizaron para determinar la posición de los contactos del electrodo. Las 
coordenadas de cada contacto se calcularon desde el centro del artefacto 
causado por el electrodo en la RM postoperatoria. El centro de cada contacto 
se calculó utilizando una plantilla del electrodo. Estas coordenadas se 
trasladaron a la RM preoperatoria con el fin de evitar el artefacto. Dos 
neurocirujanos ciegos a las valoraciones clínicas y parámetros de estimulación 
determinaron la posición de cada contacto que se definió con dos variables: 
segmento de NST (superior, anteromedial, central, posterolateral e inferior) y 
relación con estructuras que rodean al núcleo (dentro del núcleo, medial, 
lateral, superior, inferior al NST) (figura 2.3, apartado metodología). Para 
facilitar el análisis estadístico los contactos activos se clasificaron en: grupo Ic -
buena localización- el contacto se encuentra dentro del NST (segmento central 
o superior) o adyacente al borde superior del NST y grupo IIc, para aquellos 
que no cumplían los criterios anteriores. Se utilizó un análisis univariante para 
estudiar el impacto de  la posición del contacto activo sobre varias variables 
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dependientes: eficacia de la ECP, energía total suministrada, voltaje, tipo de 
ajuste de los PE durante el estudio y dosis diaria equivalente de levodopa.  
Asimismo, un neurocirujano determinó qué contacto del electrodo era más 
óptimo para la estimulación en base a su localización anatómica en las 
imágenes de RM. Distintas variables clínicas y de PE se compararon entre 
aquellos contactos que coincidían con el seleccionado por el neurocirujano y 
los que no coincidían.  
4. Análisis del tipo de ajuste “cambio de contacto” en la ECP del NST en 
la EP 
Este apartado se centró en la descripción y análisis clínico y anatómico 
de aquellos electrodos que requirieron un “cambio de contacto” en el A1 y los 
que requirieron un “cambio de contacto” en A1 y A2 y/o A3. Se utilizaron 
pruebas no paramétricos cuando el tamaño de la muestra permitía realizar una 
comparación estadística.  
5. Papel de los potenciales de campo locales (PCL) intraoperatorios en la 
optimización de los parámetros de estimulación en la ECP del NST en la 
EP
El registro de los PCL se realizó desde el electrodo de ECP en pasos de 
2 mm desde 6-4 mm por encima de la diana hasta 2-4 mm por debajo (figura 
2.4, apartado metodología). Un “pico” en la banda beta se definió como un 
aumento de al menos 100% de la media de la potencia de la banda beta en el 
contacto 01 del electrodo entre las sucesivas profundidades del registro. Las 
valoraciones clínicas y la programación de la estimulación fueron realizadas por 
un neurólogo ciego a los datos del registro. La localización anatómica de los 
contactos terapéuticos se definió en dos grupos: grupo Ic, el contacto se 
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encuentra dentro o al menos adyacente al borde superior del NST; y grupo IIc, 
el contacto se encuentra en una localización distinta a la del grupo I. La 
profundidad del contacto terapéutico también se describió con referencia a la 
profundidad planificada preoperatoria (misma referencia que la utilizada para la 
profundidad del pico en la banda beta). Para el análisis estadístico se utilizó la 
correlación de la Rho de Spearman para acomodar la distribución no 
paramétrica de la muestra y evitar observaciones aberrantes.  
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D. RESULTADOS 
1. Estudio longitudinal sobre el  impacto de sesiones consecutivas de 
programación de los parámetros de estimulación en la ECP del NST en la 
EP  
1.1 Evaluación del efecto agudo y crónico de tres ajustes consecutivos de 
los parámetros de estimulación  
Treinta y un pacientes con EP (19 hombres; edad 56.356.8; duración de la 
enfermedad 12.395.3 años) tratados con ECP del NST durante al menos 12 
meses (media 29.94 meses) fueron incluidos en el estudio. El beneficio 
obtenido en la parte motora de la UPDRS con la ECP fue de 49.53% en la 
condición off-medicación (comparación tiempo basal del estudio con 
puntuaciones preoperatorias) (tabla 1.1, apartado de resultados).  
El impacto producido por los ajustes en los parámetros de estimulación fue 
similar en la UPDRS III total y por hemicuerpos. Todos los ajustes produjeron 
un beneficio inmediato estadísticamente significativo, sin embargo en A1 y A2 
este beneficio no se mantuvo y no se produjo un beneficio global del ajuste;  
mientras que en A3 sí que perduró, obteniéndose una mejoría global (tablas 1.2 
a 1.10; figura 1.3 apartado de resultados).  
El tipo de ajustes “no cambio” no produjo variaciones en la UPDRS III por 
hemicuerpos salvo en el A3 donde se observó una mejoría crónica significativa 
que se tradujo en una mejoría global (figura 1.7, apartado de resultados). 
El “cambio en voltaje” no causó variaciones en la UPDRS III por hemicuerpos, 
salvo en el A3 donde se observó una mejoría en el efecto agudo que se 
mantuvo en el tiempo (figura 1.7, apartado de resultados).  
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El tipo de ajuste “cambio de contacto” fue el que produjo mayores variaciones 
en las puntaciones motoras. En el A1, se observó un beneficio inmediato, 
seguido de empeoramiento y sin obtener un beneficio global. Sin embargo en el 
A2 y A3, se volvió a producir un beneficio inmediato y mantenido, obteniéndose 
un beneficio global en estas dos sesiones de programación (figura 1.7, 
apartado de resultados).  
Cuando no fueron necesarios ningún ajuste, las puntuaciones motoras se 
mantuvieron estables (figura 1.7, apartado de resultados).  
1.2 Factores predictores de mejoría global en cada sesión de 
programación 
El factor que mejor predijo una mejoría global en cada sesión de 
programación fue la mejoría aguda en la escala UPDRS III (total y por 
hemicuerpos) (tabla 1.14 y 1.15, apartado de resultados). En el A1, aumentar la 
profundidad de la zona de estimulación (es decir, seleccionar un contacto 
localizado más caudalmente) predijo un deterioro motor; mientras que en el A2, 
revertir esta situación (estimular un contacto más superficial) mostró una 
tendencia hacia la mejoría. La magnitud del efecto agudo sobre la UPDRS III-
hemicuerpo presentó una relación lineal con la mejoría global de cada sesión 
de programación (figura 1.9, apartado de resultados). Conforme se progresó en 
las sesiones de programación, una menor magnitud de efecto agudo fue 
necesaria para asegurar una mejoría global [A1: 5 puntos (rango -5.47 a -2.43, 
95% IC); , A2: 3 puntos (rango -3.23 a -1.39, 95% IC) y A3: 1 punto (rango -
3.28 a – 1.50, 95% IC)].  
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2. Resultado final de ajustes consecutivos en los parámetros de 
estimulación en la ECP del NST en la EP 
Se observó una mejoría significativa al final del estudio (comparación 
puntuaciones del tiempo crónico de A3 con tiempo basal de A1) en la UPDRS 
III total y por hemicuerpos, UPDRS I y II off-medicación. Los requerimientos de 
medicación dopaminérgica se redujeron en un 30% (tabla 2.1, apartado de 
resultados). La mejoría final se produjo en un 42.3% de los pacientes y un 
59.6% de los hemicuerpos.  
Los electrodos que sufrieron un solo cambio en el contacto de estimulación 
presentaron una mejoría final estadísticamente significativa. Aquellos en los 
que sólo se modificó el voltaje, mostraron una tendencia hacia la mejoría. En 
los que no se realizaron cambios de los PE o en los que requirieron dos o más 
cambios en el contacto de estimulación las puntuaciones motoras no variaron 
(figura 2.2, apartado de resultados).  
Ser mujer, joven o tener puntuaciones basales de la UPDRS III total o por 
hemicuerpos más altas se relacionó con una mayor probabilidad de mejoría al  
final del estudio (tabla 2.4, apartado de resultados).  
3. Sitio óptimo de estimulación en la ECP del NST en la EP 
3.1 Análisis de la posición anatómica del electrodo de estimulación 
cerebral profunda 
En 50 electrodos (24 pacientes) se disponía de la  información sobre la 
localización  anatómica del electrodo de ECP y de sus contactos.  El 88% de 
los electrodos presentaban uno o más contactos en el área de estimulación 
definida como óptima y 19 pacientes presentaron ambos electrodos con uno o 
más contactos en dicha zona. Las puntuaciones en la UPDRS III-hemicuerpo 
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mostraron una tendencia hacia valores inferiores para aquellos electrodos con 
una óptima localización. También fueron inferiores los requerimientos de  
energía total suministrada y voltaje.  Sin embargo, la programación intensiva de 
los PE permitió obtener beneficios similares en los dos grupos de electrodos 
(tabla 3.2, apartado de resultados). La dosis equivalente diaria de levodopa fue 
inferior en aquellos pacientes en los que ambos electrodos estaban 
correctamente implantados al final del estudio pero no en la situación basal 
(tabla 3.3, apartado de resultados).  
3.2 Análisis de la posición anatómica del contacto activo de estimulación 
cerebral profunda 
El contacto activo evolucionó hacia una posición más superficial a lo 
largo del estudio. Al inicio del estudio los contactos estimulados se encontraron 
con mayor frecuencia dentro del segmento central del NST o mediales al 
segmento central y superior del núcleo. Al final del estudio los contactos 
localizados en el segmento central del NST disminuyeron y aumentaron los 
localizados en el segmento superior o rostrales a él (figura 3.5, 3.6, apartado de 
resultados). Al final del estudio 12% de los contactos cambiaron hacia una 
posición más óptima para la estimulación.  
Se observó una tendencia hacia un mayor beneficio de la ECP y valores 
más bajos de UPDRS III-hemicuerpo cuando el contacto activo estaba 
localizado en la zona de estimulación definida como óptima. En este grupo, la 
estimulación resultó también ser más eficiente (menores requerimientos de  
energía eléctrica suministrada por el neuroestimulador). Las dosis de 
medicación antiparkinsoniana también fueron menores en este grupo al inicio 
del estudio. Sin embargo, la energía eléctrica suministrada aumentó en los dos 
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grupos al final del estudio y la mejoría motora obtenida tras los ajustes de los 
PE no difirió entre ellos. Los requerimientos de medicación disminuyeron en los 
dos grupos a lo largo del estudio y no se observaron diferencias al final del 
mismo (tabla 3.5, apartado de resultados).    
Once pacientes (13 hemicuerpos) presentaron discinesias inducidas por 
la estimulación del NST. En estos casos el contacto activo se localizó dentro 
del NST (fundamentalmente en segmento central o superior) en todos los 
casos, excepto en dos en el que el contacto se encontraba rostral al segmento 
superior del NST. Los contactos activos que provocaron discinesias se 
encontraron con mayor frecuencia dentro del NST en comparación con 
aquellos que no produjeron discinesias. Las puntuaciones en la UPDRS III-
hemicuerpos, la energía total suministrada y las dosis de medicación 
dopaminérgica fueron significativamente menores en el grupo que presentaba 
discinesias inducidas por la estimulación (tabla 3.6, apartado de resultados). 
3.3 Papel de la neuroimagen postoperatoria  en la selección del contacto 
óptimo para la estimulación 
No se encontraron diferencias significativas en las variables clínicas 
(UPDRS III hemibody, eficacia de ECP o efecto global del estudio) entre 
aquellos contactos que mostraban concordancia entre el contacto seleccionado 
clínicamente y el contacto seleccionado en la RM y los que no presentaban 
concordancia. Sin embargo, los incrementos del voltaje y de la energía total 
suministrada fueron significativamente superiores en el grupo sin concordancia. 
Se encontró un porcentaje significantemente superior de concordancia cuando 
el contacto activo se encontraba en una localización óptima. Así mismo, 
aquellos contactos que requirieron ser cambiados en más de una ocasión 
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mostraron mayor frecuencia de discrepancia entre contacto clínico y contacto 
de RM.  
4. Análisis del tipo de ajuste “cambio de contacto” en la ECP del NST en 
la EP 
Veintiocho electrodos requirieron un “cambio de contacto” en el A1. De 
éstos, 21 mostraron una mejoría del efecto agudo mantenida y no requirieron 
nuevos cambios en el contacto en el A2; mientras que siete, presentaron un 
claro empeoramiento clínico. En éstos últimos siete, aunque se produjo una 
mejoría aguda, esta fue significativamente menor que los 21 contactos que no 
requirieron un nuevo cambio de contacto (tabla 4.1, apartado de resultados). 
En la mayoría de estos siete, el nuevo contacto seleccionado tras A1 
correspondió a un contacto localizado más caudalmente. Tras el A2, la mayoría 
volvieron al mismo contacto utilizado al inicio del A1. La mayoría de los 
contactos que no requirieron nuevo cambio en A2 cambiaron hacia un contacto 
más rostral, siendo la localización final más frecuente en este grupo dentro o 
adyacente al segmento superior del NST.  
5. Papel de los potenciales de campo locales intraoperatorios en la 
optimización de los parámetros de estimulación en la ECP del NST en la 
EP
Treinta y un pacientes (17 hombres) se incluyeron en esta parte del 
estudio [edad media 577.4; duración media de la EP 11.7 años (rango 5-28); 
duración media del tratamiento con ECP 19 meses (rango 6-51)]. Se registró un 
pico en la banda beta (11-35 Hz) en todos los lados excepto en dos. Se 
encontró una correlación entre la  profundidad en la que se detectó el pico de 
actividad beta  y la profundidad del contacto terapéutico (Rho= 0.35, p=0.01; 
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figura 5.2, apartado de resultados). La diferencia absoluta entre la profundidad 
del generador beta y el contacto terapéutico mostró correlación con el voltaje 
utilizado para la estimulación crónica (Rho= 0.322, p=0.017); es decir, un 
mayor voltaje era requerido si la profundidad del contacto terapéutico difería de 
la del contacto que registró el pico en la actividad beta.  
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E. CONCLUSIONES 
1. El efecto agudo valorado de forma subjetiva no se traduce siempre en 
un efecto agudo objetivo 
2. La variable que mejor predice una mejoría motora de la programación de 
la estimulación es el efecto agudo sobre los síntomas motores producido 
por los parámetros de estimulación  
3. La magnitud del efecto agudo necesaria para asegurar una mejoría 
mantenida depende de sesiones previas de optimización de la 
estimulación. 
4. El impacto mantenido sobre los síntomas motores de los diferentes tipos 
de ajuste es fundamentalmente mediante el efecto agudo.  
5. La reprogramación de la estimulación en pacientes tratados de forma 
crónica con ECP del NST puede aportar beneficios adicionales en 
cuanto a la mejoría de los síntomas motores y reducción en los 
requerimientos de medicación dopaminérgica.  
6. Existe una probabilidad disminuida de mejorar con la reprogramación en 
pacientes varones y de mayor edad.  
7. La zona óptima de estimulación en la ECP del NST es el segmento 
superior del núcleo. 
8. Una implantación precisa en el segmento central/superior del NST 
proporciona una estimulación más eficaz y eficiente 
9. La integración de la información anatómica de la localización de los 
contactos del electrodo de DBS ayuda en la selección del contacto 
óptimo para la estimulación.  
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10.  Los potenciales de campo locales, registrados desde el electrodo de 
ECP, ayudan en la localización funcional del NST 
11.  Los potenciales de campo locales intraoperatorios son útiles en la 
selección del contacto óptimo para la estimulación  
 
